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seizures, intellectual disability, marked hypotonia, and autistic features. Despite the strong genetic linkage
between CDKL5 mutations and neurodevelopmental disorders, the biological function of CDKL5 and its
pathogenic mechanisms remain largely uncharacterized. Consequently, treatments for CDKL5 disorder have
been largely ineffective and limited to symptom management. This study aims to dissect the molecular and
cellular basis of CDKL5 disorder using novel mouse models and to identify signaling pathways that can be
targeted for therapeutic development.
To determine the genetic causality of CDKL5 disorder, we generated the first Cdkl5 knockout (KO) mouse
and found that mice lacking CDKL5 mimic key symptoms of CDKL5 disorder, including impaired motor
control, poor learning and memory, and autistic-like behaviors. KO mice also show deficits in neural circuit
communication and alterations in many signal transduction pathways, but do not develop spontaneous
seizures. Previous studies using in vitro cell cultures and shRNA-mediated knockdown have implicated
CDKL5 in dendritic morphogenesis and the phosphorylation of MeCP2, mutations of which cause Rett
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Cdkl5 from forebrain glutamatergic neurons (Nex-cKO) results in the development of spontaneous seizures.
The separation of distinct aspects of CDKL5 disorder-related phenotypes in the two complementary
conditional KO lines suggests that the epileptic and autistic phenotypes of CDKL5 disorder are mediated by
distinct neural circuits and that loss of CDKL5 in specific cell types may differentially disrupt signaling
pathways and impair neuronal function.
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ABSTRACT 
 
PATHOGENIC MECHANISMS UNDERLYING THE EARLY EPILEPTIC 
ENCEPHALOPATHY CDKL5 DISORDER 
Judy I-Ting Wang 
Zhaolan (Joe) Zhou 
 
Cyclin-dependent kinase-like 5 (CDKL5) is an X-linked gene associated with early 
infantile epileptic encephalopathy, atypical Rett Syndrome, and autism spectrum 
disorders.  Patients with CDKL5 mutations display a heterogeneous array of clinical 
symptoms, the most prominent of which include early-onset epileptic seizures, 
intellectual disability, marked hypotonia, and autistic features.  Despite the strong 
genetic linkage between CDKL5 mutations and neurodevelopmental disorders, the 
biological function of CDKL5 and its pathogenic mechanisms remain largely 
uncharacterized.  Consequently, treatments for CDKL5 disorder have been largely 
ineffective and limited to symptom management.  This study aims to dissect the 
molecular and cellular basis of CDKL5 disorder using novel mouse models and to 
identify signaling pathways that can be targeted for therapeutic development. 
 
To determine the genetic causality of CDKL5 disorder, we generated the first Cdkl5 
knockout (KO) mouse and found that mice lacking CDKL5 mimic key symptoms of 
CDKL5 disorder, including impaired motor control, poor learning and memory, and 
autistic-like behaviors.  KO mice also show deficits in neural circuit communication and 
alterations in many signal transduction pathways, but do not develop spontaneous 
seizures.  Previous studies using in vitro cell cultures and shRNA-mediated knockdown 
have implicated CDKL5 in dendritic morphogenesis and the phosphorylation of MeCP2, 
mutations of which cause Rett Syndrome, but the results of these studies are 
contentious.  Therefore, to understand the in vivo function of CDKL5 and to investigate 
how loss of CDKL5 contributes to epileptic and autistic features, we have generated 
Cdkl5 conditional KO mice.  Notably, our studies show that selective deletion of Cdkl5 
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from forebrain GABAergic neurons (Dlx-cKO) recapitulates autistic-like phenotypes, 
whereas selective removal of Cdkl5 from forebrain glutamatergic neurons (Nex-cKO) 
results in the development of spontaneous seizures.  The separation of distinct aspects 
of CDKL5 disorder-related phenotypes in the two complementary conditional KO lines 
suggests that the epileptic and autistic phenotypes of CDKL5 disorder are mediated by 
distinct neural circuits and that loss of CDKL5 in specific cell types may differentially 
disrupt signaling pathways and impair neuronal function.  
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Chapter 1: 
THE PAST, PRESENT, AND FUTURE STATE OF CDKL5 RESEARCH  
 
Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) cause 
CDKL5 disorder, an infantile epileptic encephalopathy with features of intractable 
seizures, intellectual disability, and autism (Nabbout and Dulac, 2011; Prince and Ring, 
2011; Sakai et al., 2011).  Historically, CDKL5 disorder has been classified as a variant 
form of Rett Syndrome (RTT) and consequently, early mechanistic studies were limited 
to establishing a common pathway linking CDKL5 to MeCP2, the methyl-CpG binding 
protein underlying RTT (Amir et al., 1999; Bertani et al., 2006; Mari et al., 2005; Rusconi 
et al., 2008; Tao et al., 2004; Weaving et al., 2004).  Emergent clarity in the CDKL5 
clinical profile and evidence from recent studies in mouse models, however, have 
suggested that CDKL5 disorder is a early-onset epileptic encephalopathy that is distinct 
from Rett Syndrome (Bahi-Buisson et al., 2008b; Fehr et al., 2012) and that its disease 
mechanism is independent of MeCP2 (Amendola et al., 2014; Chen et al., 2010; Fuchs 
et al., 2014; Lin et al., 2005; Ricciardi et al., 2012; Wang et al., 2012; Zhu et al., 2013).  
This chapter aims to introduce the history of CDKL5 disorder and describe the current 
understanding of CDKL5 disorder, including CDKL5 clinical disease profile, animal 
models, and cellular functions.  It will conclude with a discussion of how these findings 
have shaped the future challenges for the field. 
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CDKL5 History 
The first report of CDKL5 disorder is credited to Dr. Folker Hanefeld in 1985, who 
described a patient presenting initially with infantile spasms and later developing 
symptoms consistent with Rett Syndrome (Hanefeld, 1985), although a CDKL5 mutation 
in this patient was never confirmed.  When CDKL5 was initially cloned, it was named 
STK9 (serine-threonine kinase 9), and its proximity to genes related to X-linked 
retinoschisis and Nance Horan Syndrome suggested that it may be a disease-related 
locus (Montini et al., 1998).  It was not until 2003, however, that a link between CDKL5 
mutation and disease was described, in a report of infantile spasms and mental 
retardation in two patients with balanced autosomal translocations commonly disrupting 
CDKL5 (Kalscheuer et al., 2003).  In the following year, two independent studies 
reported that mutations in CDKL5 are common to the early-onset seizure variant of RTT 
(Tao et al., 2004; Weaving et al., 2004).  Subsequently, cohorts of atypical RTT patients 
were screened for CDKL5 mutations (Evans et al., 2005; Mari et al., 2005; Scala et al., 
2005).  Although RTT and CDKL5 share several clinical features, it is likely that this early 
link between CDKL5 disorder and RTT has biased CDKL5 diagnosis and biochemical 
research (discussed below).  In the recent years, a broader understanding of the 
features of CDKL5 patients has revealed that the clinical profile of CDKL5 disorder is 
distinct from that of Rett Syndrome (Bahi-Buisson et al., 2008b; Guerrini and Parrini, 
2012) and therefore, CDKL5 disorder should be classified as a distinct early-onset 
epileptic encephalopathy (Fehr et al., 2012).   
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CDKL5 clinical profile 
Concomitant with the emergence of clarity in CDKL5 disorder as an epileptic 
encephalopathy is a steady increase in rate of CDKL5 diagnoses each year, likely due to 
increased awareness of the disorder.  Indeed, the frequency of CDKL5 mutations in 
epileptic or autistic cohorts is notably high (Archer et al., 2006; Bahi-Buisson et al., 
2008a; Nemos et al., 2009; White et al., 2010), suggesting that the disorder may be 
more prominent than currently understood, and confirms that CDKL5 disorder is not 
limited to RTT or atypical RTT populations.  To date, less than 200 individuals with 
CDKL5 mutations have been described, hampering the formation of a strong genotype-
phenotype correlation.  Publications from larger cohorts of CDKL5 patients, however, 
have described common phenotypes and a generalized clinical course for CDKL5 
patients. 
	  
	  
Distinction from Rett Syndrome 
The diagnosis of the early-onset seizure, or Hanefeld, variant of Rett Syndrome requires 
the fulfillment of a subset of the following main RTT criteria: partial or complete loss of 
acquired purposeful hand skills and spoken language, gait abnormalities, and 
stereotypic hand movements, as well as a subset of the following supportive RTT 
criteria: breathing disturbances, bruxism, impaired sleep pattern, abnormal muscle tone, 
peripheral vasomotor disturbances, scoliosis, growth retardation, small cold hands and 
feet, inappropriate laughing/screaming spells, diminished response to pain, and intense 
eye gaze (Artuso et al., 2010; Neul et al., 2010).  In addition, patients must demonstrate 
a period of regression followed by recovery or stabilization.  The majority of CDKL5 
patients, however, lack the clear period of regression and intense eye gaze, suggesting 
a departure from the Rett Syndrome clinical course (Bahi-Buisson et al., 2008b; Guerrini 
and Parrini, 2012).  Indeed, a recent study of 86 CDKL5 patients found that less than 
25% of the cohort fulfilled the diagnostic criteria for the early seizure variant of Rett 
Syndrome (Fehr et al., 2012). 
 
Both the CDKL5 seizure phenotype and the percentage of CDKL5 patients with drug-
resistant seizures are dramatically different from that of RTT (Pintaudi et al., 2008).  In 
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RTT, seizures manifest in adolescence, usually decrease in severity after teenage years, 
and are amenable to therapies, whereas CDKL5 patients develop seizures that are 
largely intractable within the first few months after birth (Pintaudi et al., 2008).  In 
addition, breathing disturbances and autonomic dysfunction, while reported in CDKL5 
disorder, are much less prevalent than in classical RTT (Fehr et al., 2012; Hagebeuk et 
al., 2013; Pini et al., 2013), and the percentage of males with CDKL5 disorder is much 
higher than that of RTT (discussed below) (Mei et al., 2014; Mirzaa et al., 2013).  
Together, these data support CDKL5 disorder as an independent early-onset seizure 
disorder that is distinct from Rett Syndrome (Fehr et al., 2012).  
 
 
Features of CDKL5 disorder 
The key clinical features that identify CDKL5 patients are early onset seizures that 
develop into intractable epilepsy and result in severe intellectual disability (Archer et al., 
2006; Artuso et al., 2010; Bahi-Buisson et al., 2008a; 2008b; 2010; 2012; Bartnik et al., 
2011; Bertani et al., 2006; Boutry-Kryza et al., 2014; Castrén et al., 2011; Córdova-
Fletes et al., 2010; Das et al., 2013; Elia et al., 2008; Erez et al., 2009; Ermel et al., 
2013; Evans et al., 2005; Grosso et al., 2007; Guerrini and Parrini, 2012; Hadzsiev et al., 
2011; Hagebeuk et al., 2013; Intusoma et al., 2011; Jähn et al., 2013; Kalscheuer et al., 
2003; Klein et al., 2011; Liang et al., 2011; Maortua et al., 2012; Masliah-Plachon et al., 
2010; Mei et al., 2014; 2010; Melani et al., 2011; Mirzaa et al., 2013; Nectoux et al., 
2006; Nemos et al., 2009; Pini et al., 2013; Psoni et al., 2010; Rademacher et al., 2011; 
Raymond et al., 2013; Rosas-Vargas et al., 2008; Russo et al., 2009; Saitsu et al., 2012; 
Sartori et al., 2009; Scala et al., 2005; Sprovieri et al., 2009; Stalpers et al., 2011; Tao et 
al., 2004; Van Esch et al., 2007; Veeramah et al., 2013; Weaving et al., 2004; White et 
al., 2010; Willemsen et al., 2012; Wong and Kwong, 2014; Zhao et al., 2014).  The 
majority of CDKL5 patients also show poor acquisition of language, hypotonia, and 
limited hand skills (Bahi-Buisson and Bienvenu, 2012; Bahi-Buisson et al., 2008b).  
Hand stereotypies, aberrant gait, sleep disturbances, and autistic phenotypes, including 
avoidance of eye gaze and reduced social interaction, are common (Bahi-Buisson et al., 
2008b; Fehr et al., 2012) and some breathing abnormalities and autonomic dysfunction 
have been reported.  Although the physical features of CDKL5 patients are fairly 
heterogeneous, subtle dysmorphisms including deep sunken eyes with straight and well-
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defined eyebrows, a prominent or broad forehead, high hairline, and full lips have been 
described (Archer et al., 2006; Fehr et al., 2012).   
 
Approximately 20% of reported cases of CDKL5 disorder are in boys (Elia et al., 2008; 
Liang et al., 2011; Masliah-Plachon et al., 2010; Mei et al., 2014; Mirzaa et al., 2013; 
Wong and Kwong, 2014).  This small percentage may reflect the reduced probability of 
X-chromosome mutations in males relative to females, or it may be the consequence of 
an RTT-biased low ascertainment.  Strikingly, however, this percentage is higher than 
that of boys diagnosed with RTT, suggesting that CDKL5 mutations may be better 
tolerated in males than MECP2 mutations.  Boys with MECP2 mutations rarely show 
RTT-like phenotypes, as they usually develop severe early postnatal encephalopathy 
and die shortly after birth (Kankirawatana et al., 2006).  In contrast, boys with CDKL5 
mutations show a similar (Bahi-Buisson et al., 2008b; Elia et al., 2008; Liang et al., 2011; 
Mei et al., 2010; Nemos et al., 2009), or in some cases, more severe phenotype (Fehr et 
al., 2012; Mirzaa et al., 2013) relative to that of girls.  Whether the CDKL5 clinical course 
is actually more severe in males has yet to be determined, owing the small number of 
CDKL5 patients overall.  Regardless, it is clear that the CDKL5 clinical profile in boys is 
markedly different from that of RTT. 
 
Descriptions of the adult CDKL5 phenotype are similarly limited by the small patient 
population.  A 2011 review comprised of 10 female CDKL5 patients ages 18-47 showed 
intractable seizures and motor impairment in all 10 patients and concluded that adult 
CDKL5 patients show poor developmental and seizure outcome (Willemsen et al., 
2012).  As the prevalence of regression, autonomic disturbances, breathing 
abnormalities, and scoliosis appears to increase with age (Fehr et al., 2012), it is likely 
that the adult CDKL5 clinical profile includes multiple persistent handicaps. 
 
 
Epilepsy 
Epilepsy in CDKL5 patients spans a broad phenotypic range, depending on the severity 
of CDKL5 disorder.  Milder forms involve seizures that are amenable to control with the 
possibility of autonomous walking, whereas severe forms involve intractable seizures 
lasting into adulthood, severe microcephaly, and absence of autonomous motor function 
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(Guerrini and Parrini, 2012; Jähn et al., 2013).  On average, the onset of seizures occurs 
within 2 months after birth, and the majority of patients experience seizures daily (Fehr 
et al., 2012).  Some patients experience seizures weekly or monthly, and a small 
number of patients report having seizures on a frequency of once a year or less.  
 
Seizure types vary across individuals, and include infantile spasms (Weaving et al., 
2004), brief subtle seizures evolving into choking or breath-holding (Archer et al., 2006), 
and partial and multifocal seizures, with tonic, myoclonic, atonic, and generalized tonic-
clonic features (Mirzaa et al., 2013).  The majority of MRIs are normal in CDKL5 
patients, with scattered reports of white matter hyperintensities in temporal poles and 
dentate nuclei, as well as cerebellar atrophy (Bahi-Buisson et al., 2008b), and some 
reports of frontal lobe cerebral atrophies (Liang et al., 2011).   
 
A spectrum of EEG patterns has been described, with some reports of hysparrythmia 
(Jähn et al., 2013), multifocal paroxysmal activity (Grosso et al., 2007), multifocal bursts 
of polyspike activity (Mirzaa et al., 2013), slow background, and continuous 
bihemispheric epileptiform discharges (Moseley et al., 2012).  Despite this broad 
heterogeneity, some distinctive CDKL5 EEG patterns have been described.  One study 
has proposed that the first year of CDKL5-related epilepsy may be characterized by a 
“prolonged generalized tonic-clonic” electroclinical pattern.  In this pattern, seizures 
progress from tonic-tonic/vibratory contraction to clonus to spasms and gradually to 
rhythmic distal myoclonic jerks (Melani et al., 2011).  Although this motor sequence is 
not associated with a specific EEG pattern, its relevance toward clinical diagnosis of 
CDKL5 disorder in infants has been suggested (Arts, 2011). 
 
A distinctive seizure type in adolescents involving a hypermotor-tonic-spasms sequence 
characterized by distinct motor and EEG patterns has also been identified (Klein et al., 
2011).  The hypermotor phase, lasting 10-60 seconds, consists of rocking, kicking, 
and/or vocalization with delta waves; the tonic phase, lasting 20-45 seconds, consists of 
extension of all limbs with fast EEG; and the spasms phase, lasting 1-15 minutes, 
consists of extensor spasms with high voltage sharp complexes.   
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Another distinctive seizure pattern that has been described is a “three-stage epilepsy” 
(Bahi-Buisson et al., 2008a).  The first stage, classified as “early epilepsy,” manifests as 
generalized convulsive seizures in a neurologically delayed baby with poor eye contact 
and axial hypotonia.  The second stage, classified as “epileptic encephalopathy,” 
includes a “honeymoon” seizure-free period, developmental arrest, epileptic 
encephalopathy with infantile spasms, and hypsarrhythmia.  The last stage, classified as 
“late multifocal and myoclonic epilepsy,” differs according to patient outcome, 
manifesting as fewer seizures and occurrence of physiological EEG features in patients 
with a favorable outcome, and refractory epilepsy with tonic seizure and myoclonia in 
patients with an unfavorable outcome.  How accurately these seizure patterns describe 
the general CDKL5 population, however, will require more case reports, as they were 
identified in cohorts of 5 (Klein et al., 2011) and 12 patients (Bahi-Buisson et al., 2008a), 
respectively.  
 
 
Neuropathology 
Neuropathological data has been limited to a single study to date, a female with an exon 
16 splice site mutation who was diagnosed with infantile spasms and atypical Rett 
Syndrome (Paine et al., 2012).  Post-mortem histological examination showed significant 
abnormalities only in the central nervous system, particularly flatted occipital lobes and 
enlarged lateral and 3rd ventricles.  The majority of pathological findings were in the 
cerebellum, where heterotopias in vermis white matter and gliosis in the Purkinje cell 
layer were identified.  Degeneration was evident in the cerebellum and vermis, but 
whether this was a consequence of disease progression or seizure treatment was 
unknown.  More neuropathological data is required to determine how generalizable 
these findings will be to the CDKL5 patient population.  Of particular interest would be 
descriptions of neuronal migration and outgrowth in CDKL5 patients, as both are altered 
in CDKL5 mouse studies (Amendola et al., 2014; Chen et al., 2010; Ricciardi et al., 
2012).  The authors of this neuropathological study did not report any such findings 
(Paine et al., 2012), but it is unclear whether these phenotypes were investigated in 
detail. 
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Treatments 
CDKL5 seizures are largely intractable and current treatments target symptom 
management, rather than disease mechanism (Bahi-Buisson and Bienvenu, 2012).  The 
majority of prescribed therapeutics aim to reduce seizure frequency, but are largely 
ineffective (Bahi-Buisson and Bienvenu, 2012).  Common anti-epileptic drugs include 
topiramate, valproate, and vigabatrin, and in some patients, a ketogenic diet and vagus 
nerve stimulators have demonstrated some efficacy (Evans et al., 2005; Moseley et al., 
2012; Tao et al., 2004).  The current limited understanding of the biological function of 
CDKL5 and of the mechanisms underlying disease pathogenesis has impeded the 
development of targeted therapeutics.  Therefore, the identification of signaling 
pathways and proteins regulated by CDKL5 as well as the cell types and neural circuits 
in which CDKL5 functions is key to advancement in the treatment of CDKL5 disorder. 
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CDKL5 genetics 
CDKL5 mutations 
CDKL5 translocations, deletions, insertions, and missense mutations have been linked 
to disease (Bahi-Buisson and Bienvenu, 2012), and more than half of CDKL5 patient 
mutations are located within the highly conserved kinase domain, suggesting that many 
CDKL5 mutations disrupt kinase function.  Due to the small number of CDKL5 patients 
to date and the mosaic expression of CDKL5 in females, a strong genotype-phenotype 
correlation has yet to be formed.  Mutations in the N-terminal kinase domain, however, 
have been proposed to be more severe than mutations in the C-terminus (Bahi-Buisson 
et al., 2012).  Furthermore, the pathogenicity of mutations in exons 22-23 has been 
questioned, as several CDKL5 patient mutations in these regions have also been 
identified in healthy siblings or parents (Diebold et al., 2013).  Because these exons are 
not conserved in lower organisms, including rodents, mutations in this region of the C-
terminus have been proposed to be normal genetic variations or polymorphisms.   
 
A small number of recurrent CDKL5 mutations have been identified, but they do not 
appear to cluster within a specific region of the gene (Mastrangelo and Leuzzi, 2012).  In 
addition, clinical phenotypes among patients with recurrent mutations are 
heterogeneous.  For example, patients with the most common recurrent mutation, the 
A40V missense mutation, range from having severe epileptic encephalopathy to mild 
RTT-like phenotypes (Bahi-Buisson et al., 2012; Nemos et al., 2009).   
 
Other mutation types, including somatic mosacism and gene duplications, have been 
reported in both boys and girls with CDKL5 disorder, suggesting that CDKL5 protein 
levels are also relevant to disease.  Patients with somatic mosaic CDKL5 mutations 
display early-onset seizures (Bartnik et al., 2011; Boutry-Kryza et al., 2014; Masliah-
Plachon et al., 2010; Mei et al., 2014) whereas CDKL5 duplications have been 
associated with autism and intellectual disability, but not epilepsy (Froyen et al., 2007; 
Szafranski et al., 2014; Thorson et al., 2010).  CDKL5 dosage regulation has also been 
implicated in studies of balanced chromosomal abnormalities (BCAs) (Talkowski et al., 
2012), where CDKL5 has been identified as a BCA hotspot, and both deletion and 
duplication of CDKL5 are associated with autism spectrum disorder. 
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Reports of skewed X-chromosome inactivation in CDKL5 patients are rare, but because 
X-chromosome inactivation is measured from peripheral blood samples, it is difficult to 
determine whether the same ratio is found in the brain.  Skewed X-chromosome 
inactivation has been proposed to explain the cases of more severe CDKL5 patients or 
differing phenotypes in monozygotic twins or family members sharing the same mutation 
(Bahi-Buisson et al., 2008a; 2008b; Kalscheuer et al., 2003; Mirzaa et al., 2013; 
Weaving et al., 2004).  Conversely, it is believed that skewed X-chromosome 
inactivation can be protective, particularly in the cases of CDKL5 mutations that are 
present in both affected proband and unaffected family members (Szafranski et al., 
2014; Wong and Kwong, 2014). 
 
 
CDKL5 isoforms 
The CDKL5 gene (OMIM 300203), located in the Xp22.13 region, was originally cloned 
in a transcriptional mapping experiment in 1998.  It was initially named serine-threonine 
kinase 9 (STK9), due to its homology to the catalytic domain of other serine-threonine 
kinases (Montini et al., 1998).  It later became more commonly known as cyclin-
dependent kinase-like 5 (CDKL5), due to the homology of its kinase domain to other 
cyclin-dependent kinases.  
 
The CDKL5 gene spans ~240kb and encodes 23 exons.  The first three exons are 
noncoding (exon 1, 1a, and 1b), and the remaining 20 exons encode a 1030 amino acid 
protein product (Kalscheuer et al., 2003).  The full-length CDKL5 protein is translated 
from two RNA isoforms, which differ in their 5’ UTR but produce the same 115 kDa 
protein.  CDKL5 isoform I contains exon 1 and is expressed in a wide range of tissues 
and cell lines, whereas CDKL5 isoform II contains exons 1a and 1b and is expressed 
only in the testis and fetal brain tissue (Kalscheuer et al., 2003). 
 
In the recent years, other isoforms of CDKL5 and an additional coding exon have been 
identified.  In 2011, a 123-bp interval between exons 16 and 17 with conserved 
sequence homology across multiple species was identified in two independent studies 
(Fichou et al., 2011; Rademacher et al., 2011).  The novel exon, referred to as exon 16a 
or16b, is expected to encode a 41-aa product, thus producing a 1071-aa full-length 
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CDKL5 protein.  Although the variant transcript was unable to be detected by in situ 
hybridization or Northern blot, quantitative RT-PCR showed low levels of transcript in the 
brains of adult mice, suggesting that this variant, if in existence, has a brain-specific 
function. 
 
A truncated CDKL5 isoform terminating in intron 18 has also been identified and is 
predicted to encode a 107 kDa protein (Williamson et al., 2011).  RT-PCR data indicates 
that the transcript encoding the 115 kDa protein is expressed primarily in the testis, 
whereas the novel transcript encoding the 107 kDa protein product is the predominant 
transcript in the brain.  This expression pattern, however, has yet to be demonstrated at 
the protein level, and the in vivo relevance of the brain-specific truncated CDKL5 isoform 
remains unclear. 
	  
	   	  
12	  
	  
Animal models of CDKL5 disorder 
Despite the strong clinical data supporting a link between mutations in CDKL5 and 
neurodevelopmental disorder, the monogenic etiology underlying CDKL5 disorder was 
not established until the development and characterization of the first knockout mouse 
model in 2012 (Chapter 2) (Wang et al., 2012).  In this study, we generated a mouse 
model recapitulating a CDKL5 patient mutation and identified clinically relevant 
behavioral phenotypes, impaired sensory information processing, and disruptions in 
multiple signaling pathways. 
 
Specifically, we modeled our mice after a patient splice site mutation that leads to a 
premature stop codon in exon 8 (Archer et al., 2006).  In order to mimic the effects of 
this mutation in mice, we deleted the homologous mouse Cdkl5 exon 6, leading to an 
early truncation of CDKL5 in its N-terminal kinase domain, thereby disrupting kinase 
activity.  Importantly, in CDKL5 knockout (KO) animals, truncated or full-length CDKL5 
cannot be detected by Western blot using antibodies directed against CDKL5 N- or C-
terminal domains, and Cdkl5 transcript levels are dramatically reduced, likely due to 
nonsense-mediated mRNA decay (Wang et al., 2012). 
 
Given the clinical relevance of CDKL5 disorders in males and the confounding effects of 
mosaic CDKL5 expression from X-chromosome inactivation in females, we necessarily 
constrained our study to male CDKL5 knockout mice (Wang et al., 2012).  CDKL5 KO 
mice are viable and fertile, and we observed no gross anatomical or developmental 
abnormalities.  Behavioral characterization, however, showed that CDKL5 KO mice 
mirror multiple symptoms associated with CDKL5 disorder, including impaired motor 
control on the rotarod, deficits in learning and memory on a fear conditioning assay, and 
hindlimb and forelimb clasping, a phenotype believed to mimic patient hand wringing.  
CDKL5 KO animals also demonstrate autistic-like deficits in sociability on a three-
chambered social approach assay and in home-cage nesting behavior.  Given the 
prominence of motor impairment, intellectual disability, and autism in CDKL5 disorder, 
these data support face validity in our CDKL5 KO mouse and established, for the first 
time, a causal relationship between Cdkl5 mutation and disease phenotypes using a 
genetic mouse model. 
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Recently, a similar CDKL5 mouse model, a Cdkl5 exon 4 deletion, was developed and 
characterized (Amendola et al., 2014).  Importantly, these mice showed deficits in the 
Akt-S6 and Akt-GSK3b signaling pathways (Amendola et al., 2014; Fuchs et al., 2014), 
supporting a convergent deficit in downstream PTEN signaling (Wang et al., 2012).  In 
addition, these mice demonstrate many phenotypes that are consistent with our mouse 
model, including hindlimb clasping, impaired working memory, and deficits in visual-
evoked ERPs. 
 
Deficits in neuronal outgrowth and postmitotic cell proliferation were identified in these 
KO mice.  BrdU labeling of postmitotic dentate granule cells showed a transient increase 
in proliferation in CDKL5 KO mice relative to that of WT (Fuchs et al., 2014).  These 
cells, however, were later preferentially targeted for apoptotic cell death and showed 
dendritic hypotrophy, resulting in a net reduction in the total number and growth of 
newborn dentate neurons in CDKL5 KO mice.  No effect was found on gliogenesis, 
indicating that CDKL5 regulation is specific to neurons.  In addition, neuronal tracing of 
GFP-labeled cells in adult CDKL5 KO mice showed reduction in dendritic length of both 
cortical layer 5 and hippocampal pyramidal neurons, accompanied by reduced cortical 
and hippocampal thickness (Amendola et al., 2014).  Whether CDKL5 regulates 
neuronal outgrowth in a cell autonomous manner has yet to be determined.  Moreover, 
the role of CDKL5 in adult neurogenesis, and its relation to the role of CDKL5 during 
neuronal development remains unknown. 
 
Surprisingly, despite extensive video-EEG monitoring, neither CDKL5 KO mouse model 
developed spontaneous seizures or reduced seizure threshold in both C57BL/6 and 
DBA/2J genetic backgrounds (Amendola et al., 2014; Wang et al., 2012).  Although 
CDKL5 KO mice showed altered EEG patterns following seizure induction (Amendola et 
al., 2014), the absence of this key phenotype has raised questions concerning the 
differences between human and mouse and challenged the usefulness of the 
constitutive KO mouse model.  Therefore, the development of additional CDKL5 mouse 
models that recapitulate the seizure phenotype will be necessary to understand 
mechanisms underlying CDKL5 seizures. 
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What the two CDKL5 KO models do reveal, however, is that even in mice, CDKL5 
disorder has a distinct disease profile from that of Rett Syndrome.  Although disruptions 
in ERPs and Akt-mTOR signaling have been identified in both RTT and CDKL5 mouse 
models (Goffin et al., 2012; Ricciardi et al., 2011; Wang et al., 2012), these 
commonalities may reflect convergence in ASD genetics and molecular pathology (Bill 
and Geschwind, 2009; Geschwind, 2011; Voineagu et al., 2011) that are mediated by 
distinct cellular mechanisms, which will be discussed in the next section.  
 
In addition to animal models, recent advances in the development of induced pluripotent 
stem cells (IPSCs) derived from human fibroblasts that can be differentiated into distinct 
cell types have introduced a new tool in which cellular function and gene regulation can 
be studied in a disease setting (Takahashi et al., 2007).  IPSCs derived from CDKL5 
patients show increased filipodial-type spines and reduced number of synaptic puncta, 
but fail to recapitulate the deficit in neuronal outgrowth identified in mouse models 
(Ricciardi et al., 2012).  In a separate study, a small number of genes with altered 
expression have been identified in CDKL5 iPSCs, including the orphan glutamate 
receptor GRID1, but the functional relevance of these findings has yet to be determined 
(Livide et al., 2014).  Overall, data from patient-derived IPSCs will be very beneficial for 
CDKL5 research, but the significance of these findings will require more integration in 
animal model studies. 
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CDKL5 protein 
Expression pattern 
Although several laboratories have characterized the time course of CDKL5 expression, 
these studies have often yielded inconsistent results, even when using similar 
experimental techniques.  RNA in situ hybridization experiments were unable to detect 
embryonic Cdkl5 expression in one study (Montini et al., 1998), but detected weak 
expression late embryonically in a separate study (Mari et al., 2005).  Immunostaining of 
whole embryos showed broad CDKL5 expression in early embryogenesis in one study 
(Lin et al., 2005), whereas in a separate study, immunostaining of E16.5 slices showed 
minimal CDKL5 expression (Rusconi et al., 2008).  Western blot data has been similarly 
conflicted, showing onset of CDKL5 expression late embryonically (Chen et al., 2010) or 
postnatally (Rusconi et al., 2008; Zhu et al., 2013) in different studies. 
 
Similar to that of the CDKL5 time course, data supporting CDKL5 expression levels in 
organs including the heart, liver, spleen and lungs remains inconsistent (Chen et al., 
2010; Lin et al., 2005).  Multiple studies show consistently that CDKL5 is highly 
expressed in the brain.  Within the brain, however, some in situ hybridization studies 
show Cdkl5 enrichment throughout the brain (Chen et al., 2010; Mari et al., 2005; 
Weaving et al., 2004), while other in situ data show Cdkl5 enrichment specifically in the 
forebrain (Thompson et al., 2014).  The forebrain-specific enrichment is supported by 
Western blot data from our lab and others (Rusconi et al., 2008; Wang et al., 2012).  
Immunostaining of primary cultures indicates that CDKL5 is expressed in glutamatergic 
and GABAergic neurons, but not in glial cells (Rusconi et al., 2008; 2011), whereas a 
separate study has found a distinct CDKL5 isoform that is expressed in glia (Chen et al., 
2010). 
 
Early in vitro studies localized CDKL5 exclusively to the cell nucleus (Bertani et al., 
2006; Lin et al., 2005).  Later studies proposed that CDKL5 mislocalizes to the 
cytoplasm in disease (Bertani et al., 2006; Rosas-Vargas et al., 2008), is shuttled into 
the cytoplasm upon glutamate stimulation in excitatory cells (Rusconi et al., 2011), or is 
expressed in the cytoplasm in certain brain regions (Rusconi et al., 2008).  Upon 
fractionation of nuclear and cytoplasmic proteins from the brains of WT mice followed by 
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Western blots, however, we and others have found that endogenous CDKL5 under basal 
conditions exists primarily in the cytoplasm, and not in the nucleus (Chen et al., 2010; 
Wang et al., 2012).   
 
The inconsistencies related to the time course and distribution of CDKL5 may be 
partially attributed to differences in experimental methods and ineffective reagents.  
Indeed, immunostaining of both WT and CDKL5 KO brain tissue using commercially 
available and in-house generated CDKL5 antibodies yield a similar staining pattern, and 
Western blots of WT and CDKL5 brain lysate probed with these antibodies yields several 
non-specific bands (Wang et al., 2012).  Due to the persistent bias in early CDKL5 
research toward establishing a mechanistic link between CDKL5 and MeCP2, CDKL5 
expression patterns were believed to mimic that of MeCP2, both within the cell and 
across brain development (Bertani et al., 2006; Lin et al., 2005; Mari et al., 2005).  
Recent compelling evidence from animal models across different laboratories, however, 
consistently show that the CDKL5 expression pattern is distinct from that of MeCP2, and 
that CDKL5 is expressed postnatally and mainly or exclusively in the cytoplasm (Chen et 
al., 2010; Ricciardi et al., 2012; Wang et al., 2012), an expression pattern that supports 
the current understanding of CDKL5 disorder as an independent epileptic 
encephalopathy with a distinct disease mechanism. 
 
 
Function 
Whereas data supporting CDKL5 time course and expression pattern is merely 
inconsistent, data supporting CDKL5 function is contentious.  Several postulated 
mechanisms, some of which stem from the same experimental methods, are in direct 
opposition, including the role of CDKL5 in phosphorylation of MeCP2 (Lin et al., 2005; 
Mari et al., 2005), in regulation of neuronal outgrowth (Amendola et al., 2014; Chen et 
al., 2010; Fuchs et al., 2014; Ricciardi et al., 2012) and in dendritic spine development 
(Ricciardi et al., 2012; Zhu et al., 2013). 
 
The first of these, the role of CDKL5 in the phosphorylation of MeCP2, is likely a 
consequence of the aforementioned Rett Syndrome bias in the early years of CDKL5 
research.  The phenotypic similarities between RTT and CDKL5 patients and the 
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discovery that MeCP2 is regulated by phosphorylation (Chen et al., 2003; Zhou et al., 
2006), suggested that the two disorders may share a common pathway, wherein the 
putative kinase CDKL5 phosphorylates MeCP2.  To this end, in vitro studies showed that 
overexpressed CDKL5 localizes to the nucleus (Lin et al., 2005) and that CDKL5 
interacts with and phosphorylates MeCP2 (Mari et al., 2005).  Subsequent studies, 
however, have challenged this hypothesis, and showed that CDKL5 phosphorylation of 
MeCP2 is indirect or nonspecific (Lin et al., 2005) and that CDKL5 does not localize with 
MeCP2-enriched heterochromatic foci (Ricciardi et al., 2009).  
 
In addition to the contentious link to MeCP2 phosphorylation, the early belief that CDKL5 
localizes exclusively to the nucleus led to other proposed nuclear functions identified in 
vitro, including phosphorylation of DNA methyl-transferase 1 (Dnmt1) (Kameshita et al., 
2008) and regulation of RNA splicing factor-enriched nuclear speckles (Ricciardi et al., 
2009).  The in vivo relevance of these functions, however, has yet to be determined or 
confirmed. 
 
As CDKL5 expression is now largely believed to be primarily cytoplasmic, research 
focus has shifted toward its particular function in excitatory neurons.  This shift began in 
2010, when shRNA-mediated knockdown of Cdkl5 in primary neuronal cultures was 
shown to reduce neuronal outgrowth (Chen et al., 2010).  In utero electroporation of the 
same shRNA construct not only reduced neuronal outgrowth in vivo, but also delayed 
neuronal migration.  These authors showed evidence that cytoplasmic CDKL5 may 
regulate neuronal outgrowth and migration by complexing with Rac1, a known regulator 
of actin dynamics and neuronal morphology, thereby mediating Bdnf-dependent Rac1 
signaling. 
 
A separate study using the same method of in utero electroporation of an shRNA 
construct targeting Cdkl5, however, has challenged the role of CDKL5 in dendritic 
outgrowth.  These authors were able to replicate delayed neuronal migration but not 
reduced dendritic outgrowth upon CDKL5 knockdown (Ricciardi et al., 2012).  Instead of 
a dendritic phenotype, these authors found a spine development phenotype, where 
CDKL5 knockdown increases the density and length of dendritic spines.  In primary 
hippocampal cultures, CDKL5 knockdown also increased density of spines but reduced 
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the number of excitatory synapses and both amplitude and frequency of mEPSCs, 
pointing to a role for CDKL5 in spine maturation.  Furthermore, immunostaining data 
showed that CDKL5 is localized exclusively to excitatory synapses and not to inhibitory 
synapses, indicating that loss of CDKL5 impairs excitatory synapse development and 
results in the formation of more immature-type dendritic spines.  These authors showed 
evidence supporting a mechanism by which CDKL5 directly phosphorylates NGL-1, a 
netrin-G1 receptor that regulates early synapse formation and maturation, and thus 
promotes an NGL-1—PSD95 interaction in order to stabilize dendritic spines (Ricciardi 
et al., 2012). 
 
The mechanism by which CDKL5 localizes to dendritic spines, however, has also been 
challenged, as a recent study has shown that CDKL5 binds directly to palmitoylated 
PSD95, that this binding is independent of CDKL5 kinase function, and that it is the 
CDKL5-PSD95 direct interaction that recruits CDKL5 to excitatory spines (Zhu et al., 
2013).  Moreover, while the authors of this study used the same method of shRNA-
mediated knockdown of Cdkl5 and were able to replicate the decrease in excitatory 
synapse number and reduction in mEPSC amplitude and frequency identified by 
Ricciardi and colleagues (Ricciardi et al., 2012), they found a decrease, rather than an 
increase in spine density and width, and suggested a disease mechanism by which loss 
of CDKL5 inhibits both spine formation and growth (Zhu et al., 2013). 
 
Overall, the shift in research focus from a nuclear role for CDKL5 that is relevant to 
MeCP2 and Rett Syndrome to a cytoplasmic role in regulation of neuronal development 
and migration represents great progress in understanding the biological function of 
CDKL5 and its disease mechanisms.  Several uncertainties remain, including how 
CDKL5 is recruited to excitatory synapses and how neuronal outgrowth is affected upon 
Cdkl5 loss-of-function.  In addition, the mechanistic relevance or in vivo significance of 
other putative cytoplasmic functions, including phosphorylation of amphiphysin (Amph1) 
(Sekiguchi et al., 2013), which is proposed to regulate the Amph1-endophlin interaction 
and affect clatherin-mediated endocytosis, has yet to be determined. 
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CDKL5-related signaling pathways and neuronal circuits 
Given the contentious data supporting CDKL5 kinase substrates, we took an unbiased 
approach to screen for signaling pathways disrupted in CDKL5 KO mice (Wang et al., 
2012).  Through a kinome profiling assay, we identified a large number of disruptions in 
signaling pathways, including the Akt-mTOR pathway, that were specific to the forebrain 
regions in which CDKL5 is enriched and minimal in the hindbrain regions of low CDKL5 
expression.  In addition, we observed that many of the identified pathways converge into 
downstream PTEN signaling, a pathway that has been implicated in both autism and 
epilepsy (Zhou and Parada, 2012), suggesting that PTEN downstream signaling 
pathways may be candidate therapeutic targets with in vivo relevance. 
 
We also performed neurophysiological recordings in WT and CDKL5 KO mice and found 
that behavioral phenotypes demonstrated by CDKL5 KO mice may be mediated by 
deficits in neural circuit communication (Wang et al., 2012).  Delayed and attenuated 
polarity peaks in auditory-evoked event-related potential (ERP) waveforms of CDKL5 KO 
mice revealed impairments in the strength and timing of cognitive processing in these 
mice (Roberts et al., 2010; Stauder et al., 2006).  In addition, reduced oscillatory 
strength in event-related low-frequency neuronal oscillations in CDKL5 KO mice indicate 
ASD-like impairments in long-range circuit communication (Dawson et al., 1995; 
Stroganova et al., 2007).  Together, these data support a disease mechanism by which 
Cdkl5 loss-of-function disrupts multiple signaling pathways, leading to dysregulation of 
neuronal circuits and behavioral impairments.  Figure studies will aim to dissect the 
particular signaling pathways and neural circuits in which CDKL5 plays a role. 
 
 
Regulation of CDKL5  
How CDKL5 itself is regulated is poorly understood and has been investigated across 
scattered studies.  Reports include CDKL5 regulation by the oncogene MYCN (Valli et 
al., 2012), DNA methylation, or MeCP2 binding (Carouge et al., 2010).  CDKL5 also may 
be regulated by cell death pathways, as both sustained glutamate activation of 
extrasynaptic NMDA receptors and hydrogen peroxide promote CDKL5 proteosomal 
degradation (Rusconi et al., 2011).	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Future directions 
Despite the advancements made in the CDKL5 field within the past 15 years, including 
cloning the CDKL5 gene, establishing the link between CDKL5 mutation and disease, 
generating CDKL5 animal models with face validity, and gaining insight into putative 
mechanisms underlying CDKL5 function and dysfunction, a number of questions still 
remain.   
 
Classification of CDKL5 disorder has evolved from Infantile Spasms to Atypical Rett 
Syndrome, and finally to Epileptic Encephalopathy.  To date, about 200 patients have 
been diagnosed with CDKL5 disorder, but whether this low prevalence is an accurate 
reflection of the global pervasiveness of CDKL5 disorder has yet to be determined.  
Certainly, the early Rett Syndrome bias has resulted in consideration of CDKL5 disorder 
mainly in RTT patient cohorts (Das et al., 2013; Evans et al., 2005; Hadzsiev et al., 
2011; Huppke et al., 2005; Li et al., 2007; 2009; Maortua et al., 2012; Rademacher et al., 
2011; Rajaei et al., 2011; Scala et al., 2005; Tao et al., 2004; Weaving et al., 2004; 
White et al., 2010).  How significantly this bias has limited CDKL5 diagnosis will be 
determined in the upcoming years, as genetic testing for CDKL5 disorder becomes more 
efficient and expands to epileptic and autistic patient populations (Archer et al., 2006; 
Bahi-Buisson et al., 2010; Bartnik et al., 2011; Elia et al., 2008; Erez et al., 2009; Fehr et 
al., 2012; Intusoma et al., 2011; Liang et al., 2011; Mei et al., 2010; 2014; Mirzaa et al., 
2013; Nectoux et al., 2011; Nemos et al., 2009; Psoni et al., 2010; Saitsu et al., 2012; 
Veeramah et al., 2013). 
 
The severity of CDKL5 disorder in boys with CDKL5 mutations remains unclear.  It 
seems likely that the RTT bias has given rise to low male patient ascertainment, and 
perhaps selected for male CDKL5 patients with particular phenotypes.  Therefore, how 
the CDKL5 disease profile differs between males and females and whether the disease 
is actually less prevalent in males than in females will require more detailed analysis of 
male CDKL5 patients in the future.  Similarly, the establishment of a general CDKL5 
genotype-phenotype correlation, as well as a characteristic EEG/seizure pattern, will 
require more patient data. 
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Neuropathological studies in post-mortem CDKL5 tissue will be useful in the future, not 
only to identify sites of disease pathogenesis and discover new diagnostic targets, but 
also to corroborate findings from animal studies.  Currently, whether neuronal migration 
or morphology is impaired in CDKL5 patients has yet to be investigated.  Given that 
developmental abnormalities have been reported by multiple groups (Amendola et al., 
2014; Chen et al., 2010; Fuchs et al., 2014; Ricciardi et al., 2012; Zhu et al., 2013), 
establishing whether this phenotype is clinically relevant will prioritize future studies in 
this direction. 
 
The development of CDKL5 animal models has not only revealed the role of CDKL5 in 
neuronal development, but also established a causal relationship between mutations in 
Cdkl5 and disease etiology.  Mice lacking CDKL5 mirror a number of clinical 
phenotypes, including impaired motor control, reduced learning and memory, and 
autistic-like behaviors (Amendola et al., 2014; Fuchs et al., 2014; Wang et al., 2012).  
Surprisingly, however, these mice do not develop spontaneous seizures, nor do they 
show a reduction in seizure threshold (Amendola et al., 2014; Wang et al., 2012).  Given 
the severity and relevance of seizures in CDKL5 patients, the absence of the seizure 
phenotype challenges the usefulness of the constitutive CDKL5 KO mouse model and 
necessitates the development of a CDKL5 animal model that can faithfully recapitulate 
spontaneous seizures and subsequently be used to investigate seizure-related disease 
pathogenesis. 
 
One CDKL5 mouse model with great potential to investigate disease pathogenesis is a 
conditional CDKL5 knockout mouse (see Chapter 3).  Recent conditional knockout 
mouse studies have demonstrated that distinct neuronal subpopulations control different 
neural circuits, and that selective perturbation of these circuits can cause discrete 
behavioral phenotypes (Hong et al., 2014; Ozkan et al., 2014), some of which are not 
manifested in the constitutive knockout (Chao et al., 2010; Goffin et al., 2014).  
Therefore, the development of a conditional CDKL5 knockout mouse line may provide 
specific mechanistic insight that otherwise could not be obtained from the constitutive 
knockout mouse. 
 
22	  
	  
An imbalance in neuronal excitation and inhibition has been commonly proposed to 
underlie both ASDs and epilepsy, both of which are prominent in CDKL5 disorder.  
Therefore, it is possible that in CDKL5 patients, a shift in neuronal E/I balance results in 
seizures and autistic behaviors, and that in mice, selective ablation of CDKL5 from 
excitatory or inhibitory neurons would similarly shift E/I balance, producing exaggerated 
behavioral phenotypes that are somehow occluded in the constitutive knockout.  Indeed, 
mice lacking CDKL5 from excitatory neurons show hindlimb clasping, whereas mice 
lacking CDKL5 from GABAergic neurons show homecage hypoactivity (Amendola et al., 
2014), but a comprehensive behavioral assessment of these conditional knockouts has 
yet to be completed (see Chapter 3).  The development and full characterization of 
excitatory or inhibitory CDKL5 conditional knockout mice would be a tremendous asset 
for the CDKL5 research field, not only in providing novel mouse models but also in 
isolating the neuronal circuits and cell types underlying disease pathogenesis. 
 
Excitatory or inhibitory neuron conditional CDKL5 knockout mice will be useful in 
determining whether CDKL5 regulates neuronal development in a cell autonomous 
manner.  Studies in constitutive CDKL5 KO animals suggest that loss of CDKL5 impairs 
excitatory neuron outgrowth (Amendola et al., 2014), but whether this deficit is mediated 
by loss of CDKL5 from the excitatory neurons themselves or the surrounding inhibitory 
neurons has yet to be determined.  In addition, how loss of CDKL5 affects spine 
development in vivo remains unknown, as CDKL5 knockdown studies using the same 
experimental method have resulted in the development of more immature-type spines 
(Ricciardi et al., 2012) or fewer total spines (Zhu et al., 2013).  As loss of Erbb4 from 
inhibitory neurons has been found to reduce spine density of excitatory neurons (Del 
Pino et al., 2013), it is important to determine the in vivo spine phenotype upon loss of 
CDKL5 and to discern the cell types regulating spine development.  Moreover, additional 
studies will need to clarify the molecular mechanism by which CDKL5 localizes to 
dendritic spines, whether is it through direct interaction with PSD95 (Zhu et al., 2013) or 
indirectly through phosphorylation of NGL-1 (Ricciardi et al., 2012).  Increased 
understanding of this mechanism will illuminate whether CDKL5 functions in vivo 
primarily as a kinase or in a kinase-independent role. 
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As a kinase, CDKL5 was believed to phosphorylate MeCP2 (Bertani et al., 2006; Mari et 
al., 2005), but conflicting data (Lin et al., 2005) and mounting evidence toward a 
cytoplasmic role for CDKL5 in neuronal development and synapse maturation (Chen et 
al., 2010; Ricciardi et al., 2012; Zhu et al., 2013) suggests that the CDKL5 biological 
function is independent from MeCP2, and that the phenotypic commonalities between 
the disorders may be due to convergent ASD molecular pathology (Bill and Geschwind, 
2009; Geschwind, 2011; Voineagu et al., 2011).  Indeed, impaired Akt signaling was 
found in 3 independent studies from CDKL5 KO mice, and our kinome profiling data 
revealed disruptions in multiple signaling pathways in CDKL5 KO mice (Amendola et al., 
2014; Fuchs et al., 2014; Wang et al., 2012), although whether these pathway 
disruptions are primary or secondary effects of loss of CDKL5 has yet to be determined.  
Interestingly, the Akt-mTOR, Akt-S6, Akt-GSK3b, and AMPK, and MAPK pathways 
converge into signaling pathways downstream of PTEN, and disruptions in PTEN 
signaling have been described in both autism and epilepsy, (Clipperton-Allen and Page, 
2014; Costa-Mattioli and Monteggia, 2013; Gkogkas et al., 2012; Santini et al., 2013; 
Zhou and Parada, 2012).  These data suggest that CDKL5 may play a role in PTEN 
signaling pathways and that disruption of PTEN signaling may be relevant to CDKL5 
disease pathogenesis.  Future studies pharmacologically or genetically altering the 
PTEN pathway in mice lacking CDKL5, particularly in excitatory or inhibitory CDKL5 
conditional knockouts, should pinpoint the relationship between CDKL5 and PTEN 
signaling and isolate cell type-specific signaling pathways relevant to disease.   
 
Future studies should also aim to determine the relationship between CDKL5 regulation 
of adult neurogenesis and neuronal outgrowth (Fuchs et al., 2014), CDKL5 regulation of 
neuronal migration and outgrowth during brain development (Amendola et al., 2014; 
Chen et al., 2010), and whether the two processes share common mechanisms.  Given 
that Bdnf1-Rac1 signaling has been implicated in the latter (Chen et al., 2010), while 
Akt-GSK3b has been implicated in the former (Fuchs et al., 2014), follow-up studies 
investigating these putative mechanisms in conditional CDKL5 knockouts should reveal 
their in vivo relevance to neuronal development.  Moreover, although two independent 
studies have identified delayed neuronal migration upon CDKL5 knockdown, the 
consequences of this delay and its underlying mechanisms have not been investigated.  
It is possible that delayed excitatory neuron migration would result in aberrant neural 
24	  
	  
circuit connectivity, a phenotype that has been identified in both CDKL5 KO mouse 
models (Amendola et al., 2014; Wang et al., 2012).  Assessing neural circuit function 
and synapse electrophysiology, particularly in conditional knockout mice, may illuminate 
the contribution of individual cell types toward neural circuit function and isolate cell type-
specific mechanisms underlying disease manifestation, particularly how they affect 
neuronal E/I balance.   
 
Ultimately, the development of mouse models that faithfully recapitulate CDKL5 clinical 
phenotypes and utilization of these animals to gain a clear understanding of CDKL5 
biological function and disease mechanism may lead to the development of effective 
targeted therapeutics toward treatment or reversal of CDKL5 disorder.  Therefore, future 
experiments should address the therapeutic relevance of these studies.  Gene mutations 
occur in germ cells and persist throughout the organism’s lifetime, but therapeutic 
intervention in the clinic is likely constrained to postnatal time points, either during 
development or in adulthood.  Therefore, the reversibility of CDKL5 disorder must be 
established.  In Rett Syndrome mouse models, restoration of MeCP2 in post-
symptomatic adult mice is sufficient to rescue many, but not all, disease-related 
phenotypes (Guy et al., 2007), suggesting that Rett Syndrome is reversible and 
therefore, treatable.  This finding also indicates that MeCP2 may play a maintenance 
role and that many circuits and pathways regulated by MeCP2 are plastic.  Performing 
similar experiments on CDKL5 mouse models will be important steps in translating 
animal research into clinically relevant therapeutic strategies. 
 
The paucity of effective animal models and reagents has led to inconsistent and often 
contradictory results, and it is likely that the early bias linking CDKL5 to Rett Syndrome 
and MeCP2 has impeded diagnosis and research progress. The development and 
characterization of the first CDKL5 KO mouse, described in Chapter 2, represents the 
first step toward establishing in vivo mechanisms underlying CDKL5 disease 
pathogenesis, where a causal role of mutations in Cdkl5 was linked to disease etiology 
and disruptions in neural circuits and signaling pathways upon loss of CDKL5 were 
identified.  Ongoing and future studies, described in Chapter 3, that integrate mouse 
behavior, circuit function, synapse physiology, and signaling pathways in conditional 
CDKL5 knockout mice will clarify the pathogenic mechanisms by which mutations in 
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CDKL5 lead to disease and thus expedite the development of mechanism-based 
therapeutics. 
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This chapter consists of my 2012 first-author Proceedings of the National Academy of 
Sciences of the United States of America (PNAS) publication describing the 
development and characterization of the first CDKL5 knockout mouse model.  This study 
established the genetic causality of mutations in Cdkl5 in disease etiology and identified 
disruptions in neural circuits and signaling pathways as pathogenic mechanisms 
underlying CDKL5 disorder.  In addition, it provided a framework and animal model for 
future mechanistic and therapeutic studies of CDKL5 disorder. 
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Abstract 
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been 
identified in neurodevelopmental disorders including atypical Rett syndrome (RTT), 
autism spectrum disorders (ASDs), and early infantile epileptic encephalopathy. The 
biological function of CDKL5 and its role in the etiology of these disorders, however, 
remain unclear. Here we report the development of a unique knockout mouse model of 
CDKL5-related disorders and demonstrate that mice lacking CDKL5 show autistic-like 
deficits in social interaction, as well as impairments in motor control and fear memory. 
Neurophysiological recordings reveal alterations in event-related potentials (ERPs) 
similar to those observed in RTT and ASDs. Moreover, kinome profiling uncovers 
disruption of multiple signal transduction pathways, including the AKT-mammalian target 
of rapamycin (mTOR) cascade, upon Cdkl5 loss-of-function. These data demonstrate 
that CDKL5 regulates signal transduction pathways and mediates autistic-like 
phenotypes and together establish a causal role for Cdkl5 loss-of-function in 
neurodevelopmental disorders. 
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Introduction 
Cyclin-dependent kinase-like 5 (CDKL5) is an X-linked gene associated with early 
infantile epileptic encephalopathy 2 (EIEE2) (Nabbout and Dulac, 2011), atypical Rett 
syndrome (RTT) (Chahrour and Zoghbi, 2007), and autism spectrum disorders (ASDs) 
(Sakai et al., 2011; Talkowski et al., 2012). Patients with CDKL5 mutations display a 
heterogenous array of clinical phenotypes, the most prominent of which include early-
onset seizures, intellectual disability, and autistic features (Bahi-Buisson et al., 2008b)  
 
CDKL5 is a serine/threonine (S/T) kinase that is highly expressed in the brain (Kilstrup-
Nielsen et al., 2012). In vitro studies have demonstrated that CDKL5 may mediate the 
phosphorylation of methyl-CpG binding protein 2 (MeCP2) (Mari et al., 2005), DNA 
methyltransferase 1 (DNMT1) (Kameshita et al., 2008), and netrin-G1 ligand (NGL-1) 
(Ricciardi et al., 2012). RNAi-mediated knockdown studies show that CDKL5 can 
regulate neuronal outgrowth and synapse stability (Chen et al., 2010; Ricciardi et al., 
2012). Despite these proposed functions, the exact role of CDKL5 in the phosphorylation 
of MeCP2 (Lin et al., 2005; Mari et al., 2005) and in dendritic outgrowth (Chen et al., 
2010; Ricciardi et al., 2012) remains unclear, and thus requires further investigation. The 
limited understanding of CDKL5 function and its associated signal transduction 
pathways has hindered the development of therapeutics for CDKL5-related disorders. 
Current treatments focus on managing symptoms and reducing seizure frequency, but 
have limited effectiveness (Bahi-Buisson and Bienvenu, 2012).  
 
To investigate the function of CDKL5 in a disease model and identify potential avenues 
of therapeutic intervention, we developed a Cdkl5 knockout mouse. We found that mice 
lacking CDKL5 show autistic-like behavioral abnormalities, deficits in neural circuit 
communication, and alterations in multiple signal transduction pathways. We establish a 
causal link between Cdkl5 loss-of-function and disease-related phenotypes and identify 
the Akt-mammalian target of rapamycin (mTOR) pathway as a unique candidate for 
targeted therapeutic intervention of CDKL5-related disorders.  
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Results 
Generation of Cdkl5 Knockout Mice.  
To investigate the pathophysiology underlying CDKL5-related disorders, we generated a 
Cdkl5 knockout mouse that models a splice site mutation found in a CDKL5 patient. This 
mutation results in the skipping of human CDKL5 exon 7, generating a premature 
termination codon and causing an early truncation of CDKL5 in its N-terminal kinase 
domain, thereby disrupting kinase activity (Archer et al., 2006). To mimic the effects of 
this splice site mutation, we deleted mouse Cdkl5 exon 6 through homologous-mediated 
recombination in ES cells (Fig. 1A). Deletion of Cdkl5 exon 6 leads to a similar shift in 
the reading frame and premature truncation within the N-terminal kinase domain (Fig. 1 
A and B). The absence of Cdkl5 exon 6 at the DNA and mRNA levels was verified by 
PCR of genomic DNA and sequencing of cDNA prepared from Cdkl5 knockout mouse 
brains (Fig. 1 C and D). Loss of full-length CDKL5 protein was verified by Western blot 
(Fig. 1E). A truncated CDKL5 protein product in neurons isolated from Cdkl5 knockout 
mice has not been detected by antibodies raised against CDKL5 N-or C-terminal 
domains, likely due to nonsense stop codon mediated mRNA decay (Fig. S1A). In 
addition, female heterozygotes show decreased CDKL5 protein expression relative to 
WT female mice, as expected from X-linked mosaicism (Fig. S1B). Thus, deletion of 
Cdkl5 exon 6 likely represents a loss-of-function mutation. Experimental mice have been 
backcrossed onto the C57BL/6 background for at least six generations. Male mice 
lacking CDKL5 (Cdkl5
–/y
) and female heterozygotes (Cdkl5
−/+
) are viable, fertile, and 
display normal appearance, growth, and overall brain morphology (Fig. S1 C and D).  
	  
	  
Hyperactivity, Motor Impairments, and Decreased Anxiety in Cdkl5
–/y 
Mice.  
Given the clinical relevance of CDKL5-related disorders in males (Liang et al., 2011; 
Moseley et al., 2012) and the confounding effects of mosaic CDKL5 expression in 
females from random X-chromosome inactivation, we characterized the behavioral 
profile of Cdkl5 knockouts in male (Cdkl5
–/y
) mice, compared with wild-type male 
littermates (WT, Cdkl5
+/y
). We found that Cdkl5
–/y 
mice exhibit motor and anxiety 
impairments similar to those observed in other ASD and RTT mouse models (Chahrour 
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and Zoghbi, 2007; Goffin et al., 2012; Schmeisser et al., 2012; Tsai et al., 2012; Won et 
al., 2012). In a locomotor assay within a home cage-like environment, Cdkl5
–/y 
mice 
demonstrated significantly higher motor activity relative to WT littermate controls (Fig. 
2A). Similar hyperactivity was also observed in the zero maze test and social approach 
test (Fig. S2 A and B).  
 
On an accelerating rotarod assay, the latency to fall in Cdkl5
–/y 
mice increased across 
trials similarly to that of WT mice, but was consistently lower than that of WT (Fig. 2B), 
indicating that Cdkl5
–/y 
mice have comparable motor learning but impaired motor 
coordination relative to their WT littermates. Cdkl5
–/y 
mice also showed decreased 
anxiety-related behavior in a zero maze test similar to that of Mecp2 mouse models of 
RTT, spending more time in open areas and less time in the closed areas relative to WT 
littermates (Fig. 2C). In addition, we have observed hindlimb and forelimb clasping in 
Cdkl5
–/y 
mice (Fig. S2C), a phenotype also exhibited in Mecp2 mouse models (Chao et 
al., 2010; Goffin et al., 2012; Guy et al., 2001; Shahbazian et al., 2002b). These data 
demonstrate that Cdkl5
–/y 
mice exhibit hyperactivity, impaired motor control, and 
decreased anxiety, phenotypes that have also been observed in ASD and RTT patients 
(Bahi-Buisson et al., 2008b; Chahrour et al., 2008; Geschwind, 2009).  
	  
	  
Autistic-Like Social Behavior in Cdkl5
–/y 
Mice.  
Given that deficits in social interaction are a hallmark feature of ASDs and are prevalent 
in patients with CDKL5 mutations (Abrahams and Geschwind, 2008; Bahi-Buisson et al., 
2008b), we next examined sociability using a three-chambered social approach test and 
found that mice lacking CDKL5 demonstrate profound impairment in social interaction. 
During the initial habituation phase, both WT and Cdkl5
–/y 
mice explored both chambers 
equally, demonstrating no initial chamber preference (Fig. S2D). However, upon 
introduction of a novel object into one chamber (nonsocial chamber, NS) and a novel 
gonadectomized male A/J stimulus mouse into the other chamber (social chamber, S), 
Cdkl5
–/y 
mice showed reduced social preference relative to WT mice, spending less time 
in the social chamber and more time in the nonsocial chamber relative to WT mice (Fig. 
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2D). In addition, Cdkl5
–/y 
mice spent more time sniffing the novel object and a trend 
toward less time sniffing the novel stimulus mouse relative to WT mice (Fig. 2E). 
Furthermore, when barriers were removed to allow freely mobile direct interaction, 
Cdkl5
–/y 
mice spent significantly less time interacting (sniffing, allogrooming) with the 
stimulus mouse compared with WT littermates (Fig. 2F).  
 
Cdkl5
–/y 
mice also displayed impaired nesting, a phenotype related to home-cage social 
behavior that has been observed in ASD and RTT mouse models (Peñagarikano et al., 
2011; Samaco et al., 2008; Won et al., 2012) (Fig. 2G). Importantly, we found no 
olfaction impairments in either genotype (Fig. S2E), suggesting that the social deficits in 
Cdkl5
–/y 
mice are not the secondary consequence of an inability to discriminate between 
social and neutral odors. Together, these data demonstrate that Cdkl5
–/y 
mice have ASD-
like deficits in social behavior.  
	  
	  
Impaired Learning and Memory in Cdkl5
–/y 
Mice.  
Because intellectual disability is a common clinical phenotype among CDKL5 patients 
(Bahi-Buisson and Bienvenu, 2012), we also assessed learning and memory in Cdkl5 
knockout mice using context-and cue-dependent fear conditioning. During the 
acquisition phase, both WT and Cdkl5
–/y 
mice showed similar exploratory behavior 
before the foot shock and similar freezing behavior immediately following the foot shock 
(Fig. 2H). When re-exposed to the shock box or paired tone 24 h later, Cdkl5
–/y 
mice 
froze significantly less than WT littermates, indicating impaired contextual and cued fear 
memory (Fig. 2H). Taken together, these behavioral studies demonstrate that mice 
lacking CDKL5 have deficits in motor function, social behavior, and learning and 
memory.  
	  
	  
Normal EEG Patterns and Absence of Spontaneous Seizures in Cdkl5
–/y 
Mice.  
Given the prevalence of intractable seizures in patients with CDKL5 mutations (Bahi-
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Buisson and Bienvenu, 2012), we next examined the occurrence of spontaneous 
seizures in Cdkl5 knockout mice through video-EEG recordings. We did not, however, 
observe any spontaneous seizures in Cdkl5
–/y 
mice recorded for at least 72 h, with some 
mice recorded for as long as 240 h. Consistent with this finding, the basal EEG patterns 
and power distribution across different oscillation frequencies in Cdkl5
–/y 
mice were 
similar to that of WT littermates (Fig. S3 A and B). Despite the large degree of 
homology between the murine and human CDKL5 protein, the absence of spontaneous 
seizures observed in our Cdkl5
–/y 
mice may reflect a distinct function or modification of 
CDKL5 in humans that is absent in lower organisms. Moreover, the C57BL/ 6 genetic 
background is known to confer increased seizure resistance (McLin and Steward, 2006), 
thus potentially occluding spontaneous seizures in our Cdkl5
–/y 
mice.  
	  
	  
Event-Related Potential Deficits in Cdkl5
–/y 
Mice.  
The absence of spontaneous seizures in Cdkl5
–/y 
mice, however, allowed us to examine 
neural circuit deficits that are mediated by Cdkl5 loss-of-function rather than the 
secondary consequence of seizures. Sensory information processing measured as an 
event-related potential (ERP) has recently been proposed as a biomarker to monitor 
neural circuit function in ASD and RTT animal models (Gandal et al., 2010; Goffin et al., 
2012; Liao et al., 2012). We therefore recorded auditory-evoked ERPs in adult WT and 
Cdkl5
–/y 
mice, as these ERP assessments can be performed on nonanesthetized, freely 
mobile mice and are not confounded by the motor and cognitive deficits observed in 
Cdkl5
–/y 
mice. Relative to the characteristic amplitude and latency of the P1 (positive), N1 
(negative), and P2 polarity peaks in WT mice, Cdkl5
–/y 
mice display an aberrant ERP 
waveform (Fig. 3A). We observed a significant decrease in the amplitude of the N1 and 
P2 peaks and a significant increase in latency of the P2 peak (Fig. 3 A–C). Importantly, 
auditory brainstem recordings detected no hearing impairments in either genotype. As 
the amplitude and latency of these polarity peaks are believed to reflect the strength and 
timing of cognitive processes, these data indicate that Cdkl5 loss-of-function disrupts 
neural circuit communication. Notably, ASD and RTT patients have alterations in both 
ERP amplitude and latency (Roberts et al., 2010; Stauder et al., 2006). 
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Disruption of Low-Frequency Event-Related Neuronal Oscillations in Cdkl5
–/y 
Mice.  
Circuit communication is composed of neuronal oscillations over a range of frequencies. 
We therefore also performed time–frequency analysis of the ERPs to examine 
frequency-specific changes in instantaneous power and phase locking in response to the 
auditory stimuli. Cdkl5
–/y 
mice demonstrated reduced oscillatory strength specifically at 
low frequencies, showing attenuated event-related depression in the low-frequency delta 
(δ,2–4 Hz), theta (θ,4–8 Hz), and alpha (α,8–12 Hz) oscillations, but no difference in the 
high-frequency beta (β,12–30 Hz), low gamma (γlow,30–50 Hz), and high gamma 
(γhigh,70–140 Hz) oscillations relative to WT controls (Fig. 3 D and E and Fig. S4A). 
Similarly, event-related phase locking, which reflects the reliability and sensitivity of 
circuit communication, and is measured by the phase-locking factor (PLF), were also 
significantly decreased in Cdkl5
–/y 
mice exclusively in the low-frequency δ, θ, and α 
oscillations relative to WT littermates (Fig. 3 F and G and Fig. S4B). Given that 
oscillatory activity in low-frequency ranges is associated with long-range neuronal circuit 
communication and high-frequency oscillations with local circuit communication (Gandal 
et al., 2010; Winterer et al., 2000), our data suggest that ERP deficits in Cdkl5
–/y 
mice 
may be mediated by impairments in long-range communication. Notably, EEG studies in 
ASD children have reported specific deficits in low-frequency δ, θ, and α oscillations 
(Dawson et al., 1995; Stroganova et al., 2007), indicating that similar neuronal network 
defects exist in Cdkl5
–/y 
mice and ASD patients.  
	  
	  
Disrupted Kinome Profile in Cdkl5
–/y 
Mice.  
Given the highly conserved S/T kinase domain in CDKL5 (Fig. 1B), we reasoned that 
Cdkl5 loss-of-function may disrupt phosphorylation of CDKL5 kinase substrates and 
related signaling pathways, thereby mediating deficits in neuronal network 
communication and autistic-like behaviors in Cdkl5
–/y 
mice. Previous studies have 
reported that CDKL5 may mediate the phosphorylation of MeCP2 (Mari et al., 2005), 
DNMT1 (Kameshita et al., 2008), and NGL-1 (Ricciardi et al., 2012) in vitro. The CDKL5 
substrates in vivo, however, remain unknown. Therefore, to investigate the signaling 
networks affected by the absence of CDKL5 in vivo in an unbiased manner, we surveyed 
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the S/T kinome profile in Cdkl5 knockout mice, assessing the consequence of Cdkl5 
loss-of-function on overall S/T phosphorylation events. Because CDKL5 expression is 
enriched in the forebrain regions of the striatum, cortex, and hippocampus (Fig. S5), we 
probed brain region–specific lysate from WT and Cdkl5
–/y 
mice with multiple antibodies 
developed against a large set of well-characterized S/T phosphorylation motifs (Moritz et 
al., 2010; Zhang et al., 2002). We identified a range of phosphorylation profiles affected 
by the loss of CDKL5 (Fig. 4A). Of these, the phosphorylation of adenosine 
monophosphate-activated protein kinase (AMPK), protein kinase A (PKA), and AKT 
substrates were strongly decreased in Cdkl5
–/y 
mice (Fig. 4 B and C and Fig. S6), 
whereas other phosphorylation profiles were moderately or mildly affected [e.g., 
mitogen-activated protein kinase (MAPK), ataxia-telangiectasia mutated/ataxia-
telangiectasia and Rad3-related (ATM/ATR), and cyclin-dependent kinase (CDK) 
substrates] (Fig. 4A and Figs. S7 and S8). Importantly, changes in phosphorylation 
profiles were clearly evident in forebrain regions including the striatum, somatosensory 
cortex, and hippocampus where CDKL5 is enriched and less pronounced in hindbrain 
regions including the brainstem where CDKL5 expression is low (Fig. 4 B and C and 
Figs. S5–S7), supporting a role of CDKL5 in the regulation of these pathways.  
	  
	  
Disruption of AKT–mTOR Signaling in Cdkl5
–/y 
Mice.  
The changes in the AMPK, AKT, PKC, and MAPK phosphorylation profiles suggested a 
convergence on the downstream signaling of phosphatase and tensin homolog (PTEN). 
Notably, mutations and dysfunction of components of this pathway, including PTEN, 
AKT, tuberous sclerosis complex (TSC), and mTOR, have been linked to ASDs, RTT, 
and epileptic encephalopathies (Ricciardi et al., 2011; Tsai et al., 2012; Zhou and 
Parada, 2012). To validate the disruption of AKT–mTOR signaling in Cdkl5
–/y 
mice, we 
measured the phosphorylation of AKT S473 and mTOR S2448 and found decreased 
phosphorylation of both AKT and mTOR in Cdkl5
–/y 
mice, with no concomitant alteration 
in total AKT or mTOR protein levels (Fig. 4 D–H). As phosphorylation of these residues 
promote AKT activation and mTOR complex 1 (mTORC1) assembly, respectively 
(Bhaskar and Hay, 2007; Rosner et al., 2010), this finding is consistent with the overall 
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decreased phosphorylation of AKT substrates in Cdkl5
–/y 
mice (Fig. 4C and Fig. S6 B 
and D) and likely reflect decreased AKT and mTORC1 activity upon Cdkl5 loss-of-
function. Together, we conclude that multiple signal transduction pathways, including the 
AKT–mTOR cascade, are disrupted upon the absence of CDKL5.  
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Discussion  
In this study, we show that loss of CDKL5 in mice results in autistic-like behavioral 
deficits, impairment in neuronal communication, and disruptions in serine/threonine 
phosphorylation profiles. We establish a unique causal relationship between Cdkl5 loss-
of-function and disease-related phenotypes.  
	  
Core characteristics of CDKL5-related disorders include early-onset seizures, severe 
intellectual disability, and autistic-like features. In our behavioral analysis, we found that 
our Cdkl5 knockout mice mirror the latter features, but not early-onset seizures. Cdkl5
–/y 
mice display hyperactivity, motor defects, reduced anxiety, decreased sociability, and 
impaired learning and memory. These phenotypes have been described in other ASD 
and RTT mouse models (Chahrour and Zoghbi, 2007; Goffin et al., 2012; Guy et al., 
2001; Peñagarikano et al., 2011; Schmeisser et al., 2012; Won et al., 2012) and may 
mimic the absence of hand skills, intellectual disability, hyperactivity, and poor response 
to social interactions that have been described in CDKL5 patients (Bahi-Buisson and 
Bienvenu, 2012; Willemsen et al., 2012).  
 
While video-EEG monitoring revealed an absence of spontaneous seizures in Cdkl5
–/y 
mice, ERP analysis showed attenuated and delayed ERP polarity peaks suggestive of 
impaired neuronal connectivity, which is consistent with findings in ASD and RTT 
patients (Roberts et al., 2010; Stauder et al., 2006) and animal models (Gandal et al., 
2010; Goffin et al., 2012; Liao et al., 2012). Importantly, these behavioral and 
electrophysiological impairments are unlikely the secondary effects of an epileptic 
neuronal network, suggesting they are consequences of Cdkl5 loss-of-function.  
	  
Time–frequency analysis of ERPs identified a specific deficit in event-related δ, θ, and α 
low-frequency neuronal oscillations in Cdkl5
–/y 
mice. Interestingly, abnormalities in low-
frequency neuronal oscillations have been reported in ASD children (Dawson et al., 
1995; Stroganova et al., 2007). In addition, impairments in α and γ oscillations have also 
been described in ASDs, as α is believed to function in attention suppression of 
distracting stimuli and γ in feature binding (Foxe and Snyder, 2011; Uhlhaas et al., 
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2011). Alpha oscillations have also been proposed to mediate long-distance coordination 
of γ oscillations (Palva and Palva, 2007). Thus, our data suggest that the oscillatory 
network of Cdkl5
–/y 
mice may resemble that of ASD, where γ oscillations themselves are 
not affected, but rather, their α-mediated long-distance coordination. Moreover, as θ 
oscillations are proposed to support encoding and retrieval of memory (Buzsáki, 2005; 
Ward, 2003), the impairment in event-related power and PLF at the θ frequency are 
consistent with the learning and memory deficits in Cdkl5
–/y 
mice and the prominent 
intellectual disability observed in patients with CDKL5-related disorders.  
	  
Lastly, our S/T kinome study revealed that many signal transduction pathways are 
disrupted in Cdkl5 knockout mice. Of these, many pathway components, including the 
AKT–mTOR pathway, have been implicated in the etiology of ASDs (Jeste et al., 2008; 
Tsai et al., 2012). Given that mTOR is a known regulator of cell growth, proliferation, 
motility, and neural plasticity (Zoncu et al., 2011), one consequence of reduced AKT–
mTOR activity in the absence of CDKL5 is the disruption of neuronal development. 
Accordingly, RNAi-mediated knockdown of CDKL5 results in impaired dendritic 
outgrowth, neuronal migration (Chen et al., 2010), and spine maturation (Ricciardi et al., 
2012). Together, these data suggest a mechanism by which CDKL5 regulates AKT–
mTOR-mediated cellular development, thus implicating the AKT–mTOR pathway as a 
potential therapeutic target for treatment of patients with CDKL5-related disorders.  
	  
In addition to the AKT–mTOR pathway, we found that the phosphorylation profiles of 
kinases involved in synaptic plasticity, including PKA, PKC, and protein kinase D (PKD), 
as well as kinases involved in cellular metabolism, including AMPK, ATM/ATR, and 
casein kinase (CK) (Figs. S6 and S7) were also decreased in Cdkl5
–/y 
mice. Although 
many of these signaling changes may be indirect effects of Cdkl5 loss-of-function, these 
data suggest that CDKL5 plays a critical role in coordinating multiple signaling cascades. 
Indeed, CDKL5 has been shown to regulate brain-derived neurotropic factor (BDNF)-
induced activation of Rho family small GTPase Rac1 (Chen et al., 2010) and deficits in 
synaptic plasticity are commonly described in ASDs (Peça et al., 2011; Won et al., 
2012). Consistent with these cellular functions, we found that CDKL5 is predominantly 
localized in the cytoplasm (Fig. S9). Notably, links between these signaling pathways 
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have been previously described, as CK regulates glutamatergic synaptic transmission 
(Chergui et al., 2005), ATM mediates AKT S473 phosphorylation (Viniegra et al., 2005), 
and mutations in ATM cause the neurodegenerative movement disorder ataxis 
telegiectasia (Barlow et al., 1996). It is possible, therefore, that CDKL5 may serve to 
mediate cross-talk between these signaling pathways.  
 
Our data support an increasing awareness that CDKL5-related disorders are an 
independent clinical entity with an independent pathogenic mechanism, rather than a 
subclass of RTT. Strikingly, only less than one-quarter of individuals with CDKL5 
mutations meet the criteria for the early-onset seizure variant of RTT (Fehr et al., 2012; 
Neul et al., 2010). Its genetic link to neurodevelopmental disorders and recent 
identification as an ASD hotspot for balanced chromosomal rearrangements (Talkowski 
et al., 2012) highlight the need to characterize CDKL5 biological function, understand the 
mechanisms underlying CDKL5-related disorders, and identify effective therapies 
targeted toward slowing or reversing disease progression. Our study, therefore, provides 
a framework and an animal model for mechanistic and therapeutic studies of CDKL5-
related disorders.  
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Figure 1 
 
Figure 1.  Generation and verification of Cdkl5 knockout mice. 
 (a) Targeting strategy to generate Cdkl5 knockout mice.  Three loxP sites and a neomycin positive selection 
cassette (Neo) were inserted surrounding the genomic locus of Cdkl5 exon 6 via homologous recombination.  Upon Cre-
directed recombination, both the Neo cassette and exon 6 were excised. 
 (b) Schematic of CDKL5 protein in WT and knockout.  The excision of exon 6 causes a reading frame shift, 
resulting in a TAA stop codon in the 5’ end of exon 7, leading to truncation of CDKL5 in its kinase domain (red).   
 (c) PCR of genomic DNA using primers flanking exon 6.  A 300 bp PCR product in  
Cdkl5–/y mice indicates the absence of Cdkl5 exon 6. 
 (d) Sequencing of cDNA generated from Cdkl5 mRNA.  Excision of exon 6 in Cdkl5–/y mice causes the reading 
frame, highlighted in black, to be shifted in Cdkl5–/y mice, resulting in a premature stop codon (TAA, circled in red) at the 5’ 
end of exon 7.  
 (e) Western blot probed with an antibody directed against CDKL5.  Full-length CDKL5 protein is absent in Cdkl5–/y 
mice. 
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Figure 2 
 
Figure 2.  Behavioral phenotyping of Cdkl5–/y mice. 
 (a) 60-minute locomotor assay, measured by infrared beam breaks in a home cage-like environment.  Cdkl5–/y 
mice (n=19) display increased activity relative to wildtype (WT, Cdkl5+/y) littermates (n=15).  Two-way repeated measures 
(RM) -ANOVA, p<0.0001 (interaction). 
 (b) Rotarod assay, measuring latency to fall from an accelerating rotating rod.  Testing was performed 5 trials/day 
for 5 consecutive days. Latency to fall is decreased in Cdkl5–/y mice (n=18) relative to WT littermates (n=15), indicating 
impaired motor coordination in Cdkl5–/y mice.  Two-way ANOVA, p<0.01 (main effect of genotype). 
 (c) Cdkl5–/y mice (n=14) spend more time in the open arms and less time in the closed arms of a zeromaze assay 
relative to WT littermates (n=12), showing decreased anxiety.  *p<0.05, unpaired two-tailed Student’s t-test. 
 (d) Three-chambered social approach assay.  Cdkl5–/y mice (n=17) spend less time in a social chamber containing 
a stimulus mouse (S) and more time in a non-social chamber containing a novel object (NS) relative to WT mice (n=15).  
C: center.  Two-way ANOVA with Bonferroni correction, p<0.0001 (interaction); **p<0.01, ***p<0.001. 
 (e) Cdkl5–/y mice (n=17) spend significantly more time sniffing a novel object (NS) and trend toward less time 
sniffing a stimulus mouse (S) relative to WT mice (n=15).  Two-way ANOVA with Bonferroni correction, p<0.01 
(interaction); *p<0.05.  
 (f) Cdkl5–/y mice (n=17) spend less time directly interacting with a freely moving stimulus mouse compared to WT 
littermates (n=15).  ***p<0.001, unpaired two-tailed Student’s t-test. 
 (g) Cdkl5–/y mice (n=12) show impaired nesting behavior relative to WT littermates (n=11) at 4-5 postnatal weeks.  
***p<0.001, unpaired two-tailed Student’s t-test. 
 (h) Fear conditioning paradigm, measuring time spent immobile.  While Cdkl5–/y mice (n=14) freeze in response to 
a mild footshock similarly to WT littermates (post-shock), they show decreased freezing upon return to the testing 
chamber (context) and upon hearing the testing tone (cue) relative to WT littermates (n=14), demonstrating impaired 
learning and memory in Cdkl5–/y mice.  Two-way ANOVA with Bonferroni correction, p<0.01 (interaction); *p<0.05.  All 
data are presented as mean ± s.e.m.  
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Figure 3 
 
Figure 3.  Cdkl5–/y mice display impaired ERP waveform and decreased event-related power and phase-locking. 
 (a) Grand-average ERP waveform following presentation of 250 85-dB white noise stimuli with 4 s interstimulus 
intervals in adult WT (Cdkl5+/y) (n=9) and Cdkl5–/y mice (n=9).  Traces represent mean amplitude ± s.e.m.  Characteristic 
polarity peaks P1, N1, and P2 in WT are labeled.  Scale bar corresponds to 100 ms (horizontal) and 20 mV (vertical). 
 (b, c) Amplitude (b) and latency (c) of ERP peaks.  Bars represent mean ± s.e.m.;  **p<0.01, *p<0.05, unpaired 
two-tailed Student’s t-test with Bonferroni correction. 
 (d) Time-frequency plots showing changes in event-related power following an 85-dB auditory stimulus.  Color 
represents mean power, where warmer colors correspond to increased power and cooler colors correspond to decreased 
power relative to pre-stimulus baseline. 
 (e) Changes in event-related mean power averaged across δ (2–4 Hz), θ (4–8 Hz), α (8–12 Hz), β (12–30 Hz), γlow 
(30–50 Hz) and γhigh (70–140 Hz) oscillation frequencies.  Scale bars represent the length of a single δ oscillation cycle.  
Insets show power traces on an expanded timescale, denoted by the length of a single oscillation cycle.  Traces represent 
mean amplitude ± s.e.m.  
 (f) Time-frequency plots showing changes in event-related phase-locking factor (PLF) following an 85-dB auditory 
stimulus.  Color represents PLF, where warmer colors correspond to a higher PLF or lower circular variance in EEG 
phase across trials. 
 (g) Changes in event-related PLF averaged across frequencies described above.  Scale bars represent the length 
of a single oscillation cycle and insets show traces on an expanded timescale.  Traces represent mean PLF ± s.e.m.	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Figure 4 
Figure 4.  Altered kinome profile and disrupted AKT-mTOR signaling in Cdkl5–/y mice. 
 (a) Summary of changes in kinome profile in Cdkl5–/y mice relative to WT littermates.  Whole cell lysates from the 
cerebellum, striatum, somatosensory cortex, olfactory bulb, hippocampus, and brainstem of WT (n=7) and Cdkl5–/y mice 
(n=8) were probed with antibodies raised against different phosphorylation motifs representing known S/T kinases.  
Western blots were quantified using the Odyssey Infrared Imaging system and fold change in phosphorylation level 
between Cdkl5–/y and WT mice across the six brain regions are expressed as log2(phosphorylation level in WT over 
phosphorylation level in Cdkl5–/y).  Color scheme indicates relative degree of phosphorylation reduction in Cdkl5–/y mice: 
purple - strong; blue - moderate; green - mild.  
 (b, c) Whole cell lysate probed with an antibody specific for an RXRXX(s/t) phosphorylation motif representing 
AKT kinase substrates (b) and an antibody specific for an LXRXX(s/t) phosphorylation motif representing AMPK kinase 
substrates (c) shows a marked decrease in phosphorylation profiles in Cdkl5–/y mice (KO) relative to WT littermates in the 
striatum, somatosensory cortex (ss cortex), and hippocampus, but moderate decrease in the brainstem, consistent with 
regions of high and low CDKL5 expression, respectively. 
 (d) AKT S473 and mTOR S2448 phosphorylation is reduced in whole brain lysate from Cdkl5–/y mice (KO) related 
to WT mice, while total levels of AKT and mTOR are unchanged.   
 (e-f) Quantification of reduced AKT S473 (e) and mTOR S2448 (f) phosphorylation in Cdkl5–/y mice.  
Phosphorylated protein levels are normalized to GAPDH loading control and expressed relative to WT levels.  *p<0.05, 
unpaired two-tailed Student’s t-test with Bonferroni correction. 
 (g-h) Quantification of total AKT (g) and mTOR (h) in WT and Cdkl5–/y mice.  Protein levels are normalized to 
GAPDH loading control and expressed relative to WT levels.  n.s.: not significant; unpaired two-tailed Student’s t-test. 
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Figure S1 
 
Figure S1.  Western blot analysis of CDKL5 expression and examination of brain morphology in Cdkl5 knockout 
mice. 
 (a) Western blot of cortical neurons (5DIV) isolated from WT (Cdkl5+/y) and knockout Cdkl5–/y male embryos 
(E16.5) probed with antibodies raised up against the N or C-terminus of CDKL5.  Full-length CDKL5, denoted by an 
arrow, is absent in Cdkl5–/y neurons.  Non-specific bands detected by both antibodies are present in both WT and Cdkl5–/y 
lysate.  A non-specific band running at the same size as full-length CDKL5, denoted by an asterisk, is detected by the C-
terminal antibody.  Additional truncated CDKL5 is not detected in Cdkl5–/y mice by either antibody. 
 (b) Western blot of cortical neurons (5DIV) isolated from WT female (Cdkl5+/+) and heterozygous female Cdkl5–
/+embroyos (E16.5) probed with antibodies raised up against the N or C-terminus of CDKL5.  Full-length CDKL5 is 
denoted by an arrow.  CDKL5 protein levels are reduced in female heterozygous mice (Cdkl5–/+) relative to female WT 
mice, indicative of typical X-linked mosaic expression. 
 (c) Brain size of Cdkl5–/y mice is comparable to that of WT littermates. 
 (d) Nissl staining of coronal brain sections reveals comparable cortical thickness in WT and Cdkl5–/y mice. 
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Figure S2 
 
Figure S2.  Behavioral characterization of Cdkl5 knockout mice. 
 (a) Cdkl5–/y mice (n=14) travel a greater distance relative to WT (Cdkl5+/y) littermates (n=12) in a zero maze assay.  
*p<0.05, unpaired two-tailed Student’s t-test. 
 (b) Locomotor activity during three-chambered social approach test is increased in Cdkl5–/y mice (n=17) during 
both habituation and testing phase of social choice assay relative to WT littermates (n=15).  Two-way ANOVA with 
Bonferroni correction, p<0.05 (interaction); **p<0.01, ****p<0.0001. 
 (c) Hindlimb clasping in Cdkl5–/y mice. 
 (d) Both WT (n=15) and Cdkl5–/y mice (n=17) explore both L (left) and R (right) chambers equally during the 
habituation phase of social approach assay, prior to introduction of novel object or stimulus mouse into either chamber.  
C: center.  Two-way ANOVA with Bonferroni correction, p>0.05 (main effect of chamber); n.s., not significant.  
 (e) Cdkl5–/y mice (n=17) and WT littermates (n=15) show similar olfactory response in distinguishing neutral scents 
(water, vanilla), from social scents (swab from another cage).  Two-way ANOVA, p>0.05 (interaction).  All data are 
presented as mean ± s.e.m. 
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Figure S3 
 
Figure S3.  Basal EEG activity in Cdkl5–/y mice is similar to that of WT littermates. 
 (a) Representative EEG trace under basal conditions in awake, freely mobile mice.   Scale bar corresponds to 1 s 
(horizontal) and 200 µA (vertical). 
 (b) Basal EEG power in WT (Cdkl5+/y) (n=9) and Cdkl5–/y mice (n=9).  Frequency bands are represented as 
follows: δ (2–4 Hz), θ (4–8 Hz), α (8–12 Hz), β (12–30 Hz), γlow (30–50 Hz) and γhigh (70–140 Hz).  Data are presented as 
mean ± s.e.m.; n.s., not significant, unpaired two-tailed Student’s t-test with Bonferroni correction. 
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Figure S4 
 
Figure S4.  Decrease in event-related power and PLF in Cdkl5–/y mice are primarily found in low-frequency 
oscillations. 
 (a) Quantification of event-related power changes relative to pre-stimulus baseline in WT (Cdkl5+/y) (n=9) and 
Cdkl5–/y mice (n=9).  Frequency bands are represented as follows: δ (2–4 Hz), θ (4–8 Hz), α (8–12 Hz), β (12–30 Hz), 
γlow (30–50 Hz) and γhigh (70–140 Hz).  Cdkl5–/y mice show decreased event-related power relative to WT in low-
frequency δ, θ, and α oscillations.  **p<0.01, *p<0.05, n.s., not significant, unpaired two-tailed Student’s t-test with 
Bonferroni correction.  
 (b) Quantification of event-related PLF changes following 85-dB auditory stimulus.  Cdkl5–/y mice have decreased 
event-related PLF power relative to controls in low-frequency δ, θ, and α oscillations.  Data are presented as mean ± 
s.e.m.; *p<0.05, n.s., not significant, unpaired two-tailed Student’s t-test with Bonferroni correction. 
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Figure S5 
 
Figure S5.  Enrichment of CDKL5 in forebrain regions. 
 Western blot of whole cell lysate prepared from indicated brain regions from WT mice probed with a polyclonal 
antibody raised against the N-terminus of CDKL5.  CDKL5 (107 kDa) is enriched in the striatum, somatosensory cortex, 
olfactory bulb, and hippocampus relative to the cerebellum and brainstem.  *cross-reacting bands 
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Figure S6 
 
Figure S6.  Strongly altered kinome profiles in Cdkl5–/y mice. 
 (a) Description of lane contents for (b)-(f).  WT: Cdkl5+/y; KO: Cdkl5–/y  
 (b-e) Western blot of whole cell lysate isolated from indicated brain regions probed with an antibody specific for an 
RXRXX(s/t) phosphorylation motif representing AKT kinase substrates (b), an antibody specific for an LXRXX(s/t) 
phosphorylation motif representing AMPK kinase substrates (c), an antibody specific for an RXX(s/t), phosphorylation 
motif representing AKT kinase substrates (d), an antibody specific for a (K/R)(K/R)X(s/t) phosphorylation motif 
representing PKA kinase substrates (e). 
 (f) Commassie stain showing equal protein loading of all gels.  
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Figure S7 
 
Figure S7.  Moderately altered kinome profiles in Cdkl5–/y mice. 
 (a-g) Western blots of whole cell lysate isolated from different brain regions probed with antibodies specific for 
phosphorylation motifs as indicated.  Brain regions 1-14 are described in Figure S6a. 
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Figure S8 
 
Figure S8.  Mildly altered kinome profiles in Cdkl5–/y mice. 
 (a-f) Western blots of whole cell lysate isolated from different brain regions probed with antibodies specific for 
phosphorylation motifs as indicated.  Brain regions 1-14 are described in Figure S6a. 
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Figure S9 
 
Figure S9.  Enrichment of CDKL5 in the cytoplasm. 
CDKL5 is predominantly found in the cytoplasm.  As controls, Sin3a and MeCP2 are predominantly in the nucleus, while 
Tau and GAPDH are predominantly in the cytoplasm. 
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Chapter 3: 
GENETIC DISSECTION OF CDKL5 DISORDER	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This chapter consists of unpublished and ongoing work investigating the mechanisms by 
which Cdkl5 loss-of-function leads to disease.  Using a conditional knockout mouse 
approach, this study has revealed that mice lacking CDKL5 in the brain recapitulate a 
number of behavioral phenotypes of the constitutive knockout.  In addition, mice lacking 
CDKL5 from forebrain glutamatergic neurons and mice lacking CDKL5 from forebrain 
GABAergic neurons show distinct behavioral phenotypes suggestive of circuit- and cell 
type-specific mechanisms underlying CDKL5 disorder pathogenesis.  Ongoing work 
aims to investigate the neuronal circuits, synapses, and signaling pathways mediating 
these behaviors, with the ultimate goal of identifying substrates or signaling pathways 
that can be targeted for therapeutics in order to restore circuit function and rescue 
behavioral abnormalities. 
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Introduction 
Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) cause 
CDKL5 disorder, an infantile epileptic encephalopathy with features of intellectual 
disability and intractable seizures (Nabbout and Dulac, 2011; Prince and Ring, 2011).  
CDKL5 patients show a heterogeneous array of other clinical phenotypes, the most 
prominent of which include autism, poor motor learning, stereotypical hand movements, 
and hypotonia (Bahi-Buisson et al., 2008b; Fehr et al., 2012).  A subset of CDKL5 
patients have also been diagnosed with Infantile Spasms (Kalscheuer et al., 2003), the 
early seizure, or Hanefeld, variant of Rett Syndrome (RTT) (Hanefeld, 1985; Neul et al., 
2010; Tao et al., 2004; Weaving et al., 2004), and autism spectrum disorder (ASD) 
(Sakai et al., 2011).  Despite the strong genetic linkage between CDKL5 mutations and 
neurodevelopmental disorders (Archer et al., 2006; Nemos et al., 2009; White et al., 
2010), the biological function of CDKL5 and the pathogenic mechanisms underlying 
disease remain largely uncharacterized.  Consequently, treatments for CDKL5 disorder 
have been largely ineffective and limited to symptom management (Bahi-Buisson and 
Bienvenu, 2012; Kilstrup-Nielsen et al., 2012).   
 
Although patients with CDKL5 disorder represent a small total population, the steady 
increase in rate of CDKL5 diagnoses each year and the notably high frequency of 
CDKL5 mutations found in enriched populations of patients with epilepsy or autism 
(Archer et al., 2006; Bahi-Buisson et al., 2008b; Mei et al., 2014; Mirzaa et al., 2013; 
Nemos et al., 2009; White et al., 2010) suggests that the disorder may be more 
prominent than currently understood.  Moreover, several clinical phenotypes of CDKL5 
disorder are shared among epileptic encephalopathies, disorders of intellectual disability, 
and autism spectrum disorders.  Therefore, a thorough understanding of the neural 
circuits and cellular mechanisms underlying this monogenic disorder may illuminate 
therapeutic targets that are relevant to autism and epilepsy disorders with more complex 
etiologies. 
 
The presence of a highly conserved serine-threonine kinase domain in the CDKL5 N-
terminus indicates that disrupted CDKL5 kinase function may underlie CDKL5 disease 
mechanism.  The presence of Rett-like features in CDKL5 patients and that discovery 
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that MeCP2, the methyl-CpG binding protein genetically responsible for Rett Syndrome 
(Amir et al., 1999), is regulated by phosphorylation (Chen et al., 2003; Zhou et al., 2006), 
suggest that CDKL5 and MeCP2 may act in a common pathway.  Indeed, CDKL5 has 
been shown to phosphorylate MeCP2 in vitro (Mari et al., 2005), but whether MeCP2 is a 
bona fide kinase substrate of CDKL5 is contentious (Lin et al., 2005).  Other in vitro 
kinase substrates have been identified, including DNA methyltransferase 1 (Dnmt1) and 
Amphiphysin1 (Amph1), but their in vivo relevance has yet to be determined (Kameshita 
et al., 2008; Sekiguchi et al., 2013). 
 
CDKL5 has also been found to bind and phosphorylate NGL-1, a netrin-G1 receptor that 
regulates early synapse formation and maturation, which then binds PSD95 and 
localizes to dendritic spines (Ricciardi et al., 2012).  In this study, shRNA-mediated 
knockdown of Cdkl5 increases spine density and length and reduces synapse number, 
indicating that CDKL5 plays a role in spine maturation and synapse morphogenesis by 
promoting the NGL-1—PSD95 interaction.  This mechanism, however, is contested, as a 
separate group has shown that CDKL5 binds directly to palmitoylated PSD95 and is thus 
recruited to dendritic spines, and that shRNA-mediated knockdown of Cdkl5 decreases 
spine density and width (Zhu et al., 2013).  Moreover, while both groups have 
demonstrated that in utero electroporation of an shRNA construct targeting Cdkl5 delays 
neuronal migration (Chen et al., 2010; Ricciardi et al., 2012), only one group identified 
impaired neuronal outgrowth using this technique (Chen et al., 2010).  Therefore, 
despite the research progress made in establishing a developmental role for CDKL5 and 
localizing the protein to excitatory synapses, the field continues to be hindered by 
inconsistent findings and conflicting mechanisms.  
 
The development and characterization of mouse models can serve as powerful tools to 
reconcile incongruous results and to establish the in vivo relevancy of proposed 
functions.  To date, two CDKL5 knockout (KO) mouse lines have been generated, and 
reduced soma size (Wang, unpublished) and dendritic length have been identified in 
cortical layer 5 and hippocampal pyramidal neurons on CDKL5 KO mice (Amendola et 
al., 2014; Wang et al., 2012).  In addition, postmitotic newborn dentate granule neurons 
from CDKL5 KO mice show decreased survival and dendritic outgrowth (Fuchs et al., 
2014).  Together, these data demonstrate an in vivo role for CDKL5 in neuronal 
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development, but the mechanisms underlying this regulation and how they contribute to 
behavioral impairments remain unknown. 
 
Both CDKL5 KO mouse models mirror several CDKL5 clinical phenotypes, including 
poor motor coordination, impaired learning and memory, and autistic-like deficits in 
sociability (Fuchs et al., 2014; Wang et al., 2012).  These behavioral phenotypes may be 
mediated by disruptions in neuronal circuit communication, as both visual and auditory 
sensory information processing are impaired in CDKL5 KO mice (Amendola et al., 2014; 
Wang et al., 2012).  Additionally, disruptions in multiple signaling pathways, including the 
Akt/mTOR pathway have been identified in CDKL5 KO mice (Amendola et al., 2014; 
Fuchs et al., 2014; Wang et al., 2012), suggesting a disease mechanism by which loss 
of CDKL5 may disrupt signaling pathways relevant to neuronal development, leading to 
impaired neural circuit communication and behavioral abnormalities. 
 
Interestingly, neither CDKL5 KO mouse model develop spontaneous seizures or 
demonstrate altered seizure threshold, despite extensive video-EEG monitoring 
(Amendola et al., 2014; Wang et al., 2012).  Although EEG patterns in CDKL5 KO mice 
differ from that of WT mice upon seizure induction (Amendola et al., 2014), the absence 
of the spontaneous seizure phenotype, which is a diagnostic criterion for CDKL5 
disorder (Neul et al., 2010), challenges the face validity of the constitutive knockout mice 
and prompts the need for a CDKL5 mouse model that can recapitulate this key 
phenotype. 
 
Recent conditional knockout mouse studies have demonstrated that distinct neuronal 
subpopulations control different neural circuits, and that selective perturbation of these 
circuits can cause discrete behavioral phenotypes (Hong et al., 2014; Ozkan et al., 
2014), some of which are not manifested in the constitutive knockout (Chao et al., 2010; 
Goffin et al., 2014).  Moreover, these studies have illuminated the contribution of 
individual cell types toward neural circuit function and isolated cell type-specific 
mechanisms underlying disease manifestation.  We hypothesized, therefore, that CDKL5 
KO phenotypes may segregate upon cell type-specific CDKL5 ablation, and that a 
conditional knockout strategy may provide unique mouse models that recapitulate key 
features of CDKL5 disorder and pinpoint neuronal circuits and cell types through which 
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CDKL5 regulation is central, leading to novel mechanistic understanding of CDKL5 
function. 
 
A mechanism proposed to commonly underlie both ASDs and epilepsy is an imbalance 
in neuronal excitation and inhibition (E/I) (Brooks-Kayal, 2010; Rubenstein and 
Merzenich, 2003).  Given the prominence of these features in CDKL5 disorder, we 
hypothesized that loss of CDKL5 creates a shift in E/I balance and that selective ablation 
of CDKL5 from excitatory or inhibitory neuronal populations would isolate the neuronal 
circuits and cell types underlying this shift.  Interestingly, we found that selective deletion 
of CDKL5 from forebrain GABAergic neurons recapitulates autistic-like phenotypes, 
whereas selective deletion of CDKL5 from forebrain glutamatergic neurons results in 
spontaneous seizures, working memory deficits and context-dependent hyperactivity.  
The separation of distinct aspects of CDKL5 disorder-related phenotypes in the two 
complementary conditional KO lines suggests that epileptic and autistic phenotypes of 
CDKL5 disorder are mediated by distinct neural circuits and that loss of CDKL5 in 
specific cell types may differentially disrupt signaling pathways and impair neuronal 
function. 
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Results 
Generation of CDKL5 floxed mice 
We previously generated a CDKL5 KO mouse that mirrors many clinical CDKL5 
features, including autistic-like phenotypes, impaired motor control, and deficits in 
learning and memory (Wang et al., 2012).  These mice recapitulate a CDKL5 patient 
splice site mutation that leads the skipping of exon 7 and a reading frame shift that 
results in a premature stop codon in exon 8 (Archer et al., 2006).  To mimic the effects of 
this splice site mutation in mice, we deleted the homologous mouse Cdkl5 exon 6, 
leading to an early truncation of CDKL5 in its N-terminal kinase domain, thereby 
disrupting kinase activity.  Importantly, the Cdkl5 mRNA levels in these mice are 
dramatically reduced, which is likely a consequence of nonsense-mediated mRNA decay 
(Figure 1b).  In addition, full-length or truncated CDKL5 cannot be detected by Western 
blot using antibodies directed against CDKL5 N- or C-terminal domains (Figure 1c) 
(Wang et al., 2012).   
 
We used a similar genetic strategy to generate CDKL5 floxed mice, flanking exon 6 with 
loxP sites, such that a Cdkl5 loss-of-function allele can be generated upon Cre-mediated 
recombination (Figure 1a).  Male CDKL5 floxed mice (Cdkl52lox/y) mice express WT 
levels of Cdkl5 mRNA transcript and CDKL5 protein (Figures 1b, c), are viable and 
fertile on a C57BL/6 background, and show no gross developmental or behavioral 
abnormalities, and will therefore be referred to as WT hereafter. 
 
 
Loss of CDKL5 from the brain recapitulates many CDKL5-related phenotypes 
Although the time course and expression patterns of CDKL5 vary across studies, we and 
others have consistently found that the CDKL5 protein is expressed in multiple tissues 
but enriched in the brain (Chen et al., 2010; Lin et al., 2005).  To investigate the 
contribution of CDKL5 in the brain toward disease progression, we generated mice 
lacking CDKL5 specifically from the nervous system.  Given that maternal transmission 
of the imprinted Nestin-Cre transgene has been demonstrated to result in reduced 
recombination frequency (Fan et al., 2001), we crossed male mice heterozygous for 
Nestin-Cre to female mice homozygous for the CDKL5 floxed allele (Figure 2a) 
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(Tronche et al., 1999).  To avoid the confounding effects of mosaic CDKL5 expression 
from X-chromosome inactivation in females, we focused our study on male mice, and 
compared hemizygous male Cdkl52lox/y mice carrying the Nestin-Cre allele (Nestin-cKO) 
to hemizygous male Cdkl52lox/y mice (WT).  We performed a battery of behavioral assays 
and found that mice lacking CDKL5 from the central nervous system recapitulate almost 
all behavioral phenotypes identified in the CDKL5 constitutive KO mice (Wang et al., 
2012).  In a locomotor assay within a homecage-like environment, Nestin-cKO mice 
demonstrate significantly higher motor activity than WT littermate controls (Figure 2b), 
and in a zeromaze assay, they show decreased anxiety, spending more time in the open 
arms and less time in the closed arms relative to controls (Figure 2c).  We also 
observed ASD-like deficits in sociability, as Nestin-cKO mice spent less time directly 
interacting with a novel gonadectomized male A/J stimulus mouse relative to WT and 
displayed impaired nest building, a phenotype related to homecage social behavior 
(Figures 2d,e) (Deacon, 2006; Silverman et al., 2010).  Overall, the behavioral 
similarities between Nestin-cKO and CDKL5 constitutive KO mice indicate that CDKL5 
disorder is caused by Cdkl5 loss-of-function within the brain. 
 
 
Loss of CDKL5 from forebrain GABAergic neurons recapitulates ASD-like phenotypes 
Within the brain, CDKL5 is likely to play a prominent role in neurons, as it is absent or 
expressed as a different isoform in glial cells (Chen et al., 2010; Rusconi et al., 2008), 
and loss of CDKL5 does not affect gliogenesis (Fuchs et al., 2014).  In addition, CDKL5 
is enriched in the forebrain (Thompson et al., 2014; Wang et al., 2012), and is expressed 
in both glutamatergic and GABAergic neurons (Chen et al., 2010; Rusconi et al., 2008).  
Therefore, we focused our studies on forebrain conditional neuronal knockouts.  To test 
the hypothesis that loss of CDKL5 disrupts neuronal E/I balance, we generated mice 
lacking CDKL5 from forebrain glutamatergic neurons or forebrain GABAergic neurons by 
crossing female mice homozygous for the Cdkl5 floxed allele to male mice heterozygous 
for Nex-Cre (Goebbels et al., 2006) or Dlx5/6-Cre (Monory et al., 2006), respectively 
(Figure 4a).  Similarly to that of our Nestin-cKO studies, male hemizygous Cdkl52lox/y 
mice carrying the Nex-Cre allele (Nex-cKO) or the Dlx5/6-Cre allele (Dlx-cKO) were 
compared to male hemizygous Cdkl52lox/y littermates (WT).   
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Although these Cre-driver mouse lines are commonly used in conditional knockout 
studies (Chao et al., 2010; Goffin et al., 2014; Ka et al., 2014), we sought to assess the 
specificity of Cre-recombination in our complementary conditional knockout mouse lines.  
In our hands, commercially available and in-house purified CDKL5 antibodies show 
promiscuity, as Western blots using whole brain lysate from both WT and KO mice 
probed with CDKL5 antibodies detect full-length CDKL5 at the expected size (115 kDa) 
in addition to multiple non-specific immunoreactive bands (Wang et al., 2012).  Indeed, 
brain tissue slices obtained from CDKL5 KO mice immunostained for CDKL5 are 
indistinguishable from that of WT mice (Wang, unpublished).  To confirm the specificity 
and efficiency of Cre-mediated removal of CDKL5 expression in Dlx- and Nex-cKO mice, 
therefore, we performed Western blotting for CDKL5 on protein lysates prepared from 
dissected brain regions in which GABAergic or glutamatergic neurons are differentially 
enriched.  We chose to isolate tissue from the striatum and cortex, given that about 98% 
of neurons in the striatum are GABAergic and express Dlx5/6, and about 80% of 
neurons in the cortex are glutamatergic and express Nex.  As a negative control, we 
isolated the cerebellum, a brain region with low CDKL5 expression (Wang et al., 2012).  
Despite the presence of several nonspecific bands with consistent protein levels across 
samples, we found that CDKL5 expression (~115kDa) is significantly reduced in striatal 
lysate from Dlx-cKO but not Nex-cKO or WT mice, and that conversely, CDKL5 
expression is significantly reduced in cortical lysate from Nex-cKO but not Dlx-cKO or 
WT mice (Figure 3).  As expected, CDKL5 expression is consistently low in the 
cerebellum of all 3 genotypes (Figure 3).  Together, these data validate the efficiency 
and specificity of forebrain glutamatergic or GABAergic CDKL5 ablation in our Nex- and 
Dlx-cKO mice. 
 
To determine the phenotypic profile of our CDKL5 conditional knockouts, we performed 
a battery of behavioral assays and found that Dlx-cKO, but not Nex-cKO mice, display 
several autistic-like features.  In a three-chambered social approach assay, all three 
genotypes demonstrate no initial preference for empty cylinders in opposite chambers 
(Figure 4b).  Upon introduction of a novel object into one cylinder (non-social cylinder) 
and a novel gonadectomized A/J stimulus mouse into the other cylinder (social cylinder), 
both WT and Nex-cKO mice demonstrate increased preference for the social cylinder, 
reflecting the innate social nature of mice (Figure 4c) (Sankoorikal et al., 2006).  In 
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contrast, Dlx-cKO mice do not show this increased preference, indicating an autistic-like 
deficit in sociability.  Moreover, when the cylinders are removed to allow freely mobile 
direct interaction, Dlx-cKO, but not Nex-cKO mice, spend significantly less time 
interacting with the stimulus mice relative to WT mice (Figure 4d).  A similar autistic-like 
phenotype is observed in homecage sociability nesting behavior, where Dlx-cKO mice 
demonstrate a selective deficit in nest building ability, while Nex-cKO mice build nests 
comparable to that of WT mice (Figure 4e).  Importantly, no deficits in olfaction were 
identified in an olfaction habituation/dishabituation assay, indicating that the selective 
impairments in sociability in Dlx-cKO mice are not the secondary consequence of an 
inability to discriminate between social and neutral odors (Figure 4f). 
 
These data demonstrate that mice lacking CDKL5 from forebrain GABAergic neurons 
have deficits in social communication and interaction, which is the first of two main 
criteria of ASD, as defined by the 2013 DSM-5 revision.  The other core ASD domain is 
restrictive and repetitive behaviors, which can be modeled in mice through repetitive 
behavioral assays and measurements of cognitive flexibility.  Therefore, we measured 
homecage self-grooming and digging behavior, which is believed to be an indicator of 
repetitive and stereotyped behaviors (Peñagarikano et al., 2011; Silverman et al., 2010).  
Consistent with decreased sociability, we found that Dlx-cKO mice, but not Nex-cKO 
mice, spend significantly more time engaging in repetitive homecage grooming and 
digging behavior relative to WT mice (Figure 4g).   
 
To assess cognitive flexibility, or perseverative behavior in mice, we performed a Barnes 
maze forward and reversal learning test.  In this assay, mice are trained in 8 trials over 4 
days (2 trials/day) to locate a hidden escape hole from among 20 evenly spaced holes 
along the perimeter of a circular platform.  The platform is placed in a brightly lit room 
with spatial cues placed along the walls, and mice must learn where the escape hole is 
relative to the spatial cues.  All three genotypes demonstrated similar latency to enter 
the target box during training, indicating a comparable ability to learn the task (Figure 
5a).  On the 5th day, a probe trial is performed, in which the escape hole is closed and 
mice must rely solely on the spatial cues along the wall to locate the escape box.  In the 
probe trial, both Nex- and Dlx-cKO show a comparable number of visits to the target 
hole (Figure 5b), a similar pattern of number of visits to each hole (Figure 5c) and a 
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comparable amount of time spent at each hole relative to that of WT (Figure 5d).  
Together, these data indicate that all three genotypes are able to locate the target hole 
using the spatial cues and do not have impairments in spatial learning.   
 
In the Barnes maze reversal learning assay, the hidden escape hole is moved 180 
degrees to the opposite end of the circular platform, while the spatial cues in the room 
remain the same.  Therefore, mice must learn that the escape box has moved to a new 
location, and poor performance in this task is indicative of poor cognitive flexibility.  
Similar to that of forward learning, all three genotypes have comparable learning curves 
during the 8 trials across 4 days of reversal training, showing similar latency to enter the 
escape boxes (Figure 5e).  In the reversal probe trial on the 5th day, all three genotypes 
visit the new target location comparably (Figure 5f), indicating the similar use of spatial 
cues to learn the new location of the target box.  The pattern of visits to each hole and 
the amount of time spent at each hole, however, differs in both Dlx- and Nex-cKO mice, 
relative to WT (Figures 5g,h).  Whereas WT mice demonstrate no preference for the old 
hole in time spent or number of visits, both Dlx- and Nex-cKO mice demonstrate 
cognitive inflexibility, visiting the old hole significantly more times than WT animals 
(Figures 5g,i) and spending significantly more time at the old hole than WT animals 
(Figures 5h,j).  This kind of perseverative behavior has been identified in several ASD 
mouse models (Crawley, 2007; Nakatani et al., 2009) and is believed to model restrictive 
interests in ASDs.  Surprisingly, the Nex-cKO mice also demonstrate ASD-like cognitive 
inflexibility, but this phenotype may be related to a context-dependent hyperactivity 
phenotype (Figures 8e,f), discussed below.  Overall, these data indicate that the loss of 
CDKL5 from forebrain GABAergic neurons, but not glutamatergic neurons, mediates the 
selective development of autistic-like behaviors in mice. 
 
The striking restriction of ASD-like phenotypes to mice lacking CDKL5 from GABAergic 
neurons prompted us to verify this separation of phenotypes in a different and more 
broad CDKL5 GABAergic conditional knockout mouse line.  Therefore, we generated 
mice lacking CDKL5 from all GABAergic and glycinergic neurons in the brain, including 
the hindbrain, by crossing female mice homozygous for the Cdkl5 floxed allele to male 
mice heterozygous for the Viaat-Cre allele (Chao et al., 2010), and compared male 
hemizygous Cdkl52lox/y mice carrying the Viaat-Cre allele (Viaat-cKO) to male 
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hemizygous Cdkl52lox/y littermates (WT) (Figure 6a).  Western blots of brain tissue 
isolated from the striatum, cortex, and cerebellum of Viaat-cKO and WT mice showed, 
similar to that of Dlx-cKO mice, a selective loss of CDKL5 in the striatum but not the 
cortex of Viaat-cKO mice.  Importantly, the endogenously low levels of CDKL5 in the 
cerebellum were further reduced in Viaat-cKO mice, thus confirming the specificity and 
efficiency of our CDKL5 conditional deletion (Figure 6b).  In behavioral assays, these 
mice demonstrated autistic-like phenotypes identical to those of Dlx-cKO mice, including 
reduced preference for a social cylinder relative to a non-social cylinder, reduced time 
directly interacting with a stimulus mouse, impaired nesting ability, and increased 
homecage repetitive behavior relative to that of WT mice (Figures 6c-g).   
 
 
Loss of CDKL5 from forebrain glutamatergic neurons leads to development of 
spontaneous seizures 
In contrast to Dlx- and Viaat-cKO mice, Nex-cKO mice do not demonstrate autistic-like 
phenotypes.  While performing behavioral assays, however, we observed spontaneous 
seizures in several Nex-cKO mice.  These seizures ranged in severity and duration, from 
brief rearing and falling followed by normal behavior, to generalized tonic-clonic seizures 
following by extended rearing and eventually death (Figure 7).  The spontaneous 
seizure phenotype appears to be exclusive to Nex-cKO mice, as we have not observed 
seizures in WT, Dlx- and Viaat-cKO mice.  Future video-EEG monitoring of WT, Dlx- and 
Nex-cKO mice across different developmental time points will help to identify seizure 
type, onset, and frequency in mice, and whether the spontaneous seizure phenotype is 
indeed exclusively related to loss of CDKL5 from glutamatergic neurons.  In addition, 
seizure induction through acute injections of pentylenetetrazol (PTZ) or chemical kindling 
through chronic PTZ injections will determine whether seizure threshold is altered upon 
conditional loss of CDKL5 (Dhir, 2012).  This finding indicates that Cdkl5 loss-of-function 
specifically in forebrain glutamatergic neurons is central to seizure development. 
 
 
 
 
63	  
	  
Hindlimb clasping, impaired working memory, and context-dependent hyperactivity upon 
loss of CDKL5 from forebrain glutamatergic neurons 
Other prominent phenotypes in CDKL5 patients include motor impairment and 
intellectual disability.  The CDKL5 constitutive KO mouse recapitulates these 
phenotypes, demonstrating hindlimb clasping, impairments on the rotarod, and deficits in 
fear memory and working memory (Amendola et al., 2014; Fuchs et al., 2014; Wang et 
al., 2012).  We therefore characterized these phenotypes in Dlx- and Nex-cKO mice to 
determine whether these phenotypes segregate upon conditional CDKL5 ablation.  We 
observed hindlimb clasping in Nex-cKO animals, but not in Dcre-cKO or WT animals 
(Figure 8a).  On an accelerating rotarod assay, however, all animals showed similar 
latency to fall across trials and days, indicating that circuit mechanisms underlying motor 
behavior are complex and may not segregate completely upon conditional CDKL5 
ablation (Figure 8b).  In a Y-maze assay of working memory, we found that Nex-cKO, 
but not Dlx-cKO, mice show reduced spontaneous alternation.  In contrast to WT and 
Dlx-cKO mice, which show the expected ~67% preference for a previously unexplored 
arm, Nex-cKO mice do not show any preference and enter previously explored and 
unexplored arms equally (~50%) (Figure 8c).   
 
We noticed that in particular settings, Nex-cKO mice showed increased exploratory and 
locomotor activity.  On the Y-maze, Nex-cKO mice entered significantly more arms than 
WT animals and Dlx-cKO mice (Figure 8d), and in both forward and reversal Barnes 
maze, Nex-cKO mice were hyperactive, traveling a greater total distance and 
investigating significantly more holes (Figures 8e,f) than both WT and Dlx-cKO mice.  
Interestingly, however, Nex-cKO mice do not show any difference in locomotor activity 
relative to that of WT and Dlx-cKO mice in a homecage-like environment, nor do they 
demonstrate a difference in time spent in the open arm of a zeromaze (Figures 8g,h), 
indicating that Nex-cKO mice are not innately hyperactive or anxious, and that the 
hyperlocomotor phenotype is related to external stimuli.  This hypothesis is supported by 
the differences in the experimental design of these assays.  The locomotor assay is 
conducted in a homecage-like environment and the zeromaze assay is conducted in 
extremely low light levels (~4 lux).  In contrast, both Barnes maze and Y-maze assays 
are conducted under bright light, which may be an external stimulus with higher 
emotional valence.  Consistent with this hypothesis, Nex-cKO mice show similar 
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locomotor activity in Phase 1 of the social approach assay, when cylinders are empty, 
but upon introduction of a novel object or mouse in Phase 2 of the social approach 
assay, Nex-cKO mice show significantly greater locomotor activity (Figure 8i).  
Interestingly, hyperactivity and seizures have been linked in some animal models 
(Gantois et al., 2007; Peters et al., 2005) but determining how context-dependent 
hyperactivity phenotype in Nex-cKO mice is related to seizure development will require 
more investigation.   
 
 
Circuit-level mechanisms underlying separation of phenotypes upon conditional CDKL5 
ablation 
The separation of autistic and epileptic aspects of CDKL5 disorder-related phenotypes in 
the complementary Dlx- and Nex-cKO mouse lines suggests that conditional loss of 
CDKL5 disrupts neural circuits underlying these phenotypes.  To assess circuit function 
in Dlx- and Nex-cKO mice, we measured auditory-evoked event related potentials 
(ERPs), which are believed to be readouts of sensory information processing (Roberts et 
al., 2010; Stauder et al., 2006).  As described previously (Goffin et al., 2012; 2014; 
Wang et al., 2012), we implanted tri-polar hippocampal electrodes and measured ERPs 
in awake behaving animals following the presentation of 250 85-dB white noise stimuli.  
Interestingly, we did not observe any differences in event-related power between 
genotypes, as all animals exhibited the stereotypical decrease in power at low 
frequencies and increase in power at high frequencies following sound presentation 
(Figures 9a-c) (Goffin et al., 2012; Wang et al., 2012).  Additionally, all animals showed 
the stereotypical robust increase in phase-locking factor (PLF), a measure of trial-to-trial 
reliability, across all frequencies (Figures 9d-f).  Previous studies from CDKL5 
constitutive KO mice showed impairments in both auditory- and visual-evoked ERPs 
(Amendola et al., 2014; Wang et al., 2012), suggesting that loss of CDKL5 from 
forebrain excitatory or inhibitory circuits alone is not sufficient to perturb sensory-evoked 
event-related potentials. 
 
Although the ERP data indicates that circuits mediating auditory sensory information 
processing appear to be relatively intact upon conditional loss of CDKL5, we reasoned 
that distinct alterations in neural circuits are likely to underlie the separation of the 
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epileptic and autistic phenotypes in Nex- and Dlx-cKO mice, and therefore, might be 
detected using a different assay of circuit function.  Given the relevance of hippocampal 
circuits in the major CDKL5 phenotypes of epilepsy and autism (Ang et al., 2006; Pathak 
et al., 2007; Tyler et al., 2012), we performed voltage sensitive dye imaging to measure 
the dentate gyrus (DG) hippocampal microcircuit.  In WT animals, low frequency 
stimulation of entorrhinal cortical afferents, also known as the perforant path, activates 
the DG, but strong synaptic inhibition mediated by feed-forward inhibitory neurons along 
with the ratio of synaptic inhibitory/excitatory innervation prevents this activation from 
reaching CA3 (Figures 10a-c) (Acsády et al., 1998).  In Dlx-cKO mice, however, 
perforant path stimulation results in activation of both DG and downstream hippocampal 
structures, particularly area CA3 and more distal hilar regions (Figures 10a-c), 
suggesting a disruption in DG filtering of afferent inputs.  Nex-cKO mice also show a 
trend toward disruption in DG filtering, but downstream activation of CA3 in Nex-cKO 
animals is not significant (Figure 10c).  Together, these data indicate that conditional 
loss of CDKL5 may differentially affect neural circuits underlying behaviors, where a 
disruption in DG filtering properties in Dlx-cKO may be related to the development of 
autistic-like behavioral phenotypes.  Future VSD experiments activating CA3 via mossy 
fiber afferents of the dentate granule cells or activating CA1 via Schaffer collaterals of 
CA3 neurons will further isolate the primary loci of hippocampal disruptions mediating 
the autistic or epileptic phenotypes observed in our CDKL5 conditional knockout 
animals.  The connectivity within these hippocampal microcircuits and their relevance to 
behaviors has been well characterized (Ang et al., 2005; Leutgeb et al., 2007; Redondo 
et al., 2014; Wozny et al., 2005).  Therefore, understanding how conditional loss of 
CDKL5 from glutamatergic or GABAergic neurons affects the functionality and E/I 
balance within these microcircuits will pinpoint key circuit mechanisms and disease-
related loci underlying CDKL5 disorder.  
 
 
Reduced neuronal outgrowth upon conditional loss of CDKL5 
The separation of epilepsy and autistic behaviors in Dlx- and Nex-cKO mice suggest that 
the epileptic and autistic phenotypes of CDKL5 disorder may be mediated by distinct 
neural circuits or that common neural circuits are differentially affected by loss of CDKL5 
from either glutamatergic or GABAergic neurons.  The two possibilities, however, are not 
66	  
	  
mutually exclusive, and due to the complexity of the brain, the in vivo mechanism is 
likely to be a combination of the two.  As circuit formation and function can be affected 
by mislocalization or impaired development of neurons, neuronal outgrowth may serve 
as a morphological correlate of circuit function.  Given that shRNA-mediated Cdkl5 
knockdown has been shown to delay neuronal migration, reduce neuronal outgrowth, 
and impair dendritic spine formation (Chen et al., 2010; Ricciardi et al., 2012; Zhu et al., 
2013), we hypothesized that loss of CDKL5 may alter neural circuit formation by 
affecting neuronal development.  Similar effects on neuronal development in 
complementary Dlx- and Nex-cKO animals would suggest that the autistic and epileptic 
phenotypes of CDKL5 disorder are indeed mediated by distinct neural circuits, whereas 
differential effects on neuronal development would provide evidence for common circuits 
differentially affected upon conditional loss of CDKL5.   
 
To this end, we have measured soma size and dendritic morphology in CA1 
hippocampal pyramidal neurons of Nex-cKO animals.  Experimental mice were crossed 
to a Thy1-GFP/M reporter line (Feng et al., 2000), thereby generating WT and Dlx- or 
Nex-cKO mice in which a sparse population of neurons intrinsically expresses GFP 
throughout the cell body and dendritic tree, allowing for direct visualization of individual 
neurons, particularly in the hippocampal CA1 pyramidal layer (Figure 11a), as described 
previously (Wang et al., 2013).  To quantify dendritic complexity, we used the Sholl 
analysis, which measures dendritic crossings through a series of concentric circles with 
increasing radii centered around the cell soma (SHOLL, 1953).  Given the anatomic and 
functional distinctions between basal and apical dendritic arbors (Spruston, 2008), we 
imaged and quantified basal and apical dendritic complexity separately and found 
reduced dendritic complexity in both basal and apical dendritic arbors of CA1 pyramidal 
neurons of Nex-cKO mice relative to that WT mice (Figures 11b,c).  Total dendritic 
length in Nex-cKO animals was reduced as well, but this reduction was not significant 
(Figure 11d).  In contrast, soma size did not differ between Nex-cKO and WT mice 
(Figure 11e), indicating that deficits in neuronal connectivity, but not basic intrinsic 
membrane properties of CA1 neurons, are related to the neural circuits that underlie the 
development of spontaneous seizures in Nex-cKO mice.  As these data were obtained 
from 3 WT and 3 Nex-cKO mice, these trends should be confirmed with a larger sample 
size to obtain greater statistical power.  Future studies will also measure dendritic 
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outgrowth and soma size in Dlx-cKO mice, and comparison of morphological 
phenotypes in the complementary conditional knockouts should address whether CDKL5 
regulates neuronal development in a cell autonomous manner and identify how 
conditional loss of CDKL5 from glutamatergic or GABAergic neurons affects circuit 
assembly. 
 
Circuit communication is ultimately dictated by synapse function, and disruption of 
synaptic signaling has been identified in multiple ASD mouse models (Chao et al., 2007; 
Peça et al., 2011; Tsai et al., 2012).  Indeed, knockdown of CDKL5 from cultured 
hippocampal neurons results in decreased amplitude and frequency of mEPSCs 
(Ricciardi et al., 2012; Zhu et al., 2013), indicative of impaired synapse function upon 
loss of CDKL5.  We hypothesize that loss of CDKL5 will disrupt synaptic properties and 
that distinct synaptic phenotypes in Nex- and Dlx-cKO mice may mediate the distinct 
behavioral and circuit phenotypes.  Therefore, measurement of spine density, size, and 
type should also be performed in both conditional knockout mice in future studies, firstly 
to resolve the conflicting data supporting how loss of CDKL5 affects spine development 
(Ricciardi et al., 2012; Zhu et al., 2013), and secondly to establish a morphological 
correlate for synapse function (Figure 11f).  In future synaptic electrophysiology 
experiments, current clamp recordings in CA1 pyramidal neurons will measure basic 
intrinsic neuronal properties and excitability, and voltage clamp recordings will measure 
evoked and spontaneous excitatory and inhibitory synaptic activity in both Dlx- and Nex-
cKO mice.  Together, these experiments should isolate the cell types and synapses that 
require CDKL5 for proper circuit formation and reveal how changes in synaptic 
connectivity affect neuronal E/I balance, leading to distinct behavioral phenotypes in Dlx- 
and Nex-cKO mice. 
 
 
Isolating the role of CDKL5 in PTEN downstream signaling pathways 
The mechanism by which CDKL5 localizes to excitatory synapses is supported by 
conflicting data, with one study describing a kinase-dependent mechanism (Ricciardi et 
al., 2012) and the other, a kinase-independent mechanism (Zhu et al., 2013).  Akt 
signaling has been implicated in CDKL5 disease pathogenesis by three independent 
studies from CDKL5 KO mice, and we previously identified a number of signaling 
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pathways disrupted upon Cdkl5 loss-of-function (Wang et al., 2012).  Interestingly, the 
Akt-mTOR, Akt-S6, Akt-GSK3b, and AMPK, MAPK/ERK pathways converge into PTEN 
downstream signaling pathways (Amendola et al., 2014; Fuchs et al., 2014; Wang et al., 
2012).  As disruptions in PTEN signaling have been described in both autism and 
epilepsy (Clipperton-Allen and Page, 2014; Costa-Mattioli and Monteggia, 2013; 
Gkogkas et al., 2012; Santini et al., 2013; Zhou and Parada, 2012), these data suggest 
that CDKL5 may play a prominent role in coordinating or regulating PTEN signaling 
pathways.  Future studies pharmacologically and genetically altering PTEN signaling in 
mice lacking CDKL5 from either glutamatergic or GABAergic neurons should pinpoint 
the relationship between CDKL5 and PTEN signaling and isolate cell type-specific 
signaling pathways that are relevant to disease. 
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Conclusion and future directions 
In this study, we developed conditional CDKL5 knockout mouse models and 
demonstrated that loss of CDKL5 from the brain is sufficient to recapitulate several 
features of the constitutive CDKL5 KO mouse model, indicating that the role of CDKL5 is 
primarily in the brain. 
 
We also found that mice lacking CDKL5 exclusively from forebrain GABAergic neurons 
develop autistic-like phenotypes, whereas mice lacking CDKL5 exclusively from 
forebrain glutamatergic neurons develop spontaneous seizures.  The separation of these 
CDKL5-related phenotypes in the complementary conditional knockout animals suggests 
that distinct neural circuits mediate the two behaviors, or that loss of CDKL5 from 
glutamatergic or GABAergic neurons differentially affects common circuits.  VSDI 
imaging of hippocampal microcircuits indicates that dentate gyrus filtering properties are 
preferentially disrupted in mice lacking CDKL5 from forebrain GABAergic neurons, 
implicating this microcircuit in autism-like behavior. 
 
Future studies investigating the properties of CA3 and CA1 hippocampal microcircuits, 
neuronal development and outgrowth, excitatory and inhibitory synapse function, and 
PTEN downstream signaling pathways in the complementary CDKL5 conditional 
knockout animals aim to reveal the cell type-specific function of CDKL5 and isolate 
pathogenic mechanisms leading to autistic behaviors and epilepsy.  Eventually, a clear 
understanding of CDKL5 biological function should give rise to targeted therapeutics for 
CDKL5 disorder. 
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Figure 1 
 
Figure 1. Generation of CDKL5 floxed mice 
 A. Targeting strategy.  Three loxP sites and a neomycin positive selection cassette (Neo) were inserted 
surrounding the genomic locus of Cdkl5 exon 6 via homologous recombination.  Upon Cre-directed recombination, the 
Neo cassette is excised, leaving exon 6 flanked by loxP sites.   
 B. Quantitative PCR of mRNA obtained from brains of Cdkl5+/y (WT), Cdkl5-/y (KO), Cdkl52lox/y (cKO).  Cdkl5 
expression levels are normalized to Hprt. 
 C. Western blot of whole brain lysate obtained from Cdkl5+/y (WT), Cdkl5-/y (KO), Cdkl52lox/y (cKO) probed with 
an antibody directed against CDKL5 (red) and actin (green). 
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Figure 2 
 
Figure 2. Nestin-cKO behavioral phenotypes 
 A. Breeding strategy.  Female mice homozygous for the Cdkl52lox allele were crossed to male mice carrying the 
Nestin-Cre transgene.  Male progeny were used for behavioral experiments. n = 10-15 per genotype. 
 B. Sixty-minute locomotor assay, measured by infrared beam breaks in a home cage-like environment. Black 
(WT), green (Nestin-cKO).  p<0.05, Two-way RM-ANOVA (genotype). 
 C. Zeromaze assay, measured by time spent in open arm relative to total time on maze.  *p<0.05, Student’s t-test. 
 D. Three-chambered social approach assay, measured by time spent directly interacting with freely moving 
stimulus mouse.  *p<0.05, Student’s t-test. 
 E. Nest building, scored on 1-5 scale.  *p<0.05, Student’s t-test. 
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Figure 3 
 
Figure 3. CDKL5 expression in Nex-cKO and Dlx-cKO mice 
Whole cell lysates from dissected striatum, cortex, and cerebellum of WT, Nex-cKO, and Dlx-cKO mice were probed with 
antibodies raised up against CDKL5 and Actin. n = 3-4 animals per genotype. 
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Figure 4 
 
Figure 4. Autistic-like behaviors in mice lacking CDKL5 from forebrain GABAergic neurons 
 A. Breeding strategy.  Female mice homozygous for the Cdkl52lox allele were crossed to male mice carrying the 
Dlx5/6-Cre transgene or the NexCre allele.  Male progeny were used for behavioral experiments. n = 15-20 per genotype. 
 B. Three-chambered social approach assay, time spent investigating empty cylinders.  n.s., not significant, 
Student’s t-test with Bonferroni correction. Black (WT), red (Dlx-cKO), blue (Nex-cKO). 
 C. Three-chambered social approach assay, time spent investigating a cylinder that contains a stimulus mouse 
(social cylinder) or a cylinder that contains a novel object (non-social cylinder).  ****p<0.0001, n.s., not significant, 
Student’s t-test with Bonferroni correction. 
 D. Three-chambered social approach assay, time spent directly interacting with freely moving stimulus mouse. 
p<0.0001, Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison post-hoc test. 
 E. Nest building, scored on 1-5 scale. p<0.0001, One-way ANOVA with Dunnett’s multiple-comparison test. 
 F. Olfactory habituation/dishabituation assay, time spent investigating repeated presentations of odorants water, 
vanilla extract, and social (swab from soiled bedding of different cage). 
 G. Repetitive behavior, time spent digging and self-grooming in 10-minute period. **p<0.01, Kruskal-Wallis one-
way ANOVA with Dunn’s multiple comparison post-hoc test. 
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Figure 5 
 
Figure 5. Barnes maze forward and reversal learning 
 A. Forward learning training, latency to enter target hole at each trial.  Two trials were performed per day. 
 B. Forward learning probe trial (Day 5), number of visits to target hole.  n.s. not significant, Kruskal-Wallis one-
way ANOVA. 
 C. Forward learning probe trial (Day 5), number of visits to each hole during 150 second trial.  Central peak is 
target hole, peak to the right of central peak corresponds to clockwise adjacent hole, peak to the left of central peak 
corresponds to counter-clockwise. 
 D. Forward learning probe trial (Day 5), time spent investigating each hole during 150-second trial.  Central 
peak is target hole, as described in C. 
 E. Reversal learning training, latency to enter target hole at each trial.  Two trials were performed per day. 
 F. Reversal learning probe trial (Day 5), number of visits to new target hole.  n.s. not significant, Kruskal-Wallis 
one-way ANOVA. 
 G. Reversal learning probe trial (Day 5), number of visits to each hole during 150-second trial.  Central peak is 
new target hole, peak to the right of central peak corresponds to clockwise adjacent hole, peak to the left of central peak 
corresponds to counter-clockwise, peak to the far right corresponds to original target hole. 
 H. Reversal learning probe trial (Day 5), time spent investigating each hole during 150-second trial.  Central 
peak is new target hole, as described in G. 
 I. Reversal learning probe trial (Day 5), number of visits to original target hole.  **p<0.01, one-way ANOVA with 
Dunnett’s multiple comparison test. 
 J. Reversal learning probe trial (Day 5), time spent investigating original target hole.  *p<0.05, one-way ANOVA 
with Dunnett’s multiple comparison test.  n = 10-15 animals per genotype. 
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Figure 6 
 
Figure 6. Viaat-cKO behavioral phenotypes 
 A. Breeding strategy. Female mice homozygous for the Cdkl52lox allele were crossed to male mice carrying the 
Viaat-Cre transgene.  Male progeny were used for behavioral experiments. n = 10-15 per genotype. Black (WT), purple 
(Viaat-cKO). 
 B. Western blot.  Whole cell lysates from dissected striatum, cortex, and cerebellum of WT and Viaat-cKO and 
probed with antibodies raised up against CDKL5 and Actin. n = 3-4 animals per genotype. 
 C. Three-chambered social approach assay, time spent investigating empty cylinders.  n.s., not significant, 
Student’s t-test with Bonferroni correction. 
 D. Three-chambered social approach assay, time spent investigating a cylinder that contains a stimulus mouse 
(social cylinder) or a cylinder that contains a novel object (non-social cylinder). Student’s t-test with Bonferroni correction. 
 E. Three-chambered social approach assay, time spent directly interacting with freely moving stimulus mouse. 
*p<0.05, Student’s t-test. 
 F. Nest building, scored on 1-5 scale. ***p<0.001, Student’s t-test. 
 G. Repetitive behavior, time spent digging and self-grooming in 10-minute period.  **p<0.01, Student’s t-test 
with Welch’s correction. 
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Figure 7 
 
Figure 7.  Representative still images of rearing and falling during spontaneous tonic-clonic seizure observed in Nex-cKO 
animal. 
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Figure 8 
 
Figure 8. Nex-cKO behavioral phenotypes 
 A. Hindlimb clasing in Nex-cKO animals. 
 B. Rotarod assay, measured by latency to fall from cylindrical rod rotating and accelerating.  Four trials 
performed for four days.  n.s. not significant, Two-way ANOVA.  n = 15-20 per genotype 
 C. Y-maze assay, measured by percentage of entries into new arm of maze rather than returning to arm 
previously investigated.  p<0.0001, one-way ANOVA with Dunnett’s multiple comparison test. 
 D. Y-maze assay, total number of entries in Y-maze arms.  p<0.01, one-way ANOVA with Dunnett’s test. 
 E. Barnes maze forward and reversal probe trials, total distance traveled during 150-second test.  **p<0.01, 
one-way ANOVA with Dunnett’s multiple comparison test. 
 F. Barnes maze forward and reversal probe trials, total number of holes investigated during 150-second test.  
**p<0.01, one-way ANOVA with Dunnett’s multiple comparison test. 
 G. Sixty-minute locomotor assay, measured by infrared beam breaks in a home cage-like environment. n.s. not 
significant, two-way RM-ANOVA. 
 H. Zeromaze assay, time spent in open arm relative to total time on maze.  n.s. not significant, one-way 
ANOVA. 
 I. Three-chambered social approach assay.  Total distance traveled in Phase 1 (when cylinders are empty) and 
Phase 2 (when cylinders contain stimulus mouse or novel object).  **p<0.01, one-way ANOVA with Dunnett’s multiple 
comparison test.  
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Figure 9 
 
Figure 9. Time-frequency plots of auditory-evoked event-related potentials (ERPs). 
 A-C. Time-frequency plot showing changes in event-related power following an 85-dB auditory stimulus.  Color 
represents mean power, where warmed colors correspond to increased power and cooler colors correspond to decreased 
power relative to prestimulus baseline. 
 D-F. Time -frequency plot showing changes in event-related phase-locking factor (PLF) following an 85-dB 
auditory stimulus.  Color represents PLF, where warmer colors correspond to a higher PLF or lower circular variance in 
EEG phase across trials.  n = 10 animals per genotype. 
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Figure 10 
 
Figure 10. Voltage-sensitive dye imaging of dentate gyrus hippocampal microcircuit 
 A. Snapshots of peak fluorescence change during a DG EPSP elicited by perforant path stimulation. White 
arrow: increased activation of CA3 of Dlx-cKO mouse.  Insets are grey scale images of slice depicting cell areas. 
 B. Integrated voltage traces of the responses in A.  Black arrow: increased EPSP in CA3 of Dlx-cKO mouse. 
 C. Quantification of DG and CA3 activation *p<0.05, one-way ANOVA. 
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Figure 11 
 
Figure 11. Neuronal morphology of hippocampal CA1 pyramidal neurons 
 A. Thy1-GFP/M reporter imaging strategy.  CA1 neurons are labeled with GFP throughout the cell body and 
dendritic tree. 
 B. Total dendritic length of CA1 neurons in WT and Nex-cKO mice.  n = 3 animals per genotype (12 neurons 
per animal) 
 C. Sholl analysis of CA1 basal dendritic arbor.  0 um marks soma position.  *p<0.05, two-way ANOVA with 
Bonferroni correction (interaction). 
 D. Sholl analysis of CA1 apical dendritic arbor.  0 um marks soma position.  **p<0.01, two-way ANOVA with 
Bonferroni correction (interaction). 
 E. Soma size of CA1 neurons. n = 3 animals per genotype (at least 50 neurons per animal). 
 F. Thy1-GFP/M reporter imaging strategy.  Dendritic spines of CA1 neurons are labeled with GFP. 
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This chapter represents a collaboration within the lab resulting a Nature Neuroscience 
paper published in 2012 that examines Rett Syndrome (RTT), a severe neurological 
disorder characterized by the loss of acquired motor skills and cognitive ability and the 
development of distinctive hand stereotypies.  In this paper, we develop and 
characterized a mouse model of a patient T158 missense mutation and find that MeCP2 
T158A mice recapitulate a number of RTT-like behavioral phenotypes, which may be 
mediated by reduced MeCP2 DNA binding and protein stability.  We also find evidence 
for the requirement of MeCP2 in the developmental of functional circuits.  Overall, this 
paper suggests that stabilizing MeCP2 and enhancing MeCP2 affinity for DNA binding 
may be relevant for RTT therapeutics, and that developmental assessment of ERPs may 
serve as a biomarker for RTT disease progression and therapeutic efficacy.  
 
As a co-second author in this Nature Neuroscience paper, my contribution to this paper 
was in both experiments and editing.  I measured soma size in mice using a GFP 
reporter (Fig 1f), and performed all behavioral assays in Figure 2, and edited the paper 
throughout its various versions.  
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Abstract 
Mutations in the MECP2 gene cause the autism spectrum disorder Rett Syndrome 
(RTT). One of the most common mutations associated with RTT occurs at MeCP2 
Threonine 158 converting it to Methionine (T158M) or Alanine (T158A). To understand 
the role of T158 mutation in the pathogenesis of RTT, we generated knockin mice 
recapitulating MeCP2 T158A mutation. Here we show a causal role for T158A mutation 
in the development of RTT-like phenotypes including developmental regression, motor 
dysfunction, and learning and memory deficits. These phenotypes resemble those in 
Mecp2-null mice and manifest through a reduction in MeCP2 binding to methylated DNA 
and a decrease in MeCP2 protein stability. Importantly, the age-dependent development 
of event-related neuronal responses are disrupted by MeCP2 mutation, suggesting that 
impaired neuronal circuitry underlies the pathogenesis of RTT and that assessment of 
event-related potentials may serve as a biomarker for RTT and treatment evaluation.  
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Introduction 
RTT is an autism spectrum disorder caused by mutations in the X-linked gene encoding 
methyl-CpG binding protein 2 (MeCP2) (Amir et al., 1999). RTT is associated with 
different types of mutations within MECP2, including missense, nonsense, deletions and 
insertions (Bienvenu and Chelly, 2006). Classical RTT patients, irrespective of the type 
of mutation, develop normally for the first 6-18 months of age, after which they enter a 
period of regression characterized by deceleration of head growth and a loss of acquired 
motor and language skills. Frequently, patients develop stereotypic hand wringing, 
abnormal breathing, seizures and autistic behaviors (Chahrour and Zoghbi, 2007). The 
molecular mechanisms through which different types of MECP2 mutations lead to 
disruptions in proper brain function are not fully understood. 
 
Mice engineered with different Mecp2 alterations present phenotypes that are both 
similar and distinct from those observed in Mecp2-null mice (Chen et al., 2001; Collins et 
al., 2004; Guy et al., 2001; Jentarra et al., 2010; Kerr et al., 2008; Pelka et al., 2006; 
Samaco et al., 2008; Shahbazian et al., 2002b). These similarities and differences in 
mouse models suggest that different MECP2 mutations are likely to have both shared 
and distinct biochemical and physiological correlates. Intriguingly, reintroduction of 
MeCP2 into behaviorally affected Mecp2-null mice is sufficient to rescue RTT-like 
phenotypes (Guy et al., 2007) and restoration of MeCP2 function in astrocytes alone 
significantly improve the developmental outcome of Mecp2-null mice (Lioy et al., 2011), 
suggesting that RTT is reversible upon restoration of MeCP2 function. Thus, 
understanding the mechanisms by which different MeCP2 mutations lead to RTT may 
reveal effective strategies tailored to the particular mutation to restore MeCP2 function.   
 
Mutation of the Threonine 158 (T158) residue, located at the C-terminus of the methyl-
CpG binding domain (MBD) of MeCP2, represents one of the most common mutations 
observed in RTT. Approximately 10% of all RTT cases carry a single nucleotide mutation 
converting T158 to Methionine (T158M) or in rare cases to Alanine (T158A) (Bienvenu 
and Chelly, 2006). The T158 residue has been suggested to play an important structural 
role in the stabilization of the MBD and the binding of MeCP2 to methylated DNA (Ho et 
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al., 2008). Whether mutation of T158 leads to MeCP2 gain-of-function or loss-of-
function, however, is not clear.  
 
The onset of RTT symptoms occurs during the establishment and refinement of neural 
networks in early postnatal development. Studies in Mecp2-null mice have suggested 
that reductions in connectivity between excitatory pyramidal neurons are associated with 
RTT-like phenotypes (Dani and Nelson, 2009; Dani et al., 2005; Wood et al., 2009). How 
reductions in neuronal connectivity lead to the manifestation of the age-dependent 
cognitive and behavioral deficits in RTT is currently unknown. Cognitive dysfunctions are 
frequently assessed by measuring the neurophysiological responses that occur during 
passive processes or during the performance of cognitive, sensory or motor tasks. Brain 
activations that occur during these tasks manifest as event-related potentials (ERPs). 
Disruptions in ERPs and the oscillations that underlie them are associated with a 
number of cognitive disorders such as schizophrenia (Gandal et al., 2012; Uhlhaas and 
Singer, 2010) and autism (Gandal et al., 2010; Roberts et al., 2010). EEG recordings in 
Mecp2-null mice (Chao et al., 2010; D'Cruz et al., 2010) and ERP recordings in RTT 
patients (Bader et al., 1989; Stauder et al., 2006) also suggest that alterations in brain 
activity are associated with behavioral and cognitive deficits. How ERPs are affected by 
MeCP2 dysfunction and how changes in EEG and ERPs correlate with the age-
dependent progression of RTT-like symptoms, however, remains to be determined.  
 
Given the high frequency of T158 mutations in RTT and its role in methyl-DNA binding, 
we sought to model this mutation in vivo and developed knockin mice containing MeCP2 
T158A mutation. We found that these mice recapitulate a number of RTT-like symptoms 
observed in Mecp2-null mice including late onset of hypoactivity, poor motor control, 
irregular breathing, altered anxiety, impaired learning and memory, and shortened 
lifespan. We demonstrated that T158A mutation decreases the binding of MeCP2 to 
methylated DNA in vitro and in vivo, and reduces MeCP2 protein stability. Moreover, the 
amplitude and latency of ERPs in both MeCP2 T158A and Mecp2-null mice are 
significantly altered. Time-frequency analysis of these ERPs revealed that MeCP2 
T158A mice failed to show a developmental increase in event-related power and phase 
locking in contrast to wild-type (WT) mice, demonstrating that MeCP2 is required for the 
development of functional neuronal circuits. Our studies suggest that stabilization of 
85	  
	  
MeCP2 protein and enhancement of its affinity for methylated DNA may provide a 
potential therapeutic approach to treat patients with MeCP2 T158 mutation. 
Furthermore, assessment of ERPs may serve as a biomarker for RTT and the evaluation 
of therapeutic efficacy in RTT treatment. 
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Results 
Generation of MeCP2 T158A and loxP knockin mice  
Although mutation of MeCP2 T158A occurs at a lower frequency than T158M in RTT 
patients, the mechanism through which both mutations impair MeCP2 function is 
believed to be the same: the lack of hydroxyl group in alanine and methionine 
destabilizes the tandem Asx-ST motif in the MBD and thus reduces MeCP2 affinity for 
methylated DNA (Ho et al., 2008). Indeed, patients carrying MeCP2 T158A or T158M 
mutation are phenotypically similar in the identity and severity of presented symptoms 
(Schanen et al., 2004; Vacca et al., 2001). To examine the importance of the T158 
residue in the functioning of MeCP2, we developed a knockin mouse with T158A 
mutation to circumvent the potential steric interference brought about by the larger 
Methionine residue. To facilitate screening of properly targeted ES cells, we incorporated 
a silent mutation at codon 160 to create a new BstEII restriction site and a floxed 
Neomycin expression cassette in intron III of the Mecp2 gene (Supplementary Fig. 1). 
Given that our goal was to test a rather subtle mutation on MeCP2 – a single amino acid 
change of T158A – we also engineered loxP knockin mice that contain the BstEII 
restriction site and loxP insertion but that lack T158A mutation, to rule out the possibility 
that manipulation of the Mecp2 locus may affect MeCP2 expression (Supplementary 
Fig. 1). Sequencing of MeCP2 mRNA extracted from brain tissues of WT, Mecp2T158A/y, 
and Mecp2loxP/y mice verified that both Mecp2T158A/y and Mecp2loxP/y knockin mice 
contained the T to C mutation at codon 160 for the generation of the BstEII restriction 
site, whereas only Mecp2T158A/y mice contain the A to G mutation at codon 158 (Fig. 1a). 
Furthermore, an MeCP2 T158 site-specific antibody, recognized MeCP2 protein from 
WT and Mecp2loxP/y mice, but not Mecp2T158A/y mice confirming the successful generation 
of MeCP2 T158A knockin mice (Fig. 1b).  
 
 
MeCP2 T158A mice recapitulate RTT-like phenotypes 
RTT is characterized by relatively normal development during the first 6-18 months of 
life, followed by a period of developmental stagnation leading to motor impairments, 
breathing abnormalities, and intellectual disability. We evaluated the presence, 
development and progression of RTT-like phenotypes in MeCP2 T158A mice following a 
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previously reported scoring system (Guy et al., 2007). We found that male Mecp2T158A/y 
mice present no overt symptoms during the first 4 weeks of life, but become 
progressively symptomatic after 5 weeks of age as indicated by significantly increasing 
phenotypic score (Fig. 1c). The hindlimb clasping apparent in Mecp2-null mice is also 
observed in Mecp2T158A/y mice (Supplementary Fig. 2a). Mecp2T158A/y mice weighed 
significantly less than their WT littermates starting from 4 weeks of age but then 
gradually gained weight to WT levels after 8 weeks (Supplementary Fig. 2b). In 
contrast, the body weights of Mecp2loxP/y mice are indistinguishable from their WT 
littermates (data not shown). Occasionally, we also observed seizure behaviors in 
Mecp2T158A/y mice after 5 weeks of age.  
 
Given that MECP2 is an X-linked gene and that the majority of RTT patients are girls 
with mosaic MeCP2 expression due to random X-chromosome inactivation, female 
Mecp2T158A/+ mice represent a close genetic match to RTT patients. Phenotypic scoring 
revealed no apparent symptoms in these mice until 17 weeks of age, after which they 
become progressively and increasingly symptomatic (Fig. 1d). A significant increase in 
body weight also occurred in female Mecp2T158A/+ mice at the time of symptom 
presentation (Supplementary Fig. 2c) similar to that observed in heterozygous Mecp2–/+ 
female mice (Guy et al., 2007).  
 
An early diagnostic criterion for RTT is a deceleration in head growth often leading to 
microcephaly by the first two years of life (Armstrong, 2005; Chahrour and Zoghbi, 
2007). We observed a significant reduction in the sizes and weights of brains of 
presymptomatic (P30) and postsymptomatic (P90) Mecp2T158A/y mice relative to their WT 
littermates (Fig. 1e), similar to that observed in Mecp2-null mice (Chen et al., 2001; Guy 
et al., 2001). The gross brain anatomy of Mecp2T158A/y mice, however, was 
indistinguishable from their WT littermates (Supplementary Fig. 2d). The decreased 
brain size and weight in Mecp2-null mice are purported to occur, at least in part, through 
a reduction in neuronal soma size (Armstrong, 2005; Chen et al., 2001). To assess 
whether soma size is affected in Mecp2T158A/y mice, we bred MeCP2 T158A mice to 
those expressing GFP under the control of the Thy1 promoter (Feng et al., 2000). 
Focusing on the hippocampal CA1 region, confocal imaging of GFP-positive pyramidal 
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neurons revealed a significant reduction in soma size in Mecp2T158A/y mice compared to 
WT littermates at both P30 and P90 (Fig. 1f).  
 
MeCP2 mutation in boys often leads to infantile lethality (Chahrour and Zoghbi, 2007) 
and male Mecp2-null mice show shortened life span(Chen et al., 2001; Guy et al., 2001; 
Pelka et al., 2006). We find that male Mecp2T158A/y mice die prematurely, with 50% dying 
by 16 weeks of age (Fig. 1g), which is approximately 3-4 weeks longer that germline 
Mecp2-null mice (Chen et al., 2001; Guy et al., 2001). No apparent changes in the 
survival profiles of female Mecp2T158A/+ mice were observed before 6 months of age (data 
not shown). Importantly, we have not observed any significant difference in longevity, 
body weights or brain weights of Mecp2loxP/y knockin mice, supporting the conclusion that 
these changes are the result of T158A mutation (data not shown). Together, these data 
demonstrate that mice carrying MeCP2 T158A mutation manifest RTT-like phenotypes. 
 
 
MeCP2 T158A mice present similar phenotypes to Mecp2-null mice 
Given the clinical relevance of MeCP2 T158A mutation, we sought to carry out a side-
by-side comparison of behavioral phenotypes with a well-studied Mecp2-null mouse 
(Guy et al., 2001). In light of the locomotor deficits, aberrant gait and hindlimb clasping 
observed in these mice (Supplementary Video 1), we assessed locomotor activity in a 
home cage environment with a cohort of age-matched WT, Mecp2T158A/y and Mecp2–/y 
littermates on the same C57BL/6 background at approximately 9 weeks of age. We 
found a significant reduction in the locomotor activity of both Mecp2T158A/y and Mecp2–/y 
mice compared to WT littermates (Fig. 2a). However, the reduction in locomotor activity 
was significant higher in Mecp2–/y mice compared to Mecp2T158A/y mice (Fig. 2a). We 
also found a significant reduction in distance traveled by Mecp2T158A/y mice at 11 but not 
3 weeks compared to WT littermates using the open field assay (Supplementary Fig. 
3a). Similarly, locomotor activity is also significantly reduced in female Mecp2T158A/+ mice 
at 20 weeks, but not 12 weeks of age (Supplementary Fig. 3b), consistent with the age-
dependent hypoactivity observed with phenotypic scoring (Fig. 1c,d). 
 
To examine motor coordination and motor learning in these two mouse models, we 
performed the accelerating rotarod test. WT mice show an increase in the latency to fall 
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over the course of 4 trials per day and over 4 consecutive days, indicating improvements 
in motor coordination and learning over time (Fig. 2b). However, both Mecp2T158A/y and 
Mecp2–/y mice spent significantly less time on the rotarod compared to WT littermates 
and failed to improve significantly over the course of 4 days suggestive of deficits in 
motor coordination and motor learning (Fig. 2b). The latency to fall from the rotarod was 
moderately but significantly decreased in Mecp2–/y mice compared Mecp2T158A/y mice 
(Fig. 2b). We conclude that MeCP2 T158A mutation impairs motor function similar to 
that seen in RTT patients and to a lesser degree than Mecp2-null mice.  
 
RTT patients experience anxiety episodes, particularly in response to distressing events 
(Chahrour and Zoghbi, 2007). The role of MeCP2 in anxiety in mice, however, is less 
clear: Mecp2-null mice and mice with a 50% reduction in MeCP2 protein expression both 
show a decreased anxiety phenotype (Pelka et al., 2006), whereas those containing an 
early-truncating mutation show increased anxiety (Shahbazian et al., 2002b). Using the 
elevated zero maze paradigm, we found that Mecp2T158A/y and Mecp2–/y mice spend 
significantly less time in the closed arm and significantly more time in the open arm 
compared to their WT littermates (Fig. 2c). This suggests that T158A mice show 
reduced anxiety similar to those observations in Mecp2-null mice and mice with 
decreased MeCP2 protein expression.  
 
Because RTT is the primary cause of intellectual disability in females, we examined 
whether MeCP2 mutant mice have learning and memory deficits using contextual and 
cued fear conditioning paradigms. Mice were trained to associate a context (testing box) 
and a cue (auditory tone) with a co-terminating foot shock. Animals typically freeze in 
response to the shock. We found no differences in freezing behaviors in WT and 
Mecp2T158A/y littermates prior to or immediately following shocks, suggesting no 
differences in pain sensitivity. However, Mecp2–/y mice exhibit significantly increased 
freezing even prior to the shock (Supplementary Fig. 3c). This is likely due to their 
decreased locomotor activity and akinesia, thus confounding interpretation of the fear-
conditioning test. These mice were therefore excluded from this study. 24 hours after 
training, Mecp2T158A/y mice demonstrate significantly less context- and cue-dependent 
freezing compared to their WT littermates, suggesting deficits in learning and memory 
(Fig. 2d).  
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Together, these data demonstrate that MeCP2 T158A knockin mice present phenotypes 
similar to those observed in Mecp2-null mice but to a lesser extent overall. We therefore 
infer that T158A is a partial loss-of-function mutation.  
 
 
Decreased MeCP2 protein stability in MeCP2 T158A mice 
Alterations in MeCP2 protein levels, such as a 50% reduction or a two-fold increase, 
leads to the progressive development of neurological deficits in mice, albeit at much later 
time points than those observed in Mecp2-null mice (Collins et al., 2004; Kerr et al., 
2008; Samaco et al., 2008). We therefore examined whether T158A mutation alters the 
expression of MeCP2 protein during development. Quantitative Western blotting on 
whole-cell lysates from the brains of male Mecp2T158A/y mice revealed that MeCP2 
protein expression is significantly decreased at P2, P30 and P90 compared to their WT 
littermates (Fig. 3a). The down-regulation of MeCP2 expression is significantly higher at 
P90, when Mecp2T158A/y mice present overt RTT-like phenotypes, than at either P2 or 
P30, when symptoms are not present (Fig. 1c). Importantly, MeCP2 protein levels were 
not affected in Mecp2loxP/y mice indicating that the down-regulation of MeCP2 is due to 
the presence of the T158A mutation rather than genomic modification (Fig. 1b). These 
changes in MeCP2 expression are likely to be independent of gene transcription since 
quantitative RT-PCR found no significant differences in the level of MeCP2 mRNA 
expression between Mecp2T158A/y and WT mice at P0, P30 or P90 (Supplementary Fig. 
4). Despite RTT being primarily a neurological disorder (Chahrour and Zoghbi, 2007), 
MeCP2 is ubiquitously expressed in all mammalian tissues (Shahbazian et al., 2002a). 
Indeed, we found that MeCP2 protein levels are decreased to a similar extent in kidney, 
liver, lung and heart in Mecp2T158A/y mice (Fig. 3b).  
 
MeCP2 protein levels are also significantly decreased in the brains of female 
Mecp2T158A/+ mice compared to their WT littermates (Fig. 3c). The magnitude of MeCP2 
down-regulation in females is less than that observed in male Mecp2T158A/y mice and is 
likely due to the mosaic expression of MeCP2 T158A in heterozygous Mecp2T158A/+ mice. 
To investigate whether mutation at T158 disrupts MeCP2 protein expression in human 
RTT patients, we obtained fibroblast cultures derived from a female RTT patient with 
T158M mutation and an age-matched female control. We found that MeCP2 expression 
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is also significantly down-regulated by about 40% in cells with MeCP2 T158M mutation 
compared to control cells (Fig. 3c). These data demonstrate that T158 mutation, to 
either A or M, triggers the down-regulation of MeCP2 protein expression in both humans 
and mice, indicating that the reduction in MeCP2 protein expression may be a 
contributing factor to RTT.  
 
To investigate whether the reductions in MeCP2 protein levels are the consequence of 
decreased protein stability, we cultured embryonic day 16 cortical neurons isolated from 
WT and Mecp2T158A/y mice and inhibited new protein translation using Cycloheximide 
(CHX). The stability of existing MeCP2 protein was assessed at 0, 3, 6 and 9 hours 
following CHX treatment. We found that MeCP2 protein levels in WT neurons remain 
relatively constant over the course of the 9-hour CHX treatment compared to vehicle-
treated cultures (Fig. 3d). In contrast, MeCP2 T158A protein levels are significantly 
reduced following 6- and 9-hour CHX treatments (Fig. 3d), suggesting that T158A 
mutation decreases MeCP2 protein levels by increasing its rate of degradation. We did 
not observe destabilization of other proteins such as NeuN in T158A mice (Fig. 3d). 
Therefore, the development of MeCP2 T158A knockin mice has uncovered a novel 
function of T158 in the stabilization of MeCP2 protein in vivo. The reduction in MeCP2 
protein stability mediated by T158A mutation may contribute, at least in part, to the 
etiology of RTT. 
 
 
T158A mutation disrupts MeCP2 binding to methylated DNA 
Located at the 3’-end of the MBD, T158 is believed to play an important role in stabilizing 
the tertiary structure of MBD and is critical for the binding of MeCP2 to methylated DNA 
(Ho et al., 2008). We recapitulated these in vitro observations using a Southwestern 
assay (Fig. 4a). To examine the role of T158 in the regulation of MeCP2 binding to 
methylated DNA in vivo, we isolated nuclei from brains of WT and Mecp2T158A/y mice and 
performed chromatin immunoprecipitation (ChIP) assays against several known MeCP2 
binding loci. MeCP2 has been previously shown to bind across a 39 kb promoter region 
of the Bdnf locus tracking methyl-CpG sites (Skene et al., 2010). Consistent with this, we 
found a similar MeCP2 binding pattern in brains from P60 WT mice (Fig. 4b). MeCP2 
ChIP over the same region in Mecp2T158A/y brains, however, revealed a 70-75% 
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reduction in MeCP2 binding across the entire locus (Fig. 4b), suggesting that T158A 
mutation decreases MeCP2 binding at methylated DNA. To validate this finding, we also 
analyzed the binding of MeCP2 to the Xist, Snrpn and Crh loci, known MeCP2 binding 
targets (Chahrour et al., 2008; Skene et al., 2010) and found that the binding of MeCP2 
at these loci is significantly reduced by approximately 70% in Mecp2T158A/y brains (Fig. 
4c). Thus, the reduction in MeCP2 binding at the Bdnf, Xist, Snrpn, and Crh loci likely 
reflects a decreased binding of MeCP2 T158A to methylated DNA together with reduced 
MeCP2 protein expression.  
 
We reasoned that if MeCP2 T158A has a reduced affinity to methylated DNA in vivo, WT 
or MeCP2 T158A protein would be extracted differently from nuclei under the same salt 
conditions. To biochemically assay the reduced affinity of MeCP2 T158A to methylated 
DNA, we isolated neuronal nuclei from either WT or Mecp2T158A/y mouse brains and 
treated them with increasing concentrations of NaCl to extract proteins into the 
supernatant. Quantitative Western blot analysis revealed that MeCP2 T158A protein is 
extracted more readily than WT protein under low salt conditions of 250mM and 300mM 
NaCl (Fig. 4d). When the salt is raised to above 350 mM, both WT and T158A protein 
are extracted to a similar degree. Thus, mutation of T158A appears to decrease the 
affinity of MeCP2 for DNA.  
 
MeCP2 predominantly associates with heterochromatic foci in mouse cell nuclei in an 
MBD- and DNA methylation-dependent manner, resulting in a characteristic punctate 
pattern of nuclear staining (Nan et al., 1997). Indeed, we demonstrated that MeCP2 
immunoreactivity is observed throughout the nucleus with particularly high enrichment at 
heterochromatin-dense foci in nuclei from P90 WT neurons (Fig. 4e). In contrast, in 
nuclei from P90 Mecp2T158A/y neurons, MeCP2 is markedly diffuse with a clear absence 
of co-localization with DNA, indicating that the binding of MeCP2 to methylated DNA is 
disrupted (Fig. 4e). This difference is unlikely due to changes in heterochromatin 
formation as no overt differences are seen in DNA staining in T158A mice. We observed 
similar immunoreactivity patterns in P30 Mecp2T158A/y mice prior to symptom presentation 
(data not shown). Furthermore, MeCP2 immunoreactivity in female Mecp2T158A/+ mice 
shows a mosaic expression of MeCP2 with approximately 50% of nuclei showing 
MeCP2 immunoreactivity at heterochromatin-dense foci with the remaining exhibiting 
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diffuse immunoreactivity (Fig. 4f), as is expected due to random X-chromosome 
inactivation. Notably, the intensity of MeCP2 immunoreactivity is decreased in T158A 
neurons compared to WT neurons, consistent with a reduction of MeCP2 T158A protein 
expression. Together, these data demonstrate that T158A mutation impairs the binding 
of MeCP2 to methylated DNA in vivo and contributes, at least in part, to the etiology of 
RTT. 
 
 
Disruption of MeCP2 binding to methylated DNA  
Transcriptional profiling of RNA isolated from the hypothalamus or cerebellum of Mecp2-
null mice revealed changes in the expression of thousands of genes, with many of these 
changes in a tissue-specific manner (Chahrour et al., 2008). We analyzed the 
expression of a few representative targets such as Bdnf, Crh and Sgk using quantitative 
RT-PCR and found that both Bdnf and Crh transcription are significantly reduced in the 
hypothalamus but not striatum of T158A mice (Fig. 5a,b), whereas, Sgk, a gene that is 
upregulated in Mecp2-null mice (Nuber et al., 2005), is elevated in the striatum but not in 
the hypothalamus of T158A mice (Fig. 5a,b). These data support that gene transcription 
is similarly disrupted in MeCP2 T158A and Mecp2-null mice in a tissue- and/or cell-type 
specific manner.  
 
MeCP2 has been shown to regulate gene transcription through its interaction with 
histone deacetylases (HDACs) 1 and 2 and the co-repressor Sin3a (Jones et al., 1998; 
Nan et al., 1997). It is conceivable that T158A mutation may disrupt the ability of MeCP2 
to associate with these proteins through alterations in the conformation of MeCP2 and 
thus disrupt downstream gene regulation. We therefore performed co-
immunoprecipitation experiments using an antibody against MeCP2 in nuclear extracts 
prepared from WT and Mecp2T158A/y brains. Consistent with previous studies, WT MeCP2 
interacts with HDAC1 and Sin3a (Fig. 5c). We also detected the association of MeCP2 
T158A with HDAC1 and Sin3A, albeit at a reduced level consistent with the reduced 
MeCP2 T158A protein expression (Fig. 5c). Thus, these data support that MeCP2 
T158A protein retains the ability to interact with the co-repressor proteins. Together, we 
conclude that MeCP2 T158A leads to a deregulation of gene expression through 
reduced DNA binding and MeCP2 protein stability.  
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Age-dependent alterations in EEG and ERP recordings 
The manifestation of symptoms in RTT patients and Mecp2-null mice are thought to 
occur in part due to alterations in neural network activity. Since RTT symptoms appear 
at certain developmental time points, we sought to investigate the neural mechanisms 
underlying age-dependent exhibition of phenotypes in MeCP2 T158A mice. Thus, we 
performed EEG recordings in WT and Mecp2T158A/y mice at two developmental time 
periods, P30 and P90; that is, prior to and subsequent to the establishment of RTT-like 
symptoms. EEG recordings in awake, freely mobile mice demonstrated a significant 
increase in the power of high-gamma frequency (γhigh; 70-140 Hz) oscillations in 
Mecp2T158A/y mice at P90 compared to WT littermates (Fig. 6a,b). A similar increase in 
γhigh power was also observed in symptomatic Mecp2–/y mice (Supplementary Fig. 
5a,b). γhigh activity is known to be associated with epilepsy in the EEG before and during 
the seizure (Uhlhaas et al., 2011) and may thus reflect an overall hyperexcitability in the 
brains of Mecp2T158A/y and Mecp2–/y mice (Chao et al., 2010). However, we did not 
observe a significant increase in γhigh power in pre-symptomatic Mecp2T158A/y mice at P30 
(Supplementary Fig. 6a,b), suggesting that MeCP2 dysfunction induces 
hyperexcitability in the brain in an age-dependent manner.  
 
In addition to measuring electrical activity during passive processes, it is also possible to 
measure those that occur during the performance of a cognitive, sensory or motor task. 
The manifestation of these brain activities is recorded as a series of amplitude 
deflections in the EEG as a function of time and is referred to as an event-related 
potential (ERP). ERPs are small compared to the background EEG but can be resolved 
by averaging single trial epochs. They are characterized as voltage deflections defined 
by latency and polarity where the amplitude and latency of the polarity peaks are 
believed to reflect the strength and timing of the cognitive processes related to the event. 
Notably, RTT patients, as well as patients with schizophrenia and autism, are reported to 
show alterations in both the amplitudes and latencies of ERP (Bader et al., 1989; Gandal 
et al., 2010; 2012; Roberts et al., 2010; Stauder et al., 2006). 
 
To examine ERP responses in Mecp2T158A/y mice, we performed EEG recordings 
following the presentation of a series of white noise clicks. We chose to perform 
auditory-evoked ERP assessments since they can be performed on freely mobile mice 
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and are not confounded by the motor or attentional deficits associated with MeCP2 
dysfunction.  The ERP was extracted by averaging the EEG traces over single trial 
epochs. ERPs in WT and Mecp2T158A/y mice show a stereotypical initial positive peak 
(P1), followed by a negative peak (N1) and a subsequent second positive peak (P2) 
(Fig. 6c). Interestingly, we found significant increases in the latency and significant 
reductions in the amplitudes of the N1 and P2 peaks in symptomatic P90 Mecp2T158A/y 
mice compared to WT littermates (Fig. 6c-e). Similar alterations in ERP amplitudes and 
latencies were observed in Mecp2–/y mice (Supplementary Fig 5c-e). However, we 
observed no significant effect on ERPs in Mecp2T158A/y mice at P30, prior to the 
establishment of RTT-like symptoms (Supplementary Fig 6c-e). Importantly, we found 
no differences in hearing sensitivities between Mecp2T158A/y mice or Mecp2–/y mice and 
their WT littermates as measured by auditory brain stem responses, suggesting that 
these disruptions in ERP are due to alterations in cortical processing of sensory input 
(Supplementary Fig. 7). These data suggest that neural networks underlying 
information processing are disrupted by MeCP2 dysfunction in an age-dependent 
manner, corresponding to the behavioral onset of symptoms. 
 
 
Progressive alterations in event-related power and PLF 
One limitation of time-amplitude analysis of ERPs is that oscillatory information not time-
locked to the stimulus is lost through signal averaging. Using time-frequency analysis it 
is possible to analyze changes in oscillatory activity as a function of time and thus gain 
additional insight into the underlying brain activity and circuitry. Oscillatory responses 
during the performance of tasks are characterized by the average power and phase 
locking across trials (Tallon-Baudry and Bertrand, 1999). The degree of event-related 
power and phase locking at different frequencies may reflect the strength and 
connectivity of local (at high frequencies) and long-range (at low frequencies) neuronal 
circuits (Buzsáki and Draguhn, 2004). 
 
Thus, we next performed time-frequency analysis on EEG recordings used to determine 
auditory-evoked ERPs. We found that the presentation of an auditory stimulus 
modulated the mean event-related power in a frequency-specific manner. WT mice at 
P90 showed a significant depression in the mean power of oscillations in the low-
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frequency delta (δ; 2-4 Hz), theta (θ; 4-8 Hz) and alpha (α; 8-12 Hz) ranges upon 
auditory stimulation (Fig. 7a,b). The mean event-related power of high-frequency beta 
(β; 12-30 Hz), low gamma (γlow; 30-50 Hz) and high gamma (γhigh; 70-140 Hz) increased 
following the auditory stimulus and was followed by a sustained depression in power 
(Fig. 7a,b). Notably, these changes are sustained for a number of oscillation cycles at all 
frequencies and outlast the transient ERP response reflecting an effect in both evoked 
and ongoing oscillatory processes (Fig. 7a,b). Overlaying the ERP with band-pass EEG 
traces at each frequency range reveals the oscillatory information within the transient 
ERP response (Supplementary Fig. 8). Mecp2T158A/y mice, however, exhibited 
significantly attenuated event-related power in both low- and high-frequency oscillations 
at P90 when RTT-like symptoms are overt (Fig. 7a,b and Supplementary Fig. 9a). 
Similarly, highly symptomatic Mecp2–/y mice show significantly reduced event-related 
power following auditory stimulation at all frequencies (Supplementary Fig. 9b, 10a,b). 
Notably, we also found a significant reduction in event-related power in low-frequency δ, 
θ and α in P30 Mecp2T158A/y mice prior to symptom onset compared to WT littermates 
(Supplementary Fig. 9c, 11a,b). These data suggests that the underlying deficits in 
neural activity occur prior to the establishment of behavioral symptoms consistent with in 
vitro electrophysiological studies showing reduced cortical excitability in Mecp2–/y mice 
even at 2-3 weeks of age (Dani et al., 2005).  
 
Time-frequency analysis also allows for the calculation of oscillation phase locking 
across trials. The phase locking factor (PLF) quantifies the trial-to-trial reliability of 
oscillation phase with a high PLF corresponding to a low circular variance in oscillation 
phase as a function of time between trials. High PLF is thought to reflect the reliability 
and sensitivity of communications between circuits in the brain (Winterer et al., 2000). 
We find that WT mice at P90 show significant increases in PLF at all frequencies in 
response to the presentation of auditory stimuli (Fig. 7c,d). The increase in PLF in 
Mecp2T158A/y mice at P90, however, is significantly reduced compared to WT mice (Fig. 
7c,d and Supplementary Fig. 9d). A significant reduction in event-related PLF in 
Mecp2–/y mice was also observed, consistent with the expression of RTT-like 
phenotypes in both groups of mice (Supplementary Fig. 9e, 10c,d). We also detected 
significant attenuation in PLF in pre-symptomatic P30 Mecp2T158A/y mice, although only 
at δ-and high-gamma frequencies (Supplementary Fig. 9f, 11c,d). Importantly, the fact 
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that we do not observe changes in ERP amplitudes at P30 in Mecp2T158A/y mice 
(Supplementary Fig. 6, 12) suggests that time-frequency analysis of event-related 
power and PLF represents a sensitive approach to probe neural function in vivo.  
 
Interestingly, when comparing the event-related neuronal responses in WT mice at two 
developmental stages, we find that event-related power at all frequencies and PLF at 
high frequencies are significantly higher in P90 mice than those at P30 (Fig. 8a,b). This 
likely reflects the development and maturation of the underlying neuronal circuitry. In 
contrast, Mecp2T158A/y mice do not show a developmental increase in either event-related 
power (Fig. 8c) or phase locking (Fig. 8d) from P30 to P90, suggesting an impairment in 
age-dependent neural network maturation. These age-dependent differences are only 
observed using time-frequency but not time-amplitude analysis (Fig. 8 and 
Supplementary Fig. 12). Together, these data reveal that MeCP2 plays an important 
role in the regulation of event-related neuronal responses and is required for the 
maturation and restructuring of neural networks. The disruptions in event-related power 
and PLF may therefore contribute to the deficits in behavioral and cognitive functions 
observed in RTT. We propose that ERP studies may serve as a sensitive biomarker for 
the evaluation of treatments in RTT patients.  
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Discussion 
Mutation of MeCP2 T158 to M or in rare cases to A represents one of the most common 
mutations observed in RTT patients (Bienvenu and Chelly, 2006). Previous in vitro 
experiments established a critical role for this residue in the binding of MeCP2 to 
methylated DNA. To address the causal role of T158A mutation in the pathogenesis of 
RTT and the role of methyl-DNA binding in the proper functions of MeCP2, we 
developed and characterized MeCP2 T158A knockin mice. We found that MeCP2 
T158A mice develop normally for the first 4-5 weeks of life after which they present RTT-
like symptoms including decreased motor performance, altered anxiety, aberrant gait, 
hindlimb clasping, breathing abnormalities, and impaired learning and memory. The 
similarity in the identity and severity of symptoms with those observed in Mecp2-null 
mice indicates that MeCP2 T158A mutation is a partial loss-of-function mutation. 
 
The development of this mouse line allowed us to investigate the biochemical 
consequences of MeCP2 T158A mutation in vivo. In agreement with previous in vitro 
studies, we find that MeCP2 T158A mutation leads to a reduction in the affinity of 
MeCP2 for methylated DNA in vivo. Surprisingly, we also observed that T158A mutation 
concomitantly decreases MeCP2 protein expression in vivo. Consistent with these data, 
we find that fibroblasts obtained from a female RTT patient carrying MeCP2 T158M 
mutation express decreased levels of MeCP2 protein. These findings reveal two 
consequences of T158 mutation: impaired MeCP2 binding to DNA and decreased 
MeCP2 protein stability of MeCP2.  
 
Previous studies have demonstrated that MeCP2 protein levels must be tightly regulated 
to ensure its proper function. A 50% reduction in MeCP2 protein levels leads to 
progressive neurological symptoms (Kerr et al., 2008; Samaco et al., 2008), although 
symptoms appeared later and do not fully recapitulate RTT-like symptoms as in Mecp2-
null mice. Therefore, the destabilization of MeCP2 protein alone, as observed in our 
T158A mice, may not be sufficient to cause the RTT-like symptoms. We propose that the 
combined reduction in MeCP2 protein levels and the decreased binding to methylated 
DNA contribute to the loss-of-function phenotype in T158A knockin mice. The 
development of knockin mice carrying other mutations that disrupt DNA binding will 
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provide further insights into this hypothesis. Given that the reintroduction of MeCP2 
protein into Mecp2-null mice is sufficient to rescue RTT-like phenotypes (Guy et al., 
2007) we suggest a dual approach to restore MeCP2 function in patients carrying 
MeCP2 T158 mutations: increasing MeCP2 affinity for methylated DNA and enhancing 
MeCP2 protein stability. Indeed, the feasibility of increasing affinity for DNA has been 
shown for other DNA-binding proteins such as p53 (Foster et al., 1999). It is conceivable 
that increasing MeCP2 affinity to methylated DNA may help stabilize MeCP2 protein 
expression. Targeting one or both of these possibilities may lead to the amelioration of 
RTT-like phenotypes. Our study also suggests that different therapeutic strategies 
should be considered for treating patients with different MeCP2 mutations.  
 
Given their neurological origin, many of the symptoms associated with RTT have been 
hypothesized to result from imbalanced neural networks (Chahrour and Zoghbi, 2007). 
Evidence to support this arises from observed alterations in synaptic connectivity and 
plasticity (Dani and Nelson, 2009; Dani et al., 2005; Guy et al., 2007; Kishi and Macklis, 
2004; Wood et al., 2009) and hyperexcitability in the EEG (Chao et al., 2010; D'Cruz et 
al., 2010) of Mecp2-null mice. Furthermore, ERP analysis in RTT females suggests 
alterations in sensory processing of information (Bader et al., 1989; Stauder et al., 
2006). Given the delayed onset of symptoms in RTT patients, MeCP2 T158A mice and 
Mecp2-null mice, we sought to examine whether neurophysiological responses as 
measured by EEG were altered during development in MeCP2 T158A mice. Indeed, we 
found that the power of high-gamma EEG signals is significantly increased in MeCP2 
T158A mice when these mice exhibit RTT-like symptoms, suggesting hyperexcitability in 
the brain. Furthermore, assessment of auditory-evoked ERPs revealed a significant and 
marked reduction in the amplitude and increased latency of ERPs in MeCP2 T158A and 
Mecp2-null mice suggesting deficits in information processing in the brain similar to that 
observed in RTT females (Bader et al., 1989; Stauder et al., 2006), autism (Gandal et 
al., 2010; Roberts et al., 2010) and other disorders including schizophrenia (Uhlhaas and 
Singer, 2010). Further studies are needed to address the neuronal mechanisms that 
underlie these deficits in ERP response. 
 
Our data show that disturbances in event-related power and phase locking also occur in 
MeCP2 mouse models and may play a role in the etiology of RTT. In humans and 
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animal models, changes in the power and phase locking of neuronal responses 
coordinate neuronal activity across different brain regions. These changes are involved 
in the development and efficacy of motor, perceptual and memory tasks and deficits in 
neuronal oscillations are consistently observed in neurological disorders in which these 
functions are impaired (Uhlhaas and Singer, 2006; 2010). Our findings that both low- 
and high-frequency event-related oscillations are disrupted lead us to hypothesize that 
deficits in local and long-distance neuronal circuitry occur following MeCP2 dysfunction. 
The neurophysiological mechanisms that lead to disturbances in these oscillations are 
not known, but may involve the reduced neuronal connectivity that leads to a 
redistribution of neuronal activity away from excitation and towards inhibition as 
observed in Mecp2-null mice (Dani and Nelson, 2009; Dani et al., 2005; Wood et al., 
2009). Furthermore, given the important role that event-related neuronal responses play 
in the development of the nervous system (Ben-Ari, 2001), their disruption prior to 
symptom presentation may augment the deficits in neuronal activity caused by MeCP2 
dysfunction. Indeed, MeCP2 T158A mice do not exhibit developmental increases in 
event-related power or phase locking suggestive of stagnation in the developmental of 
neuronal circuits. Moreover, our findings that event-related changes in power and phase 
locking occur in MeCP2 T158A mice with no behavioural symptoms suggest that 
disruptions in neuronal networks may precede the behavioral RTT-like phenotypes. The 
identification of the mechanisms that lead to these disturbances will provide valuable 
insights into the pathogenesis of RTT and the neuronal networks underlying 
manifestation of behavioral phenotypes in RTT.  
 
In summary, the development of MeCP2 T158A mice has uncovered a novel role for 
T158 in the pathogenesis of RTT and revealed an alternative strategy to restore MeCP2 
function. These mice provide an in vivo animal model for assessing therapeutic efficacy 
in pre-clinical trials. Moreover, given that ERP studies can be readily performed in 
humans, assessment of ERP and the changes in oscillation and phase locking may 
serve as a valuable biomarker for evaluating RTT phenotypes. 
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Figure 1 
 
Figure 1.  Generation and phenotypic characterization of MeCP2 T158A knockin mice 
 (a) Sequencing chromatogram of RT-PCR products from MeCP2 mRNA. Mutation of T158 codon ACG to 
Alanine codon GCG (first box) and creation of BstEII restriction site (second box) with a silent mutation are marked with *.  
 (b) Western blots probed with a site-specific MeCP2 T158 antibody, a total MeCP2 antibody and Sin3a 
antibody.  
 (c) Developmental presentation of RTT-like phenotypes in male Mecp2T158A/y mice (n = 6; F1,252 = 27.75, p-value 
< 0.0001; two-way ANOVA) relative to WT littermates (n = 5).  Symbols represent mean score ± SEM. Phenotypic score is 
significantly higher in Mecp2T158A/y mice compared to WT littermates at 5 weeks and thereafter; * p-value < 0.05; two-way 
ANOVA with Bonferroni correction.  
 (d) Developmental presentation of RTT-like phenotypes in female Mecp2T158A/+ mice (n = 7; F1,224 = 198.6, p-
value < 0.0001; two-way ANOVA) relative to Mecp2+/+ littermates (n = 6). Phenotypic score is significantly higher in 
Mecp2T158A/+ mice compared to WT littermates at 17 weeks and thereafter; * p-value < 0.05; two-way ANOVA with 
Bonferroni correction.  
 (e) Brain weights at P30 (n = 4 for both genotypes) and P90 (n = 6 for both genotypes). Bars represent mean ± 
SEM. ** p-value < 0.01; two-tailed t-test with Bonferroni correction.  
 (f) Soma size in hippocampal CA1 pyramidal neurons. Bars represent mean ± SEM (n = 100 cells from 5 
animals per genotype). ** p-value < 0.01; two-tailed t-test with Bonferroni correction.  
 (g) Survival of male Mecp2T158A/y (n = 43) and Mecp2+/y littermates (n = 43).   
0!
50!
100!
150!
200!
P30! P90!
0!
100!
200!
300!
400!
500!
P30! P90!
0!
25!
50!
75!
100!
0! 4! 8! 12! 16! 20! 24!
0!
4!
8!
12!
0! 2! 4! 6! 8! 10! 12!
0!
4!
8!
12!
0! 4! 8! 12! 16! 20! 24!
P
e
rc
e
n
ta
g
e
 s
u
rv
iv
a
l
Age (weeks)
Sin3a
MeCP2 T158
Total MeCP2
+
/y
T
1
5
8
A
/y
+
/y
lo
xP
/y
f
c
b
d
e g
a
P
h
e
n
o
ty
p
ic
 s
c
o
re
Age (weeks)
P
h
e
n
o
ty
p
ic
 s
c
o
re
Age (weeks)
+/y
T158A/y
loxP/y
* *
*
T/AD F V T G R
T158A/y+/y
B
ra
in
 w
e
ig
h
t 
(m
g
)
** **
** **
S
o
m
a
 s
iz
e
 (
μm
2
)
* *
T158A/y
+/y
T158A/+
+/+
T158A/y
+/y
102	  
	  
Figure 2 
 
Figure 2.  Behavioral characterization of MeCP2 T158A mice 
 (a) Locomotor activity in Mecp2T158A/y mice (n = 15), Mecp2–/y mice (n = 14) and Mecp2+/y littermates (WT; n = 
33) at 9 weeks of age. Bars represent mean ± SEM. * p-value < 0.01, *** < 0.001 and ## < 0.01; one-way ANOVA with 
Tukey’s post hoc test.  
 (b) Motor coordination and motor learning assessed using a rotarod assay in Mecp2T158A/y mice (n = 16; F1,645 = 
447.2, p-value < 0.0001; two-way ANOVA) and Mecp2–/mice (n = 14; F1,602 = 841.46, p-value < 0.0001; two-way ANOVA) 
and WT littermates (n = 27) at 9 weeks of age. The deficit in Mecp2–/y mice is significantly more than that observed in 
Mecp2T158A/y mice (F1,437 = 83.82, p-value < 0.0001; two-way ANOVA). Symbols represent mean ± SEM.  
 (c) Anxiety-like behavior in Mecp2T158A/y mice (n = 15) and Mecp2–/y mice (n = 11) measured using elevated zero 
maze compared to WT littermates (n = 32) at 9 weeks of age. Bars represent mean ± SEM. * p-value < 0.05 and ** < 0.01; 
one-way ANOVA with Tukey’s post hoc test.  
 (d) Learning and memory assessed using context- and cue-dependent fear conditioning in Mecp2T158A/y mice (n 
= 16) and WT littermates (n = 33) at 10 weeks of age. Bars represent mean ± SEM. * p-value < 0.05 and *** < 0.001; two-
tailed t-test with Bonferroni correction.  
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Figure 3 
 
Figure 3.  Decreased MeCP2 protein stability in MeCP2 T158A mice 
 (a) MeCP2 protein levels in forebrains of Mecp2T158A/y mice at P2, P30, and P90 compared to Mecp2+/y 
littermates (n = 3 for each genotype). Bars represent mean ± SEM. ** p-value < 0.01; one-sample t-test with Bonferroni 
correction. # < 0.05; one-way ANOVA with Tukey’s post hoc test.  
 (b) MeCP2 protein levels are significantly reduced in kidney, liver, lung and heart tissues of Mecp2T158A/y (n = 3) 
compared to Mecp2+/y littermates at P90 (n = 3). Bars represent mean ± SEM. * p-value < 0.05; one-sample t-test with 
Bonferroni correction.  
 (c) MeCP2 protein levels in female Mecp2T158A/+ mice (n = 3) and Mecp2+/y littermates at P90 (n = 3). MeCP2 
protein levels in fibroblasts derived from a female RTT patient carrying the MeCP2 T158M mutation compared to 
fibroblasts derived from an age-matched female control (n = 3 separate passages). Bars represent mean ± SEM. * p-
value < 0.05; one-sample t-test.  
 (d) E16 + 7 DIV cortical neurons derived from Mecp2T158A/y (n = 3) and Mecp2+/y littermates (n = 3) were treated 
with vehicle (0) or 100 µM Cycloheximide (CHX) for 3, 6 or 9 hours. Bars represent mean MeCP2 levels relative to vehicle 
± SEM. * p-value < 0.05; two-way ANOVA with Bonferroni correction. 
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Figure 4 
 
Figure 4.  Reduced MeCP2 binding to methylated DNA in T158A mice 
 (a) MeCP2 binding to methylated DNA (methylated oligonucleotides spanning the -148 CpG site of Bdnf 
promoter IV) is reduced by T158A mutation relative to WT and MeCP2 S421A mutation in Southwestern assay.  
 (b) MeCP2 binding across a 39 kb of the promoter region of the Bdnf locus in brains obtained from Mecp2T158A/y 
mice mice and Mecp2+/y littermates (n = 3; two-way ANOVA, F1,84 = 639.1, p-value < 0.0001). Symbols represent mean ± 
SEM. Alternative Bdnf exons are indicated with black rectangles.  
 (c) MeCP2 binding to the Xist, Snrpn, and Crh loci in Mecp2T158A/y mice (n = 3) compared to Mecp2+/y littermates 
(n = 3). Bars represent mean ± SEM. *** p-value < 0.001; two-tailed t-test with Bonferroni correction.  
 (d) Salt extraction of WT MeCP2 and MeCP2 T158A protein with increasing concentrations of NaCl (n = 3). 
Bars represent mean ± SEM normalized to MeCP2 levels extracted with 700 mM NaCl. ** p-value < 0.01 and *** < 0.001; 
two-way ANOVA with Bonferroni correction.  
 (e) MeCP2 co-localization with heterochromatin-dense foci in male WT but not Mecp2T158A/y mice at P90. 
Representative images of neuronal nuclei shown are single confocal planes at 100X magnification. Scale bar corresponds 
to 20 µm.  
 (f) MeCP2 staining in nuclei obtained from female Mecp2T158A/+ mice. Nuclei showing diffuse MeCP2 staining 
are marked with an *. Scale bar corresponds to 20 µm.  
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Figure 5 
 
Figure 5.  Disruption of MeCP2 methyl-DNA binding leads to deregulation of gene expression 
 (a) Bdnf, Crh and Sgk mRNA expression in the hypothalamus of Mecp2T158A/y mice compared to Mecp2+/y 
littermates (n = 4). Bars represent mean ± SEM. * p-value < 0.05; two-tailed t-test with Bonferroni correction.  
 (b) Bdnf, Crh and Sgk mRNA expression in the striatum of Mecp2T158A/y mice and Mecp2+/y littermates (n = 4). 
Bars represent mean ± SEM. * p-value < 0.05; two-tailed t-test with Bonferroni correction.  
 (c) MeCP2 T158A mutation does not impair the association of MeCP2 with HDAC1 or Sin3a. MeCP2 
immunoprecipitation from brain nuclear extracts prepared from Mecp2T158A/y and Mecp2+/y littermates are probed with 
indicated antibodies. 
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Figure 6 
 
Figure 6.  EEG and ERP recordings in MeCP2 T158A mice 
 (a) Representative EEG traces from awake, freely mobile mice. Scale bar corresponds to 1 second (horizontal) 
and 200 µA (vertical).  
 (b) Basal EEG power measurements in P90 Mecp2T158A/y mice (n = 7) compared to Mecp2+/y littermates (n = 8). 
Frequency bands are represented as follows: δ (2-4 Hz), θ (4-8 Hz), α (8-12 Hz), β (12 – 30 Hz), low-γ (30-50 Hz), and 
high-γ (70-140 Hz). Insets show β and high-γ mean amplitudes across EEG recordings. Scale bars represent one 
oscillation cycle (horizontal) and 20 µA (vertical). Bars represent mean ± SEM. *** p-value <0.001; two-tailed t-test with 
Bonferroni correction.  
 (c) Grand average event-related potential (ERP) traces following presentation of 85-dB white-noise clicks with 
4-second interstimulus intervals. Traces represent mean amplitude (solid line) ± SEM (dashed lines). The characteristic 
polarity peaks P1, N1 and P2 are highlighted with straight lines with the length indicating latency range. Scale bar 
corresponds to 50 ms (horizontal) and 20 µA (on vertical).  
 (d) Latencies and (e) amplitudes of ERP peaks. Bars represent mean ± SEM. * p-value < 0.05 and ** < 0.01; 
two-tailed t-test with Bonferroni correction  
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Figure 7 
 
Figure 7.  Decreased event-related power and PLF in Mecp2T158A/y mice 
 (a) Time-frequency plots showing changes in event-related power in response to 85-dB auditory stimulation in 
P90 Mecp2T158A/y mice and Mecp2+/y littermates. Time is plotted on the abscissa (where t = 0 at sound presentation) and 
frequency on the ordinate. Color represents mean power with warmer colors corresponding to an increased power and 
cooler colors representing decreased power compared to pre-stimulus baseline.  
 (b) Changes in event-related mean power averaged across δ (2-4 Hz), θ (4-8 Hz), α (8-12 Hz), β (12 – 30 Hz), 
low-γ (30-50 Hz), and high-γ (70-140 Hz) frequencies. Scale bars represent the length of a single oscillation cycle of the 
lowest frequency in the range. Insets showed power traces on expanded time-scale denoted by length of single oscillation 
cycle. Traces represent mean power ± SEM.  
 (c) Time-frequency plots showing changes in event-related phase locking factor (PLF) in response to 85-dB 
auditory stimulation. Color represents PLF with warmer colors corresponding to a higher PLF or lower circular variance in 
EEG phase across trials.  
 (d) Changes in event-related PLF averaged across frequencies as above. Scale bars represent the length of a 
single oscillation cycle and insets show traces on expanded time-scale. Traces represent mean PLF ± SEM. 
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Figure 8 
 
Figure 8.  Age-dependent increase in event-related power and PLF is absent in Mecp2T158A/y mice  
 (a) Event-related power changes in Mecp2+/y (WT) mice at P30 and P90.  
 (b) Event-related phase-locking factor (PLF) changes in WT mice at P30 and P90.  
 (c) Event-related power changes in Mecp2T158A/y mice at P30 and P90.  
 (d) Event-related PLF changes in Mecp2T158A/y mice at P30 and P90. Bars represent mean ± SEM.  * p-value < 
0.05, ** < 0.01 and *** < 0.001; two-tailed t-test with Bonferroni correction. 
  
0.0!
0.2!
0.4!
0.6!
"! #! $! %! &low! &high!
0.0!
0.2!
0.4!
0.6!
"! #! $! %! &low! &high!
-4!
-2!
0!
2!
4!
6!
"! #! $! %! &low! &high!
-4!
-2!
0!
2!
4!
6!
"! #! $! %! &low! &high!
a
P90 +/y
P30 +/y
P
o
w
e
r 
(d
B
)
P
L
F
c
b
d
* ** **
*** ***
*
P
L
F
* *
**
P
o
w
e
r 
(d
B
)
P90 T158A/y
P30 T158A/y
P90 +/y
P30 +/y
P90 T158A/y
P30 T158A/y
109	  
	  
 
  
	  
	  
	  
110	  
	  
 
	  
111	  
	  
 
	  
112	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
113	  
	  
 
	  
114	  
	  
 
	  
115	  
	  
 
	  
116	  
	  
 
 
	  
117	  
	  
 
	  
118	  
	  
 
	  
119	  
	  
 
 
	  
120	  
	  
 
	  
121	  
	  
 
 
	  
122	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
123	  
	  
 
	  
124	  
	  
Chapter 5: 
NEURONAL MORPHOLOGY IN MECP2 MOUSE MODELS IS INTRINSICALLY 
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This chapter consists of my 2013 first-author Neurobiology of Disease publication 
describing neuronal morphology and soma size across development in three 
independent Mecp2 mouse models that represent Mecp2 loss-of-function, partial loss-of-
function, and gain-of-function mutations.  Arith Reyes, an undergraduate student-turned-
lab manager, co-first authored the manuscript with me and performed much of the 
imaging and analysis.  Overall, we found that Mecp2 loss-of-function reduces dendritic 
complexity in a brain region-specific manner that correlates with the onset of behavioral 
phenotype.  The degree of these changes, however, is mild, domain-specific, and 
dependent on Mecp2 mutation.  In contrast, a robust decrease in soma size persists 
throughout development in both Mecp2 loss-of-function mouse models.  Mecp2 gain-of-
function does not affect dendritic outgrowth or soma size, even after onset of behavioral 
phenotypes.  Together, these data suggest that changes soma size are more consistent 
than changes in dendritic complexity upon Mecp2 loss-of-function mutation, and may 
therefore be a more reliable marker in assessing MeCP2 function and therapeutic 
efficacy in RTT studies.  
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Abstract 
Rett Syndrome (RTT), a progressive neurological disorder characterized by 
developmental regression and loss of motor and language skills, is caused by mutations 
in the X-linked gene encoding methyl-CpG binding protein 2 (MECP2). Neurostructural 
phenotypes including decreased neuronal size, dendritic complexity, and spine density 
have been reported in post-mortem RTT brain tissue and in Mecp2 animal models. How 
these changes in neuronal morphology are related to RTT-like phenotype and MeCP2 
function, and the extent to which restoration of neuronal morphology can be used as a 
cellular readout in therapeutic studies, however, remain unclear. Here, we systematically 
examined neuronal morphology in vivo across three Mecp2 mouse models representing 
Mecp2 loss-of-function, partial loss-of-function, and gain-of-function mutations, at 
developmental time points corresponding to early- and late-symptomatic RTT-like 
behavioral phenotypes. We found that in Mecp2 loss-of-function mouse models, 
dendritic complexity is reduced in a mild, age-dependent, and brain region-specific 
manner, whereas soma size is reduced consistently throughout development. Neither 
phenotype, however, is altered in Mecp2 gain-of-function mice. Our results suggest that, 
in the cell types we examined, the use of dendritic morphology as a cellular readout of 
RTT phenotype and therapeutic efficacy should be cautioned, as it is intrinsically 
variable. In contrast, soma size may be a robust and reliable marker for evaluation of 
MeCP2 function in Mecp2 loss-of-function studies.  
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Introduction 
Rett Syndrome (RTT) is a neurological disorder that is caused by mutations in the X-
linked gene encoding methyl-CpG binding protein 2 (MECP2) (Amir et al., 1999). It 
primarily affects young girls, with a prevalence of 1 in 10-15,000 live births. One striking 
feature of RTT is the time course at which clinical symptoms appear. After 6-18 months 
of apparently normal development, affected individuals enter a period of developmental 
stagnation, characterized by microcephaly, growth arrest and hypotonia. This stage is 
followed by a period of developmental regression, where patients display stereotypic 
hand wringing and social withdrawal, lose acquired motor and speech skills, and develop 
respiratory abnormalities (Chahrour and Zoghbi, 2007).  
 
Phenotypic variability is present within the classic RTT profile, where affected girls differ 
by clinical severity (Chahrour and Zoghbi, 2007). This variability may be attributed to 
random X-chromosome inactivation and the variety of MECP2 mutations, including 
missense, nonsense, deletion, and insertion mutations, that have been identified in RTT 
patients (Bienvenu and Chelly, 2006). In vitro biochemical studies have demonstrated 
that the majority of these mutations lead to Mecp2 loss-of-function (Kriaucionis and Bird, 
2003). Notably, genetic studies have also identified patients carrying duplication or 
triplication of MECP2 (Bienvenu and Chelly, 2006). These patients are classified under 
MECP2 duplication syndrome and bear a similar but distinct clinical profile to that of 
classical RTT (Chahrour and Zoghbi, 2007). Mice carrying two-fold levels of Mecp2 
expression also show behavioral abnormalities (Collins et al., 2004; Luikenhuis et al., 
2004), highlighting the importance of MeCP2 dosage and the detrimental effect of 
Mecp2 gain-of-function. 
 
Histological analysis of postmortem RTT brain tissue has revealed morphological 
phenotypes including decreased cellular size with increased cell-packing density 
(Bauman et al., 1995), decreased dendritic complexity (Armstrong, 2005; Belichenko et 
al., 1994), and decreased spine density (Belichenko et al., 1994; Chapleau et al., 2009). 
Interestingly, these changes are selective, as decreased dendritic complexity has been 
observed in the motor, frontal, and inferior temporal cortices, but not in the visual cortex 
or hippocampus (Armstrong, 2005). Moreover, these changes appear to be cortical 
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layer-specific, even within the same cortical area (Armstrong, 2005). No evidence of 
neuronal degeneration or atrophy has been identified (Armstrong, 2005; Jellinger et al., 
1988), indicating that these morphological changes are a consequence of impaired 
neuronal development or structural maintenance, rather than neurodegeneration. What 
remains unclear, however, is how mutations in MECP2 lead to these changes in 
neuronal morphology and whether they contribute to RTT disease pathology or are 
secondary consequences of long-term illness. 
 
To investigate the pathogenic mechanisms underlying RTT, several mouse models 
harboring different Mecp2 loss-of-function mutations have been developed and 
characterized (Brendel et al., 2011; Chen et al., 2001; Goffin et al., 2012; Guy et al., 
2001; Jentarra et al., 2010; Pelka et al., 2006; Shahbazian et al., 2002a). Although the 
mouse models recapitulate several RTT clinical features, each Mecp2 mutation confers 
a discrete behavioral profile, supporting the link between heterogeneity in MECP2 
mutations and phenotypic variability in RTT. Similarly, underlying cellular structure in 
Mecp2 mutant mice differs across Mecp2 mutation (Belichenko et al., 2008; 2009b). 
While reduced dendritic complexity, soma size, and spine density are commonly 
identified in Mecp2 mutant mice (Belichenko et al., 2009a; 2009b; Fukuda et al., 2005; 
Kishi and Macklis, 2004; Robinson et al., 2012; Stuss et al., 2012; Tropea et al., 2009), 
these structural phenotypes also differ by cellular subtype and developmental time point 
(Chapleau et al., 2012; Fukuda et al., 2005). The extent to which these factors influence 
cellular structure, however, is not well understood, as the use of different techniques and 
Mecp2 mouse models have made direct comparisons across studies difficult (Belichenko 
et al., 2008; 2009a; Chapleau et al., 2009; Cohen et al., 2011; Fukuda et al., 2005; 
Jentarra et al., 2010; Kishi and Macklis, 2004; Metcalf et al., 2006; Moretti et al., 2006; 
Robinson et al., 2012; Stuss et al., 2012; Zhou et al., 2006). For example, reduced spine 
density has been reported in motor cortex layer II/III and V pyramidal neurons in 3-week-
old Mecp2-null mice (Belichenko et al., 2009a; 2009b), and in layer V at 8 weeks 
(Tropea et al., 2009), while no change in spine density has been reported in the 
somatosensory cortex layer II/III pyramidal neurons in 8-week-old Mecp2-null mice (Kishi 
and Macklis, 2004). Whether these dissimilar findings are consequences of brain region-
specific or age-dependent regulation of neuronal morphology is difficult to evaluate, as 
studies have used different imaging techniques, including Golgi staining, neuron dye 
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labeling, and fluorescent reporters, and different Mecp2 mutant mice (Chen et al., 2001; 
Guy et al., 2001). Indeed, Golgi staining has revealed reduced spine density in 
hippocampus CA1 of 12-week-old Mecp2-null mice (Robinson et al., 2012), but DiI 
labeling shows decreased spine density in the same cells at 1 week, and not at 2 or 7 
weeks (Chapleau et al., 2012). A comprehensive and systematic analysis using a single 
experimental method, therefore, is needed to clarify how age, brain region, and Mecp2 
mutation influence RTT-related neuronal morphology.  
 
Importantly, recent studies have shown that RTT-like symptoms can be ameliorated 
through the reintroduction of MeCP2 in mice (Giacometti et al., 2007; Guy et al., 2007; 
Lioy et al., 2011; Robinson et al., 2012). The reversibility of RTT phenotypes has 
stimulated wide interest in developing cellular assays to measure MeCP2 function. 
Morphological phenotypes such as spine density, dendritic outgrowth, and soma size 
have been used as readouts of therapeutic efficacy upon restoration of MeCP2 
(Giacometti et al., 2007; Robinson et al., 2012) or IGF-1 treatment in mice and induced 
pluripotent stem cells (iPSCs) (Marchetto et al., 2010; Tropea et al., 2009). Thus, 
understanding the relationship between MeCP2 function, neuronal structure, and RTT-
like phenotype, as well as identifying robust and reproducible morphological phenotypes 
as readouts of MeCP2 function, are imperative.  
 
In this study, we systematically analyzed neuronal morphology in three Mecp2 mouse 
models, Mecp2–/y, Mecp2T158A/y, and Mecp2Tg1, that represent the spectrum of MECP2 
mutations contributing to the phenotypic heterogeneity of RTT and MECP2 duplication 
syndrome. The Mecp2–/y mice lack MeCP2 and demonstrate the most severe behavioral 
phenotype, representing Mecp2 loss-of-function (Guy et al., 2001). The Mecp2T158A/y 
mice, mimicking a common RTT patient missense mutation at the Threonine 158 
residue, demonstrate a moderately severe behavioral phenotype, representing Mecp2 
partial loss-of-function (Goffin et al., 2012). Lastly, the Mecp2Tg1 mice express two-fold 
levels of MeCP2 and are believed to model MECP2 duplication syndrome, representing 
Mecp2 gain-of-function (Collins et al., 2004). Importantly, although neuronal morphology 
in Mecp2 loss-of-function models has been individually studied (Belichenko et al., 2008; 
2009a; Chapleau et al., 2009; Fukuda et al., 2005; Kishi and Macklis, 2004; Moretti et 
al., 2006; Robinson et al., 2012; Stuss et al., 2012), a direct comparison of 
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morphological phenotypes in Mecp2 mouse models across the RTT phenotypic 
spectrum, including the less severe partial loss-of-function Mecp2 mutations and Mecp2 
duplication, has yet to be conducted. 
 
Given the progressive nature of RTT-like phenotypic onset, we focused on early and late 
developmental time points representative of none-to-mild behavioral phenotype (“early” 
time point) and overt behavioral phenotype (“late” time point) in each mouse model. By 
using the same experimental method to analyze neuronal morphology in vivo across 
these mouse models and developmental time points, we aimed to address the following 
questions in this study: 1) The effect of Mecp2 loss- or gain-of-function on the 
development of neuronal morphology, 2) The relationship between RTT-like behavioral 
symptomatic severity and underlying neuronal morphology, and 3) The brain region or 
cell type-specific effects of Mecp2 mutation on neuronal morphology. 
 
We found that Mecp2 loss-of-function reduces dendritic complexity in a brain region-
specific manner that correlates with the onset of behavioral phenotype. The degree of 
changes in dendritic complexity, however, was mild, domain-specific, and dependent on 
Mecp2 mutation. In contrast, a significant decrease in soma size upon Mecp2 loss-of-
function persisted throughout development and across both Mecp2 loss-of-function 
mutations. Mecp2 gain-of-function, however, did not affect dendritic outgrowth or soma 
size, even after onset of gain-of-function behavioral phenotypes, suggesting that 
changes in cellular structure may not be effective readouts of therapeutics targeted 
toward MECP2 duplication syndrome. The subtlety of changes in dendritic outgrowth 
and the dependence on Mecp2 mutation, developmental time point, and brain region 
raise caution in using dendritic complexity as a cellular readout of RTT-like phenotype. 
Changes in soma size, however, are reproducible and robust, suggesting that soma size 
may be a more reliable marker in assessing MeCP2 function and therapeutic efficacy in 
RTT studies. 
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Results 
Neuron imaging strategy 
To minimize experimental manipulation and variation in our analysis of neuronal 
morphology in Mecp2 mutant mice, we took advantage of a genetic labeling approach 
that has been successfully utilized in other RTT morphological studies, a Thy1-GFP/M 
reporter line (Belichenko et al., 2009a; Cohen et al., 2011). In this line, a sparse 
population of neurons intrinsically expresses GFP throughout the cell body and dendritic 
tree in various brain regions (Figure 1a, 1b), allowing for direct visualization of individual 
neurons (Feng et al., 2000). To visualize neurons in Mecp2 mutant mice, we crossed 
male Thy1-GFP/M reporter mice to female Mecp2 heterozygotes (Mecp2–/+, 
Mecp2T158A/+, or Mecp2Tg1). Given the confounding effects of mosaic MeCP2 expression 
in females from random X-chromosome inactivation, all experiments were performed 
using male littermates with the following genotypes: Mecp2–/y;Thy1-GFP/M and 
Mecp2+/y;Thy1-GFP/M; Mecp2T158A/y;Thy1-GFP/M and Mecp2+/y;Thy1-GFP/; or 
Mecp2Tg1;Thy1-GFP/M and Mecp2+/y;Thy1-GFP. For simplicity, we will refer to 
Mecp2+/y;Thy1-GFP/M as WT and Mecp2 mutant mice expressing the Thy1-GFP/M 
transgene as Mecp2–/y, Mecp2T158A/y, or Mecp2Tg1. 
 
Previous studies have shown that disruption of MeCP2 results in deficits in neuronal 
organization, dendritic complexity and synaptic connectivity in the somatosensory cortex 
in both postmortem RTT tissue and mice (Cohen et al., 2011; Dani and Nelson, 2009; 
Kaufmann and Moser, 2000). We therefore analyzed neuronal morphology in layer V 
pyramidal neurons of the somatosensory cortex. These neurons are distinct in their 
cellular architecture, characterized by apical and basal dendritic trees and a pyramid-
shaped soma (Spruston, 2008), and thus can be consistently identified. We measured 
dendritic complexity and soma size in layer V pyramidal neurons extending their apical 
dendrites to the pial surface and their basal dendrites into deep layer VI (Fig 1c). Given 
the anatomic and functional distinctions between basal and apical dendritic arbors 
(Spruston, 2008), we imaged and quantified basal and apical dendritic complexity 
separately, using Sholl analysis (Fig 1d-e), which measures dendritic crossings through 
a series of concentric circles with increasing radii centered around the cell soma 
(SHOLL, 1953). 
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Dendritic complexity in Mecp2 loss-of-function mice 
The majority of mutations in MECP2 leading to RTT are loss-of-function mutations 
(Chahrour and Zoghbi, 2007). Therefore, we first assessed neuronal morphology in 
Mecp2-null mice (Mecp2–/y) that lack both Mecp2 transcript and MeCP2 protein, and 
represent one of the most phenotypically severe Mecp2 mutant mice (Guy et al., 2001). 
Like RTT patients, Mecp2–/y mice show no initial RTT-like phenotype, but begin to 
develop aberrant gait and reduced mobility around 3 postnatal weeks. By 8 postnatal 
weeks, Mecp2–/y mice display overt RTT-like phenotypes including hindlimb clasping, 
tremor, and irregular breathing. We therefore chose to investigate neuronal morphology 
upon Mecp2 loss-of-function at P30 and P60, time points representative of early-
symptomatic and late-symptomatic RTT-like phenotype, respectively. At the early-
symptomatic P30 time point, Sholl analysis of somatosensory cortex layer V pyramidal 
neurons revealed a statistically significant decrease in dendritic complexity in Mecp2–/y 
mice relative to WT littermates (WT: n=24 neurons, Mecp2–/y: n=19 neurons; p<0.0001) 
(Fig. 2a). Post hoc tests revealed that this decrease was most pronounced in Mecp2–/y 
mice in both basal and proximal apical dendrites 140–160 µm from soma and in the 
distal apical tuft 700 µm from soma. As RTT-like behavioral phenotypes in P30 Mecp2–/y 
mice are mild but present, these data suggest that decreased dendritic complexity 
accompanies RTT-like behavioral phenotype.  
 
At the late-symptomatic P60 time point, Mecp2–/y mice also showed reduced dendritic 
complexity (WT: n=36 neurons; Mecp2–/y: n=31 neurons; p<0.0001) (Fig. 2b). Although 
mild, these decreases were more widespread than that of P30 and most pronounced in 
the basal arbor 100–140 µm from soma and in the distal apical arbor 680–700 µm from 
soma, where the significant reduction in the apical tuft is likely a reflection of reduced 
cortical thickness and brain size in these mice (Kishi and Macklis, 2004). Given the overt 
RTT-like behavioral phenotypes in P60 Mecp2–/y mice, the mild reduction in dendritic 
complexity is surprising but consistent with reports of normal cortical lamination and 
organization in 7–10 week-old Mecp2–/y mice (Belichenko et al., 2008; Guy et al., 2001; 
Metcalf et al., 2006) and unaffected dendritic length and complexity from in vitro studies 
using the same mice (Chao et al., 2007). Therefore, as excitatory input onto proximal 
dendrites comes primarily from local or adjacent collaterals, while input onto distal 
dendrites comes from more distant cortical or thalamic projections (Spruston, 2008), our 
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data indicate that the mild but widespread reduction in dendritic complexity across 
domains results in altered total excitatory input onto Mecp2–/y neurons, both in early-
symptomatic and late-symptomatic Mecp2–/y mice.  
 
 
Dendritic complexity in MeCP2 T158A partial loss-of-function mice 
One of the most common MECP2 missense mutations occurs at Threonine 158, 
converting it to methionine (T158M) or alanine (T158A). We recently developed and 
characterized an Mecp2 T158A knockin mouse and found that Mecp2T158A/y mice show a 
similar but delayed progression of RTT-like behavioral phenotypes relative to that of 
Mecp2–/y mice, where phenotypes begin to develop at 4–5 weeks and are overt by 13 
weeks (Goffin et al., 2012). At P60, Mecp2T158A/y mice express milder locomotor, anxiety, 
and motor coordination phenotypes compared to age-matched Mecp2–/y mice, indicating 
that Mecp2 T158A is a partial loss-of-function mutation. In addition, the MeCP2 T158A 
protein is expressed but is less stable and shows reduced binding to methylated DNA 
(Goffin et al., 2012). To investigate neuronal morphology upon Mecp2 partial loss-of-
function, we measured dendritic complexity at P30, prior to onset of RTT-like 
phenotypes, and P90, when RTT-like phenotypes are overt. Sholl analysis of layer V 
pyramidal neurons in the somatosensory cortex of P30 animals revealed a similar 
pattern of dendritic complexity in Mecp2T158A/y and WT littermates (WT: n=40 neurons; 
Mecp2T158A/y: n=34 neurons; p>0.05; Fig. 3a). Although both Mecp2T158A/y and Mecp2–/y 
mice represent Mecp2 loss-of-function mutations, their RTT-behavioral profiles at P30 
are distinct, where RTT-like phenotypes are mild in Mecp2–/y mice but absent in 
Mecp2T158A/y mice. These data, therefore, support the hypothesis that decreased 
dendritic complexity accompanies RTT-like phenotype. 
 
At the late-symptomatic P90 time point, Mecp2T158A/y mice showed decreased dendritic 
complexity relative to WT littermates (WT: n=36 neurons; Mecp2T158A/y: n=39; p<0.0001; 
Fig. 3B). Strikingly, the decrease was specific to the basal arbor 60–140 µm from soma 
and was not present in the apical arbor. Given that pyramidal neuron dendritic domains 
are believed to receive unique synaptic inputs and contain synapses with distinct 
properties (Spruston, 2008), the domain-specific decrease in dendritic complexity in 
Mecp2T158A/y mice suggests a cellular mechanism underlying a distinct behavioral profile. 
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Although both P60 Mecp2–/y mice and P90 Mecp2T158A/y mice show similar RTT-like 
phenotypic severity, the selective decrease in basal dendritic complexity in Mecp2T158A/y 
mice in contrast to the widespread morphological phenotype seen in Mecp2–/y mice 
supports an Mecp2 mutation-specific effect on neuronal architecture that may underlie 
RTT-like phenotypic heterogeneity. 
 
 
Brain region-specific dendritic complexity in Mecp2 partial loss-of-function 
Given the brain region-specific changes in neuronal architecture in RTT post-mortem 
tissue (Armstrong, 2005) and compartment-specific changes in Mecp2 mouse models 
(Stuss et al., 2012), we next addressed whether the age-dependent and domain-specific 
decrease in dendritic complexity identified in the somatosensory cortex of Mecp2T158A/y 
mice would be replicated in a different brain region from the same mice. Therefore, we 
examined neuronal morphology in hippocampal CA1 pyramidal neurons in Mecp2T158A/y 
mice at the pre- and post-symptomatic ages P30 and P90. Similar to what we observed 
in the cortex, Mecp2 partial loss-of-function did not affect dendritic complexity in 
hippocampal CA1 pyramidal neurons at the early-symptomatic P30 time point (WT: n=27 
neurons; Mecp2T158A/y: n=33 neurons; p>0.05; Fig. 4a). At the late-symptomatic P90 time 
point, however, we observed a small but significant change in dendritic complexity in 
Mecp2T158A/y mice (WT: n=32 neurons; Mecp2T158A/y: n=40 neurons; p<0.05; Fig. 4b). 
Post hoc tests revealed that this difference was specific to the basal dendritic arbor, and 
does not reflect a decrease in dendritic complexity, but rather, is a result of a shift 
towards the soma, as peak branching in Mecp2T158A/y mice is similar to that of controls 
(Fig 4c). This shift toward the soma may reflect reduced hippocampal volume, which 
has been reported in Mecp2 loss-of-function mice (Belichenko et al., 2008). The age-
dependent and domain-specific decrease in dendritic complexity in Mecp2T158A/y mice, 
therefore, is specific to layer V somatosensory cortex and absent in CA1 hippocampus, 
consistent with RTT post-mortem studies (Armstrong et al., 1995). Together, these data 
support age-dependent and brain region-specific regulation of dendritic outgrowth upon 
Mecp2 loss-of-function. 
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Soma size is regulated throughout development by MeCP2 
As both reduced dendritic outgrowth and soma size are believed to contribute to RTT 
patient microcephaly and reduced soma size has been reported in RTT post-mortem 
tissue (Bauman et al., 1995), we also measured soma size in our Mecp2 mutation mice 
at both early- and late-symptomatic time points. In striking contrast to the age-
dependence and brain region-specificity of changes in dendritic complexity, we found 
that changes in soma size persisted throughout development and were consistent 
between Mecp2 loss-of-function mutations. Soma size in somatosensory cortex layer V 
pyramidal neurons was reduced in both P30 early-symptomatic Mecp2–/y mice (WT: 
282.9 ± 4.0 µm2, n=124 neurons; Mecp2–/y: 237.6 ± 4.7µm2, n=103 neurons; p<0.01) and 
in P60 late-symptomatic Mecp2–/y mice (WT: 287.9 ± 4.4 µm2, n=126 neurons; Mecp2–/y: 
237.2 ± 4.4 µm2, n=104 neurons; p<0.01; Fig. 5a), relative to WT littermates, indicating 
that Mecp2 loss-of-function leads to reduced soma size in both early and late 
development of RTT-like phenotypes. Similarly, soma size was reduced in both P30 pre-
symptomatic Mecp2T158A/y mice (WT: 290.6 ± 3.9 µm2, n=115 neurons; Mecp2T158A/y: 
251.3 ± 4.6 µm2, n=121 neurons; p < 0.01) and in P90 late-symptomatic Mecp2T158A/y 
mice (WT: 311.1 ± 5.0 µm2, n=81 neurons; Mecp2T158A/y: 262.6 ± 3.3 µm2, n=106 
neurons; p<0.01) relative to WT littermates (Fig 5b), indicating that reduced soma size 
may even precede onset of RTT behavioral phenotypes and is a consequence of Mecp2 
loss-of-function. Moreover, we previously reported that hippocampal CA1 pyramidal 
neuron soma size is decreased in both pre- and post-symptomatic Mecp2T158A/y mice 
(Goffin et al., 2012). The persistent reduction in soma size in Mecp2 loss-of-function 
mouse models throughout development contrasted with the age-dependent and brain 
region-specific changes in dendritic complexity suggests that MeCP2 regulates dendritic 
outgrowth and soma size through distinct mechanisms and that soma size may be a 
more reproducible and reliable cellular marker for MeCP2 function than dendritic 
complexity. 
 
 
Dendritic complexity in Mecp2 gain-of-function mice 
As the importance of MeCP2 dosage has been highlighted though the link between gain-
of-function MECP2 mutations and neurodevelopmental disorder (Chahrour and Zoghbi, 
2007), we next examined a transgenic mouse line expressing two-fold levels of MeCP2 
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(Mecp2Tg1) to determine how Mecp2 gain-of-function affects neuronal morphology 
(Collins et al., 2004). Importantly, neuronal morphology has yet to be described in 
Mecp2 gain-of-function mice. While these mice, similar to that of Mecp2 loss-of-function 
models, develop normally, they show enhanced LTP and learning behavior by 20 
postnatal weeks and after 30 postnatal weeks, exhibit seizures, ataxia, and premature 
death (Collins et al., 2004). We therefore examined dendritic complexity and soma size 
in Mecp2Tg1 mice at P30 and P140, time points representative of pre- and post-
development of gain-of-function phenotype, respectively. Strikingly, we found similar 
patterns of dendritic complexity in Mecp2Tg1 mice and WT littermates in layer V 
somatosensory cortex by Sholl analysis at P30 (WT: n=16 neurons; Mecp2Tg1: n=19 
neurons; p>0.05) (Fig. 6a) and P140 (WT: n=23 neurons; Mecp2Tg1: n=23 neurons; 
p>0.05) (Fig 6b). These data are in contrast to the reduced dendritic complexity 
observed in late-symptomatic Mecp2 loss-of-function animals (Fig 2b, 3b), and suggest 
a separate mechanism of dendritic outgrowth regulation in Mecp2 gain-of-function that is 
not coupled to behavioral phenotype. 
 
Similarly, we found no changes in soma size in Mecp2Tg1 mice relative to WT littermates, 
both prior to (P30; WT: 266.3 ± 4.3 µm2, n=101 neurons; Mecp2Tg1: 272.8 ± 3.0 µm2, 
n=110 neurons) and after the development of behavioral phenotypes (P140; WT: 268.9 
± 4.2 µm2, n=110 neurons; Mecp2Tg1: 265.0 ± 4.2 µm2, n=113 neurons; p>0.05) (Fig. 
6c). This finding is consistent with in vitro studies showing no effect of MeCP2 
overexpression on soma size (Jugloff et al., 2005). Together, these data suggest that 
neuronal morphology may be affected by Mecp2 loss-of-function, but is not sensitive to 
two-fold MeCP2 dosage. This is not surprising, as MECP2 duplication syndrome is 
considered to be a separate neurodevelopmental disorder from typical RTT (Ramocki et 
al., 2009) and likely has a distinct pathogenic mechanism. Neuronal morphology, 
therefore, may be an appropriate therapeutic readout specifically for RTT patients with 
MECP2 loss-of-function mutations. 
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Discussion 
RTT phenotypes are believed to originate from disruptions in neuronal circuits caused by 
MeCP2 dysfunction in the brain (Goffin and Zhou, 2012; Katz et al., 2012), and changes 
in neuronal morphology provide a cellular basis for alterations in circuit function. Given 
the rise in the use of morphological phenotypes as readouts of therapeutic efficacy 
(Marchetto et al., 2010; Tropea et al., 2009) or restoration of MeCP2 function 
(Giacometti et al., 2007; Robinson et al., 2012), understanding how MECP2 mutations 
impact the maintenance of proper neuronal structure and the relationship between RTT-
like phenotype and underlying cellular morphology has become vital. Robust and 
reproducible RTT-related morphological phenotypes have been difficult to identify, as the 
use of different techniques, animal models, cell types, and developmental time points 
across different labs have made direct comparisons between studies difficult. Therefore, 
we sought to eliminate the confounds of methodological bias by using the same 
experimental method to analyze neuronal morphology in vivo across the development of 
Mecp2 loss-of-function, partial loss-of-function, and gain-of-function mouse models. 
Given the successful utilization of Thy1-GFP/M reporter mice in other cortical and 
hippocampal morphological studies (Belichenko et al., 2009a; Cohen et al., 2011) and 
the absence of added experimental manipulations for cellular visualization, we chose to 
cross our Mecp2 mutant mice to a Thy1-GFP/M reporter line in which neurons are 
intrinsically labeled with GFP in a mosaic manner in several brain regions, including the 
somatosensory cortex and hippocampus CA1 (Feng et al., 2000). In our study, we aimed 
to address the following three questions: 1) How does Mecp2 loss- or gain-of-function 
affect the development of neuronal morphology? 2) What is the relationship between 
RTT-like behavioral phenotypic severity and underlying neuronal morphology? 3) Are 
these changes in neuronal morphology brain region or cell type-specific? 
 
To address the first question, we measured dendritic complexity and soma size in 
Mecp2–/y and Mecp2T158A/y mice, representing Mecp2 loss-of-function and Mecp2 partial 
loss-of-function, respectively, and Mecp2Tg1 mice, representing Mecp2 gain-of-function. 
We found decreased dendritic complexity and soma size in Mecp2 loss-of-function mice 
(Mecp2–/y, Mecp2T158A/y) and no change in either phenotype in Mecp2 gain-of-function 
mice (Mecp2Tg1) relative to WT littermates. These data suggest that MeCP2 expression 
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levels may play a role in the regulation of neuronal outgrowth, but increased MeCP2 
expression has no structural effect. Our data also indicate that a greater reduction in 
MeCP2 may cause more severe morphological defects, as we observed a more 
widespread reduction in dendritic branching in Mecp2–/y mice, which lack MeCP2 protein 
(Guy et al., 2001), relative to Mecp2T158A/y mice, which have reduced MeCP2 protein 
expression (Goffin et al., 2012).  
 
To our knowledge, neuronal morphology has not been studied in Mecp2 gain-of-function 
mouse models, and the effect of MeCP2 overexpression in vitro on neuronal morphology 
remains unclear due to reports of increased (Jugloff et al., 2005; Larimore et al., 2009), 
decreased {Zhou:2006dp}, and unchanged dendritic complexity {Chapleau:2009bf} in 
cultured neurons and organotypic slices, and decreased dendritic outgrowth in 
Drosophila and Xenopus models {Marshak:2012gl, Vonhoff:2012bs}. Our findings 
suggest that both dendritic outgrowth and soma size are reduced upon Mecp2 loss-of-
function, whereas neither phenotype is affected by Mecp2 gain-of-function with two-fold 
MeCP2 expression. Notably, Mecp2Tg1 mice were maintained on a mixed FVB/C57BL/6 
background, and both Mecp2 loss-of-function models were maintained on a pure 
C57BL/6 background. Therefore, the different genetic backgrounds may contribute to the 
differences seen between loss-of-function and gain-of-function models. It is possible 
that, although two-fold expression of MeCP2 is sufficient to impair synaptic function 
leading to circuit defects {Chao:2007jg, Na:2012fu}, it is not sufficient to disrupt 
cellular morphology in vivo. Future study of neuronal morphology in mice expressing 
three-fold levels of MeCP2 may address this hypothesis, as MECP2 triplication produces 
more severe phenotypes both clinically and in mice (Samaco et al., 2012; Van Esch et 
al., 2007). 
 
To address the second question, the relationship between RTT-like phenotypic severity 
and underlying neuronal morphology, we measured dendritic complexity and soma size 
in Mecp2–/y and Mecp2T158A/y mice prior to or at the onset of RTT-like phenotypes (P30) 
and after development of RTT-like phenotypes. Because RTT-like behavioral 
progression differs across these mouse models, the ages corresponding to late-
symptomatic RTT similarly differed (P60, P90, respectively). Overall, we observed a 
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subtle age-dependent effect of Mecp2 mutation on dendritic complexity in Mecp2 loss-of 
function, where progression of RTT-like behavioral phenotype correlates with underlying 
cellular changes. At the early-symptomatic P30 time point, only the mildly-symptomatic 
Mecp2–/y mice showed decreased dendritic complexity, while the pre-symptomatic 
Mecp2T158A/y mice did not, indicating that early in the development of RTT-like 
phenotypes, changes in neuronal structure vary across different Mecp2 mutations and 
may reflect development of RTT-like behavioral phenotypes. This hypothesis is 
consistent with findings from a comparative study of brain morphology in two 3-week-old 
Mecp2 loss-of-function mouse models, in which Mecp2–/y mice with a more severe RTT-
like phenotype exhibited more widespread and marked changes in brain structure than 
Mecp2–/y mice with a milder RTT-like phenotype (Belichenko et al., 2008). 
 
Similarly, we found greater changes in dendritic complexity in late-symptomatic P60 
Mecp2–/y and P90 Mecp2T158A/y mice relative to that of P30. The reduction in dendritic 
complexity in P60 Mecp2–/y mice was slightly more widespread than that of P30 Mecp2–/y 
mice, and P90 Mecp2T158A/y showed changes in dendritic complexity that were absent at 
the pre-symptomatic time point. These data indicate that changes in dendritic outgrowth 
accompany the development of RTT-like phenotypes upon Mecp2 loss-of-function and 
are consistent with RTT post-mortem histological data showing a correlation between 
the degree of morphological abnormality and RTT symptom severity at time of death 
(Bauman et al., 1995).  
 
The developmental changes in dendritic complexity we identified, however, were 
relatively mild, compared to reports from other Mecp2 loss-of-function studies (Kishi and 
Macklis, 2004; Robinson et al., 2012; Stuss et al., 2012), and limited to specific dendritic 
domains. This is surprising, as the overt behavioral phenotypes present at both late-
symptomatic time points would predict underlying cellular architecture to be severely 
disrupted. One factor in this subtle dendritic outgrowth phenotype may be experimental 
bias from the Thy1-GFP/M reporter line. While an interaction between MeCP2 and a 
different reporter transgene Thy1-YFP/H has been reported (Stuss et al., 2012), we did 
not identify GFP-labeling biases in our mice. Our selection of layer V cortical neurons 
extending their apical tufts to the pial surface, however, could have introduced a bias for 
analysis of neurons with a less severe morphological phenotype within the Mecp2 
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mutant neuronal network. As changes in dendritic morphology have been shown to 
widely differ between individual neurons within a population (Belichenko et al., 2009b), 
we cannot exclude the possibility that our experimental method was selective for 
neurons with intact dendritic structures, resulting in a mild dendritic complexity 
phenotype.  
 
Data from other Mecp2 mouse models, however, indicate that changes in dendritic 
arborization may not reflect the severity of behavioral phenotype. While MeCP2 A140V 
knockin mice with no obvious RTT-like behavioral phenotypes show decreased dendritic 
complexity (Jentarra et al., 2010), Mecp2308/y mice with motor, social, and learning 
deficits that model an MeCP2 early truncation show no changes in dendritic complexity 
or post-synaptic density in cortical and hippocampal CA1 neurons, both before and after 
onset of RTT-like phenotypes (Moretti et al., 2006). In addition, a developmental time 
window may exist in which neuronal morphology is more sensitive to MeCP2 function, as 
previous work has shown that newborn neurons in the hippocampus are severely 
affected by Mecp2 loss-of-function (Smrt et al., 2007). Together, these data suggest that 
while decreases in dendritic arborization may accompany the development of RTT-like 
behavioral phenotypes in Mecp2 loss-of-function, the degree of these changes does not 
necessarily match the behavioral phenotypic severity and therefore, dendritic 
arborization may not be a robust and consistent cellular readout of RTT-like phenotype. 
 
In contrast to the intrinsic variability of dendritic outgrowth in Mecp2 mice, we found that 
MeCP2 soma size regulation is persistent throughout development and dependent on 
MeCP2 function. Both Mecp2 loss-of-function mouse models, Mecp2–/y and Mecp2T158A/y, 
showed decreased soma size at early- and late-symptomatic time points relative to WT, 
suggesting that soma size decreases upon Mecp2 loss-of-function but does not change 
with increasing RTT-like symptomatic severity. These data are consistent with findings 
from ESC-differentiated neurons, where neurons originating from several lines of Mecp2 
loss-of-function mice show decreased soma size relative to controls throughout the 
course of neuronal maturation (Yazdani et al., 2012), and can be rescued upon 
restoration of MeCP2. Together, these data indicate that soma size is regulated by 
MeCP2 function throughout development and can be an indicator of MeCP2 function. 
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To address the third question, whether changes in neuronal morphology are brain region 
or cell type-specific, we assessed neuronal morphology in a separate brain region by 
measuring dendritic complexity in hippocampal CA1 pyramidal neurons in pre-and post-
symptomatic Mecp2T158A/y mice. In contrast to the age-dependent decrease in basal 
dendritic complexity we observed in somatosensory cortex layer V pyramidal neurons of 
Mecp2T158A/y mice, we found no age-dependent reduction in dendritic complexity of 
hippocampal CA1 pyramidal neurons. These data are consistent with region-specific 
morphological phenotypes identified in RTT post-mortem brain tissue, where pyramidal 
neurons of the motor, frontal, and inferior temporal cortices show decreased dendritic 
complexity, but pyramidal neurons in the visual cortex and hippocampus exhibit no 
change with respect to age-matched controls (Armstrong et al., 1995; Belichenko et al., 
1994). Specificity may even extend to cortical layer, as decreased dendritic arborization 
has been identified in both basal and apical dendrites of layer V motor cortex cells but 
only in basal dendrites of layer III motor cortex cells (Armstrong et al., 1995). A 
comparison of data from different studies also supports a cortical layer-specific 
regulation of neuronal morphology in mice, where neocortical layer II/III pyramidal 
neurons show decreased dendritic complexity in both proximal basal and apical 
dendrites and no change in spine density (Kishi and Macklis, 2004) but layer V 
pyramidal neurons show decreased dendritic complexity in only proximal basal and 
distal apical dendrites and decreased spine density (Stuss et al., 2012).  
 
In contrast to the cell type-specific changes in dendritic outgrowth, multiple lines of 
evidence indicate that soma size is consistent across cell types. We previously reported 
decreased soma size in hippocampal CA1 pyramidal neurons in both pre- and post-
symptomatic Mecp2T158A/y mice (Goffin et al., 2012), similar to what we observed in the 
somatosensory cortex in this study. In addition, decreased soma size has been reported 
in RTT post-mortem brain tissue (Armstrong, 2005) and in the locus ceruleus (Taneja et 
al., 2009), hippocampus CA2 (Chen et al., 2001), layer II/III somatosensory cortex (Kishi 
and Macklis, 2004), layer II/III motor cortex (Robinson et al., 2012), and layer V motor 
cortex (Stuss et al., 2012) of different Mecp2-null mouse strains. Moreover, various lines 
of Mecp2-deficient ESC-derived neurons (Yazdani et al., 2012) and RTT patient-derived 
induced pluripotent stem cells (Marchetto et al., 2010) also show reduced soma sizes, 
indicating that, in contrast to dendritic arborization, a reduction in soma size upon Mecp2 
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loss-of-function is a phenotype that is consistent across cell types and experimental 
systems. Similarly, our finding that soma size is not affected upon Mecp2 gain-of-
function has also been observed in vitro (Jugloff et al., 2005), indicating that the absence 
of a change in soma size upon Mecp2 gain-of-function is also conserved across cell 
types. 
 
This consistent and robust reduction in soma size across studies, Mecp2 mutations, 
experimental systems, cell types, and developmental time points, is in sharp contrast to 
changes in dendritic complexity, which varies across these parameters and can be 
subtle and context-dependent (Stuss et al., 2012). Therefore, in accordance with a 
recent study evaluating spine density throughout development in Mecp2 loss-of-function 
mice (Chapleau et al., 2012), we caution the use of dendritic complexity as a phenotypic 
endpoint for therapeutic evaluation, and suggest that soma size may be a more robust 
and reproducible readout of MeCP2 function. Evidence supporting soma size as a 
reliable morphologic phenotype comes from existing rescue experiments, where 
activation of a quiescent Mecp2 gene in adults results in partial restoration of dendritic 
complexity and length but a full restoration of soma size (Robinson et al., 2012). In 
addition, postnatal neuron-specific reactivation of MeCP2 sufficient to rescue 
hippocampal and cortical soma size in Mecp2-deficient mice (Giacometti et al., 2007) 
and neuronal size is restored by the re-expression of MeCP2 in several strains of 
MeCP2-deficient ESC-derived neurons (Yazdani et al., 2012). Future studies are needed 
to understand how soma size and dendritic outgrowth are differentially regulated by 
MeCP2. It is conceivable that dendritic arborization is more sensitive to the cellular 
environment, growth factors, and homeostatic regulation, whereas soma size is more 
directly affected by the function of nuclear proteins such as MeCP2. 
 
Overall, our data indicates that within a population of excitatory neurons in RTT mouse 
models, in vivo changes in dendritic complexity upon Mecp2 loss-of-function are brain 
region-specific, correlated with behavioral phenotype, and mild. In contrast, soma size is 
regulated throughout development and may be a reliable marker for evaluating MeCP2 
function and therapeutic efficacy. These phenotypes are specific to Mecp2 loss-of-
function, as in vivo morphological changes upon Mecp2 gain-of-function are absent. The 
use of neuronal morphology as a cellular readout of RTT phenotype and restoration of 
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neuronal circuitry, therefore, should be cautioned, as morphological phenotypes are 
intrinsically variable. 
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Figure 1 
 
Figure 1. Thy1-GFP/M reporter imaging strategy. 
(a) Somatosensory cortex layer V pyramidal neurons are labeled with GFP throughout the cell body and dendritic tree in 
Thy1-GFP/M reporter mice. Scale bar = 250 µm. 
(b) Hippocampus CA1 pyramidal neurons are labeled with GFP throughout the cell body and dendritic tree in Thy1-GFP/M 
reporter mice. Scale bar = 250 µm. 
(c) Somatosensory cortex layer V pyramidal neurons extend their apical dendrites to the pial surface (arrow) and their basal 
dendrites deep into layer VI. Scale bar = 50 µm. 
(d) Basal dendrites of somatosensory cortex layer V pyramidal neurons, quantified by Sholl analysis, measuring number of 
intersections between concentric circles drawn around the cell soma (Sholl radii) and dendritic branches. Scale bar = 50 
µm. 
(e) Apical dendrites of somatosensory cortex layer V pyramidal neurons, quantified by Sholl analysis. Scale bar = 50 µm. 
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Figure 2 
 
Figure 2. Dendritic complexity in somatosensory cortex of Mecp2–/y mice. 
(a) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P30 WT (n=24 neurons from 4 mice) and Mecp2–/y 
mice (n=19 neurons from 4 mice) shows reduced dendritic complexity in Mecp2–/y mice relative to WT. Basal dendritic 
arbor is denoted by negative distance from soma, 0 µm marks soma position within cortex, and apical dendritic arbor is 
denoted by positive distance from soma. Two-way ANOVA with Bonferroni correction, p<0.0001 (interaction); *p<0.05, 
**p<0.01, ***p<0.001. Bars represent mean ± sem. 
(b) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P60 WT (n=36 neurons from 4 mice) and Mecp2–/y 
mice (n=31 neurons from 4 mice) show more widespread reduction in dendritic complexity in Mecp2–/y mice relative to WT 
than seen in P30 animals. Two-way ANOVA with Bonferroni correction, p<0.0001 (interaction); *p<0.05, ***p<0.001. 
  
a b
145	  
	  
Figure 3 
 
Figure 3. Dendritic complexity in somatosensory cortex of Mecp2T158A/y mice. 
(a) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P30 WT (n=40 neurons from 4 animals) and 
Mecp2T158A/y mice (n=34 neurons from 4 animals) show no change dendritic complexity in Mecp2T158A/y mice relative to 
WT. Two-way ANOVA, p>0.05. Bars represent mean ± sem. 
(b) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P90 WT (n=36 neurons from 4 mice) and 
Mecp2T158A/y mice (n=39 neurons from 4 mice) show reduced dendritic complexity in Mecp2T158A/y mice relative to WT 
specifically in the basal dendritic arbor. Two-way ANOVA with Bonferroni correction, p<0.0001 (interaction); **p<0.01. 
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Figure 4 
 
Figure 4. Dendritic complexity in hippocampus CA1 of Mecp2T158A/y mice. 
(a) Sholl analysis of hippocampal CA1 pyramidal neurons in P30 WT (27 neurons from 5 mice) and Mecp2T158A/y mice (n=33 
neurons from 5 mice) show no change dendritic complexity in Mecp2T158A/y mice relative to WT. Two-way ANOVA, p>0.05. 
Bars represent mean ± sem. 
(b) Sholl analysis of hippocampal CA1 pyramidal neurons in P90 WT (n=32 neurons from 5 mice) and Mecp2T158A/y mice 
(n=40 neurons from 5 mice) show altered dendritic complexity in Mecp2T158A/y mice relative to WT specifically in the basal 
dendritic arbor. Two-way ANOVA with Bonferroni correction, p<0.0001 (interaction); *p<0.05, **p<0.01. 
(c) Sholl analysis of basal dendritic complexity of hippocampal CA1 pyramidal neurons in P90 WT and Mecp2T158A/y mice 
show no difference in peak number of crossings in Mecp2T158A/y mice relative to WT. 
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Figure 5 
 
Figure 5. Soma size is regulated throughout development by MeCP2 function. 
(a) Somatosensory cortex layer V pyramidal neuron soma size is reduced in Mecp2–/y mice relative to WT at both P30 (WT: 
n=124 neurons from 4 mice; Mecp2–/y: n=103 neurons from 4 mice) and P60 (WT: n=126 neurons from 4 mice; Mecp2–/y: 
n=104 neurons from 4 mice). **p<0.01, unpaired two-tailed Student t-test with Bonferroni correction. Bars represent mean 
± SEM. 
(b) Somatosensory cortex layer V pyramidal neuron soma size is reduced in Mecp2T158A/y mice relative to WT at both P30 
(WT: n=115 neurons from 4 mice; Mecp2T158A/y: n=121 neurons from 4 mice) and P90 (WT: n=81 neurons from 4 mice; 
Mecp2T158A/y: n=106 neurons from 4 mice). **p<0.01, unpaired two-tailed Student t-test with Bonferroni correction. 
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Figure 6 
 
Figure 6. Dendritic complexity in Mecp2Tg1 mice. 
(a) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P30 WT (n=16 neurons from 2 mice) and Mecp2Tg1 
mice (n=19 neurons from 2 mice) show no change dendritic complexity in Mecp2Tg1 mice relative to WT. Two-way 
ANOVA, p>0.05. Bars represent mean ± sem. 
(b) Sholl analysis of somatosensory cortex layer V pyramidal neurons in P140 WT (n=23 neurons from 2 mice) and Mecp2Tg1 
mice (n=23 neurons from 2 mice) show no change dendritic complexity in Mecp2Tg1 mice relative to WT. Two-way 
ANOVA, p>0.05.  
(c) Somatosensory cortex layer V pyramidal neuron soma size is not affected in Mecp2Tg1 mice relative to WT at both P30 
(WT: n=101 neurons from 2 mice; Mecp2Tg1: n=110 neurons from 2 mice) and P140 (P140; n=110 neurons from 2 mice; 
Mecp2Tg1: n=113 neurons from 2 mice). p>0.05, unpaired two-tailed Student t-test. 
  
0
100
200
300
S
om
a 
ar
ea
 (!
m
2 )
P30 P140
n.s. n.s.
WT WTMecp2Tg1 Mecp2Tg1
a
c
b
149	  
	  
Chapter 6: 
DISCUSSION 
 
 
The bulk of this thesis aims to understand the pathogenic mechanisms underlying the 
early-onset epileptic encephalopathy CDKL5 disorder.  In the first body of work (Chapter 
2), I developed and characterized the first CDKL5 animal model, and found that mice 
lacking CDKL5 recapitulate a number of clinically relevant behavioral phenotypes, 
including autistic-like deficits in social interaction, motor impairment, and reduced fear 
memory.  In addition, these mice show alterations in neuronal circuit communication and 
disruption of multiple signal transduction pathways that converge into PTEN downstream 
signaling.  Prior to this study, studies of CDKL5 function were limited to in vitro and 
knockdown studies, which often yielded inconsistent results with unconfirmed in vivo 
relevance.  Therefore, the generation of a mouse model that mimicked a CDKL5 patient 
mutation was necessary in order to establish a framework and platform for future 
mechanistic studies.  In addition, this study was the first to establish a causal role of 
mutations in Cdkl5 and disease pathogenesis. 
 
In the second body of work (Chapter 3), I sought to address the mechanisms by which 
mutations in CDKL5 lead to disease using a CDKL5 conditional knockout mouse line.  
To investigate the brain-specific role of CDKL5 in disease pathogenesis, I generated 
mice lacking CDKL5 from the nervous system and found that these mice recapitulate a 
number of behavioral phenotypes identified in the CDKL5 null mutant, including 
hyperactivity, decreased anxiety, and reduced sociability.  Next, I sought to dissect the 
neuronal subpopulations in which Cdkl5 loss-of-function leads to disease.  Therefore, I 
generated mice lacking CDKL5 from either glutamatergic or GABAergic neurons, which 
are the two major neuronal subtypes in the brain.  Behavioral phenotyping of these mice 
showed that CDKL5-related phenotypes separate upon conditional ablation of CDKL5, 
such that mice lacking CDKL5 from forebrain GABAergic neurons demonstrate autistic-
like phenotypes, whereas mice lacking CDKL5 from forebrain glutamatergic neurons 
demonstrate impairments in working memory and develop spontaneous seizures.  
Importantly, these data suggest that disease mechanisms underlying CDKL5 disorder 
and Rett Syndrome are distinct, as conditional ablation of MeCP2 in these two neuronal 
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populations results in phenotypes that are distinct from those of CDKL5 conditional 
knockouts (Goffin et al., 2014).  Moreover, these data support a mechanism that is 
consistent with emerging data on CDKL5 function (Chen et al., 2010; Ricciardi et al., 
2012; Zhu et al., 2013). 
 
The dissection of these two major phenotypes of CDKL5 disorder, seizures and autistic-
like behaviors, in the two complementary conditional knockout mice have raised several 
hypotheses for CDKL5 biological function.  First, it is possible that CDKL5 plays a role in 
the synapses of glutamatergic neurons that is distinct from its role in the synapses of 
GABAergic neurons.  Immunostaining experiments have demonstrated that CDKL5 is 
localized to excitatory, but not inhibitory, synapses onto pyramidal neurons (Ricciardi et 
al., 2012).  Electrophysiological recordings from primary cultures after shRNA-mediated 
CDKL5 knockdown show reduced amplitude and frequency of mEPSCs, indicating that 
loss of CDKL5 impairs synaptic maturation.  These data, combined with the role of 
CDKL5 in regulation of neuronal migration, outgrowth, and spine development (Chen et 
al., 2010; Ricciardi et al., 2012; Zhu et al., 2013), suggest a disease mechanism by 
which loss of CDKL5 from glutamatergic neurons impairs neuronal development and 
connectivity and weakens excitatory synapses.  Mice lacking CDKL5 from glutamatergic 
neurons, however, develop spontaneous seizures, suggesting an imbalance in neuronal 
excitation and inhibition that is expected in epilepsy, where excitation is favored over 
inhibition.  Therefore, future synapse electrophysiological measurement of excitatory and 
inhibitory neurotransmission in Nex-cKO mice, along with morphological measurements 
performed in parallel, will illuminate how Cdkl5 loss-of-function affects excitatory 
synapses in vivo, and whether a shift in E/I balance contributes to the development of 
spontaneous seizures and behavioral phenotypes.   
  
Although CDKL5 is not localized to inhibitory synapses onto excitatory neurons, the 
prominent autistic-like behavioral phenotypes in mice lacking CDKL5 from GABAergic 
neurons suggests that CDKL5 plays a role in GABAergic cells.  It is currently unknown 
whether CDKL5 is localized to excitatory or inhibitory synapses onto inhibitory neurons, 
so it is possible that it may play a role at these synapses.  Therefore, future experiments 
examining the localization of CDKL5 at these two synapses, as well as 
neurotransmission at these synapses will determine whether E/I imbalance is relevant to 
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autistic-like phenotypes.  Indeed, an increased ratio of excitation/inhibition has been 
proposed to underlie autism (Rubenstein and Merzenich, 2003) and optogenetic 
elevation of E/I balance has been shown to produce autistic-like phenotypes (Yizhar et 
al., 2011).  
 
Another explanation for the separation of phenotypes in CDKL5 conditional knockout 
animals is the possibility that CDKL5 may be involved in distinct signaling pathways in 
glutamatergic and GABAergic neurons.  Studies from CDKL5 KO mice suggest that 
CDKL5 may be involved in PTEN downstream signaling (Amendola et al., 2014; Fuchs 
et al., 2014; Wang et al., 2012).  Its involvement in this pathway, however, may be 
limited to a particular cell type, or it may be differentially involved in glutamatergic cells 
and GABAergic cells.  To investigate this possibility, future experiments will aim to 
determine firstly whether PTEN downstream signaling, including Akt/mTOR, Akt/S6K, 
and Akt/GSK-3b, are differentially affected in Nex- or Dlx-cKO mice, particularly in 
glutamatergic or GABAergic neurons from these mice.  Then, the relationship between 
CDKL5 and PTEN signaling can be assessed by pharmacologic or genetic manipulation 
of PTEN in Nex- or Dlx-cKO mice.  As PTEN is the master regulator of this pathway, loss 
of PTEN should restore pAkt levels, and behavioral and electrophysiogical experiments 
can measure whether restoration of this signaling pathway in Nex- or Dlx-cKO animals is 
sufficient to rescue the neural circuit or behavioral phenotypes identified in Chapter 3.  
Ultimately, this work aims to identify signaling pathways that are regulated by CDKL5 
and can therefore be targeted for therapeutic intervention. 
 
At the circuit level, it is possible that loss of CDKL5 from glutamatergic or GABAergic 
neurons differentially disrupts neural circuits, or that the neural circuits mediating autistic 
behavior and epilepsy are inherently distinct and that CDKL5 plays a role in both circuits.  
To examine these possibilities, future experiments should continue to assess neural 
circuit function using hippocampal microcircuits as a model.  VSD imaging of the dentate 
gyrus microcircuit showed a preferential breakdown of the dentate filter in Dlx-cKO mice, 
indicating that loss of CDKL5 from GABAergic neurons preferentially disrupts the 
dentate gyrus.  Identification of disease-related microcircuits may not only serve as 
readouts for therapeutic efficacy, but may also aid in pinpointing key circuit mechanisms 
underlying disease. 
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Finally, future experiments should address the therapeutic relevance of these studies.  
Gene mutations occur in germ cells and persist throughout the organism’s lifetime, but 
therapeutic intervention in the clinic is likely constrained to postnatal time points, either 
during development or in adulthood.  Therefore, the reversibility of CDKL5 disorder must 
be established.  In Rett Syndrome mouse models, restoration of MeCP2 in post-
symptomatic adult mice is sufficient to rescue many, but not all, disease-related 
phenotypes (Guy et al., 2007), suggesting that Rett Syndrome is reversible and 
therefore, treatable.  This finding also indicates that MeCP2 may play a maintenance 
role and that many circuits and pathways regulated by MeCP2 are plastic.  Performing 
similar experiments on CDKL5 mouse models will be an important step in translating 
animal research into clinically relevant therapeutic strategies. 
 
In the second half of this thesis, I collaborated with other members of the lab to 
investigate Rett Syndrome.  In the third body of work (Chapter 4), I helped to 
characterize a novel Mecp2 mouse model containing a knockin mutation at the MeCP2 
Threonine 158 residue.  This residue is located within the methyl-binding domain of 
MeCP2 and is the most common site for MECP2 missense mutations.  We found that 
MeCP2 158A mutant mice recapitulate a number of RTT-like behavioral phenotypes and 
demonstrate developmental impairments in auditory-evoked event-related processing.  
Biochemical assays identified that MeCP2 T158A mutation causes a reduction in 
MeCP2 protein stability and DNA binding, suggesting that stabilization of MeCP2 and 
enhancement of affinity for DNA may be possibilities for RTT therapeutic development, 
and that measurement of ERPs during development may serve as a biomarker for Rett 
Syndrome progression. 
 
In the final body of work (Chapter 5), I engaged in a collaboration to perform a 
comprehensive and systematic analysis of how age, brain region, and Mecp2 mutation 
influences RTT-related neuronal morphology.  We found that Mecp2 loss-of-function 
mutations mildly reduce dendritic complexity in a brain region- and Mecp2 mutation-
specific manner that correlates with the onset of behavioral phenotype.  Soma size, in 
contrast, is robustly reduced upon Mecp2 loss-of-function across development, whereas 
Mecp2 gain-of-function does not influence dendritic complexity or soma size.  These 
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data suggest that soma size, rather than dendritic complexity, may be a more reliable 
and robust marker for MeCP2 function. 
 
Together, this body of work represents significant advancement in the understanding of 
how mutations in CDKL5 lead to disease and in the mechanisms underlying Rett 
Syndrome pathogenesis.  The generation and characterization of multiple mouse models 
of CDKL5 disorder and Rett Syndrome with face validity that mimic patient mutations 
have provided valuable tools and reagents for the research community and have 
identified novel protein functions and signaling pathways that may serve as potential 
targets for therapeutic intervention.  
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